
<html lang="en"     class="pb-page"  data-request-id="fb8830ea-1ea3-45e5-bac1-8421b415234b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c00909;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere" /></meta><meta name="dc.Creator" content="Rosa María  Rodríguez&#xA;Sarmiento" /></meta><meta name="dc.Creator" content="Caterina  Bissantz" /></meta><meta name="dc.Creator" content="Johan  Bylund" /></meta><meta name="dc.Creator" content="Anja  Limberg" /></meta><meta name="dc.Creator" content="Werner  Neidhart" /></meta><meta name="dc.Creator" content="Roland  Jakob-Roetne" /></meta><meta name="dc.Creator" content="Lisha  Wang" /></meta><meta name="dc.Creator" content="Karlheinz  Baumann" /></meta><meta name="dc.Description" content="Starting from RO6800020 (1), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC50), pharmacokinetic properties including..." /></meta><meta name="Description" content="Starting from RO6800020 (1), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC50), pharmacokinetic properties including..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 24, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00909" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00909" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00909" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00909" /></link>
        
    
    

<title>Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00909" /></meta><meta property="og:title" content="Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0022.jpeg" /></meta><meta property="og:description" content="Starting from RO6800020 (1), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC50), pharmacokinetic properties including the free fraction (fraction unbound (fu)) in plasma, and in vivo efficacy. Importantly, we used novel CF3-alkoxy groups as bioisosteric replacements of a fluorinated phenyl ring and properties such as lipophilicity, solubility, metabolic stability, and free fraction could be balanced, maintaining low Pgp efflux needed for CNS penetration. In addition, by reducing aromaticity, we prevented phototoxicity. Additional substitution in the triazolopyridine core disturbed the binding to phosphatidylinositol 4-kinase, catalytic β (PIK4CB). We also introduced less lipophilic head heterocycles devoid of covalent binding (CVB) liability. After these changes, further modifications to the trifluoroethoxy bioisosteric replacement allowed rebalancing of properties, such as lipophilicity, and also potency. Our optimization strategy culminated with in vivo active RO7101556 (18B) having excellent properties and being selected as an advanced candidate." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00909"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00909">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00909&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00909&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00909&amp;href=/doi/10.1021/acs.jmedchem.0c00909" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8534-8553</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00908" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00940" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rosa María Rodríguez Sarmiento</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rosa María Rodríguez Sarmiento</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d1a3bea2b08ebcb0a3b8b0ffa3beb5a3b8b6a4b4ab8ea2b0a3bcb8b4bfa5be91a3beb2b9b4ffb2bebc"><span class="__cf_email__" data-cfemail="4c3e233f2d13212d3e252d623e23283e252b392936133f2d3e2125292238230c3e232f2429622f2321">[email protected]</span></a>. Tel.: (+41) 61-688-3585.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rosa+Mar%C3%ADa++Rodr%C3%ADguez%0ASarmiento">Rosa María Rodríguez Sarmiento</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0737-8885" title="Orcid link">http://orcid.org/0000-0003-0737-8885</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Caterina Bissantz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Caterina Bissantz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Caterina++Bissantz">Caterina Bissantz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Bylund</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Bylund</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Bylund">Johan Bylund</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anja Limberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anja Limberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anja++Limberg">Anja Limberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Werner Neidhart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Werner Neidhart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Werner++Neidhart">Werner Neidhart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roland Jakob-Roetne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roland Jakob-Roetne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roland++Jakob-Roetne">Roland Jakob-Roetne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisha Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisha Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisha++Wang">Lisha Wang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Karlheinz Baumann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karlheinz Baumann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karlheinz++Baumann">Karlheinz Baumann</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00909&amp;href=/doi/10.1021%2Facs.jmedchem.0c00909" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8534–8553</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 24, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 May 2020</li><li><span class="item_label"><b>Published</b> online</span>24 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00909" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00909</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8534%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRosa%2BMar%25C3%25ADa%2BRodr%25C3%25ADguez%250ASarmiento%252C%2BCaterina%2BBissantz%252C%2BJohan%2BBylund%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00909%26title%3DStepwise%2BDesign%2Bof%2B%25CE%25B3-Secretase%2BModulators%2Bwith%2Ban%2BAdvanced%2BProfile%2Bby%2BJudicious%2BCoordinated%2BStructural%2BReplacements%2Band%2Ban%2BUnconventional%2BPhenyl%2BRing%2BBioisostere%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8553%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00909"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1090</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00909" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rosa&quot;,&quot;last_name&quot;:&quot;María Rodríguez\nSarmiento&quot;},{&quot;first_name&quot;:&quot;Caterina&quot;,&quot;last_name&quot;:&quot;Bissantz&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Bylund&quot;},{&quot;first_name&quot;:&quot;Anja&quot;,&quot;last_name&quot;:&quot;Limberg&quot;},{&quot;first_name&quot;:&quot;Werner&quot;,&quot;last_name&quot;:&quot;Neidhart&quot;},{&quot;first_name&quot;:&quot;Roland&quot;,&quot;last_name&quot;:&quot;Jakob-Roetne&quot;},{&quot;first_name&quot;:&quot;Lisha&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Karlheinz&quot;,&quot;last_name&quot;:&quot;Baumann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8534-8553&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00909&quot;},&quot;abstract&quot;:&quot;Starting from RO6800020 (1), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC50), pharmacokinetic properties including the free fraction (fraction unbound (fu)) in plasma, and in vivo efficacy. Importantly, we used novel CF3-alkoxy groups as bioisosteric replacements of a fluorinated phenyl ring and properties such as lipophilicity, solubility, metabolic stability, and free fraction could be balanced, maintaining low Pgp efflux needed for CNS penetration. In addition, by reducing aromaticity, we prevented phototoxicity. Additional substitution in the triazolopyridine core disturbed the binding to phosphatidylinositol 4-kinase, catalytic β (PIK4CB). We also introduced less lipophilic head heterocycles devoid of covalent binding (CVB) liability. After these changes, further modifications to the trifluoroethoxy bioisosteric replacement allowed rebalancing of properties, such as lipophilicity, and also potency. Our optimization strateg&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00909&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00909" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00909&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00909" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00909&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00909" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00909&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00909&amp;href=/doi/10.1021/acs.jmedchem.0c00909" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00909" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00909" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00909%26sid%3Dliteratum%253Aachs%26pmid%3D32706964%26genre%3Darticle%26aulast%3DRodr%25C3%25ADguez%250D%250ASarmiento%26date%3D2020%26atitle%3DStepwise%2BDesign%2Bof%2B%25CE%25B3-Secretase%2BModulators%2Bwith%2Ban%2BAdvanced%2BProfile%2Bby%2BJudicious%2BCoordinated%2BStructural%2BReplacements%2Band%2Ban%2BUnconventional%2BPhenyl%2BRing%2BBioisostere%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8534%26epage%3D8553%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a>,</li><li><a href="/action/doSearch?ConceptID=291870" title="Piperidines">Piperidines</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Starting from RO6800020 (<b>1</b>), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC<sub>50</sub>), pharmacokinetic properties including the free fraction (fraction unbound (fu)) in plasma, and <i>in vivo</i> efficacy. Importantly, we used novel CF<sub>3</sub>-alkoxy groups as bioisosteric replacements of a fluorinated phenyl ring and properties such as lipophilicity, solubility, metabolic stability, and free fraction could be balanced, maintaining low Pgp efflux needed for CNS penetration. In addition, by reducing aromaticity, we prevented phototoxicity. Additional substitution in the triazolopyridine core disturbed the binding to phosphatidylinositol 4-kinase, catalytic β (PIK4CB). We also introduced less lipophilic head heterocycles devoid of covalent binding (CVB) liability. After these changes, further modifications to the trifluoroethoxy bioisosteric replacement allowed rebalancing of properties, such as lipophilicity, and also potency. Our optimization strategy culminated with <i>in vivo</i> active RO7101556 (<b>18B</b>) having excellent properties and being selected as an advanced candidate.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">INTRODUCTION</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Alzheimer’s disease (AD) is a severe neurodegenerative condition and is the most common form of dementia in the elderly, with a prevalence of 5% after 65 years of age, which increases to about 30% in people aged 85 years or older.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> More than 40 million people worldwide are impacted and, despite this, the current treatments offer only symptomatic relief with no or little effect upon disease progression.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Patients diagnosed with Alzheimer’s disease will experience progressive loss of cognitive function, which causes social and psychiatric disability, finally affecting the independence of the patient.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Genetic and experimental evidence indicates that β-amyloid peptides (Aβ) are contributors to the pathogenesis of AD.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Longer forms of these peptides, in particular Aβ42 and Aβ43, are thought to be neurotoxic and more prone to aggregation,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> while the shorter peptides (with 38 amino acids or less) are thought to be innocuous or even protective against formation of aggregates. We focused on γ-secretase modulation for the treatment of Alzheimer’s disease to obtain a shift in the cleavage of CTFβ (C-terminal fragment after β cleavage) to make smaller less amyloidogenic Aβ species and reduce the Aβ42. Aβ42 is made via the cleavage of the amyloid precursor protein (APP) in two key steps, by the action of two secretases (β and γ). The second step is the cleavage of CTFβ through the action of γ-secretase. An imbalance between production and degradation of these Aβ42 peptides leads to aggregation into oligomers and plaques, which is believed to be the key event in the disease.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> γ-Secretase modulators (GSMs) bind to presenilin, the catalytic subunit of γ secretase, and shift the production of the amyloid β protein toward nontoxic shorter amyloid peptides such as Aβ37 and Aβ38 at the expense of the amyloidogenic Aβ42/Aβ40.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The shorter Aβ peptides do not form aggregates and may even function as Aβ42 aggregation inhibitors.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a></div><div class="NLM_p">However, γ-secretase is an enzymatic protein complex that is involved in many biological pathways and cleaves several substrates apart from APP, including the Notch protein.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Concerns about Notch inhibition have been raised. For example, the phase III trial of Semagacestat (LY450139), the most advanced γ-secretase inhibitor (GSI), was terminated because of a reduction of cognition scores and an increase in the risk of skin cancer compared to placebo. It is thought that many of the side effects from GSIs are due to the large number of substrates cleaved by γ-secretase and that an increase in skin cancer incidents was associated with the inhibition of the γ-secretase-dependent Notch1 signaling pathway, as one of it functions is to act as a tumor suppressor.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Consequently, achieving APP selectivity over the Notch signaling protein has become an overarching goal in the design of next-generation γ-secretase inhibitors (GSIs), but this has proven challenging.<a onclick="showRef(event, 'ref11 ref15'); return false;" href="javascript:void(0);" class="ref ref11 ref15">(11,15)</a> A more attractive alternative is the γ-secretase modulation, which does not interfere with the Notch pathway. GSMs also do not cause a rebound effect on Aβ production, which may be responsible for the worsening of the cognitive function.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Our former GSM lead compound RO6800020 (<b>1</b>) was derived from several optimization cycles from patented chemical series, which were terminated due to limited <i>in vivo</i> activity together with issues such as Pgp, GSH, or drug–drug interactions.<sup>17</sup> RO6800020 (<b>1</b>) showed an improved profile and exhibited promising <i>in vivo</i> efficacy in our double transgenic APP-Swedish mice Aβ42 model (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). However, RO6800020 showed a phototoxicity flag<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> and a covalent binding liability and inhibited phosphatidylinositol 4-kinase catalytic β (PIK4CB) activity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition, compound <b>1</b> exhibited very high plasma protein binding (PPB) (the fraction unbound in plasma (fup) for <b>1</b> is 0.03% in humans and 0.29% in mice), which resulted in uncertainties regarding the predictions of human exposure needed for efficacy, also due to the difficulties to measure such low fup values with accuracy. Considering the potential differences in fup between mice and humans, a total plasma concentration above 20 μM was anticipated to be required to achieve efficacy in humans, increasing our safety concerns. Moreover, the observed high PPB consequently led to uncertainty regarding the interpretation of <i>in vitro</i> assay results,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> especially for the primary potency assay and the hepatocyte metabolic stability assay where 10% fetal calf serum (FCS) was utilized in the cellular media.</div><div class="NLM_p">Capitalizing on our internal potent GSM series and starting from our most profiled lead compound RO6800020 (<b>1</b>), we utilized sequential structural replacements to improve desired properties and potency (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). We evaluated many central piperidine replacements such as bicyclic, bridged, or azaspiro-like piperidines (data not shown). We also revisited our previously reported bridged piperidines as a replacement,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> observing that in particular with the [3.2.1] bridged piperidine (<b>2</b>), we improved the overall potency, reducing lipophilicity (log <i>D</i> = 4.1) while maintaining the apparent metabolic stability. Our new GSM (<b>2</b>) had higher potency, which resulted in good <i>in vivo</i> efficacy with lower efficacious free concentrations. Also, higher and more reliable fraction unbound (fu) measurements (fup for <b>2</b> in humans and mice is 0.46 and 0.3%, respectively). This lowered the estimated human efficacious doses (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and allowed better predictions. Furthermore, to understand the impact of potential unspecific binding for the interpretation of potency, we measured fup in the cellular assay media for a number of compounds and calculated their free <i>in vitro</i> IC<sub>50</sub> values. Subsequently, for compounds with measurable PPBs, we established a clear correlation between the free <i>in vitro</i> IC<sub>50</sub> and free brain IC<sub>50</sub> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), where the free brain IC<sub>50</sub> was estimated by phamacokinetics and pharmacodynamics (PKPD) analysis corrected for fup and a potential brain gradient based on observed mouse Pgp efflux ratios.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Sequential improvement of the potency and properties of <b>1</b>. Increase of potency and free fraction (<b>2</b>). Improvement in the physicochemical properties and elimination of phototoxic liability upon the introduction of a phenyl ring bioisostere (<b>5A</b>). Reduction of PIK4CB side activity by disturbing the kinase hinge binding (<b>9B</b>). Elimination of covalent binding liability with new heterocyclic head rings and properties–potency rebalance with modifications on the alkoxy bioisosteric replacement (<b>18B</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Correlation between estimated free <i>in vitro</i> IC<sub>50</sub> (Aβ42) and <i>in vivo</i> free brain IC<sub>50</sub> concentrations for <b>5A</b> and compounds from the same chemical series (side A). Effects of potency (IC<sub>50</sub>) and predicted human pharmacokinetic property improvement, with a more balanced plasma protein binding, lowering efficacious human doses (side B and table). Human/mice free IC<sub>50</sub> predictions and initial human dose estimations for 50% of Aβ42 reduction at steady state for compounds <b>1</b> and <b>2</b> (see table).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Importantly, to eliminate the hyperconjugated system and prevent phototoxicity, we explored unconventional bioisosteric replacements of the phenyl ring at the core and identified fluorinated alkoxy groups as potent and non classical bioisosteres for the terminal phenyl ring (<b>5A</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Using an alkoxy chain moiety as a bioisosteric replacement, we reduced the aromaticity and, consequently, we also decreased the absorption in the UVA region (320–400 nm), preventing phototoxicity while maintaining potency. The reduction of aromaticity (or the increase of the fraction of sp3-hybridized carbon atom count) reduced lipophilicity and protein binding and increased solubility. We also introduced an additional substituent in the aminotriazole core (<b>9B</b>) to disturb the observed binding (<i>K</i><sub>d</sub> ∼ 100 μM) to PIK4CB kinase, improving selectivity. Finally, we re-evaluated the heteroaromatic head groups that we found responsible for the observed covalent binding (CVB) and introduced new heterocycles with no CVB safety liability (<b>18B</b>).</div><div class="NLM_p last">The CF<sub>3</sub> alkoxy bioisosteric replacement of the phenyl ring dramatically affects compound properties while also maintaining an excellent metabolic stability and low Pgp efflux. Further modifications on the trifluoro alkoxy moiety are readily accessible. As a consequence, we could introduce small changes on the substitution pattern of the alkoxy chain, to rebalance properties such as lipophilicity and potency, in agreement with the core changes and with the different characteristics of the different heterocyclic head groups introduced to eliminate the compounds’ CVB liability (<b>18B</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Lead Optimization</h3><div class="NLM_p">We aimed to obtain an orally available GSM without covalent binding and phototoxicity. Our most profiled GSM compound <b>1</b> has moderate potency (IC<sub>50</sub> (Aβ42) = 55 nM), high lipophilicity, very low human-plasma-free fraction (fup: 0.03%), and low solubility.</div><div class="NLM_p">Lead compound <b>1</b> also showed significant metabolically induced covalent binding (in the presence of NADPH, the CVB of <sup>14</sup>C-RO6800020 in human liver microsomes (HLMs) = 149 pmol bound per mg protein), indicating a risk for idiosyncratic toxicity and drug bioactivation via the formation of reactive metabolites.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Therefore, we decided to explore alternative central piperidine rings to see whether the difluoro piperidine could be involved in the formation of a reactive metabolite that could react with GSH, may be via enamine formation. By exploring replacements for the central ring (variously bridged, bicyclic or azaspiro piperidine analogues), we realized that the best replacement was the reported [3.2.1] bridged piperidine,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> as it did not compromise the metabolic stability and gave an excellent improvement in potency (<b>2</b>). Compound <b>2</b> has improved potency along with decreased protein binding (hfu: 0.4%) compared to compound <b>1</b> (hfu: 0.03%) (see table in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). This contributed to a reduction of the estimated efficacious human dose for compound <b>2</b> (7–25 mg/day), as well as an increased confidence in human predictions due to reduction of unspecific binding on <i>in vitro</i> assays. Furthermore, compound <b>2</b>, despite having similar covalent binding (105 pmol/mg, measured with the radiolabeled C<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> compound) as compound <b>1</b>, shows lower risk for idiosyncratic toxicity due to the lower predicted human dose (7–25 mg/kg).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">We observed that alternatively bridged (e.g., [3.3.1]) and non bridged (e.g., bicyclic or aza-spiro) piperidine analogues are less potent than the [3.2.1] bridged piperidines (<b>2</b>) on binding to γ-secretase. The particular potency improvement for the [3.2.1] bridged piperidine series compared to other replacements including the difluoro piperidines can be caused by a most favorable conformational change due to the repulsion between the bridge and the lone electron pair from the piperidine nitrogen that enforces an almost linear orientation of the two exit vectors from the piperidine, enabling an optimal binding to γ-secretase (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Conformational differences between compounds <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unfortunately, with respect to safety, compound <b>2</b> showed <i>in vitro</i> phototoxicity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) (cytotoxicity after UV irradiation (IC<sub>50</sub> UVA): 1.67 μM), which was confirmed also <i>in vivo</i>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vitro</i> phototoxicity of compound <b>2</b> measured with cells exposed to the compound in the presence (+Irr) or absence (−Irr) of UVA light. The phototoxic potential (indicated by high UVA absorption) is expressed through the use of the photoirritancy fFactor (PIF) by comparing the IC<sub>50</sub> +Irr to the IC<sub>50</sub> −Irr. PIF > 5 indicates phototoxicity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We realized that, in addition to compound <b>2</b>, compound <b>1</b> also has a phototoxicity safety risk due to the high UVA absorption. For this reason, we wanted to reduce the aromaticity, decreasing the phototoxic risk from the hyperconjugated system. In this regard, we successfully exchanged the terminal fluorinated phenyl ring with an alternative fluorinated alkoxy chain that behaves as a bioisosteric structural moiety.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> After evaluation of fluorinated alkoxy groups, trifluoroethoxy was the most suitable as a non cyclic bioisosteric replacement (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The increase of the sp3-hybridized carbon atom count has a positive impact on physicochemical properties, decreasing lipophilicity (increasing fup) and improving solubility and human metabolic stability while maintaining low P-glycoprotein efflux (compounds <b>2</b> and <b>5A</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Fluoro phenyl ring bioisostere. Reduced UV absorption, resulting in no phototoxicity risk.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Alkoxy Bioisosteric Replacement of the Phenyl Ring Affects Compound Properties</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center"><b>5A</b> (A = N)</th><th class="colsep0 rowsep0" align="center"><b>9A</b> (A = C)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human IC<sub>50</sub> Aβ42 total/free [nM]<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.5/1</td><td class="colsep0 rowsep0" align="left">21/12</td><td class="colsep0 rowsep0" align="left">4/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse IC<sub>50</sub> total/free [nM]</td><td class="colsep0 rowsep0" align="left">4/0.9</td><td class="colsep0 rowsep0" align="left">9/5</td><td class="colsep0 rowsep0" align="left">4/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>In vivo</i><u class="uu">remaining % Aβ42</u> @ 1–3–10 mg/kg p.o.</td><td class="colsep0 rowsep0" align="left">56–27–22</td><td class="colsep0 rowsep0" align="left">59–33–15</td><td class="colsep0 rowsep0" align="left">75–47–*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4.14</td><td class="colsep0 rowsep0" align="left">3.17</td><td class="colsep0 rowsep0" align="left">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility [μg/mL]<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">198</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">f.u. (h/m): [%]<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.4/0.3</td><td class="colsep0 rowsep0" align="left">2.8/ 10.1</td><td class="colsep0 rowsep0" align="left">1.7/1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl heps (h/m): [μL/min/M cells]<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">6.6/5.4</td><td class="colsep0 rowsep0" align="left">1.3/4</td><td class="colsep0 rowsep0" align="left">3.3/15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pgp h/m<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">1.59/1.72</td><td class="colsep0 rowsep0" align="left">1.3/1.5</td><td class="colsep0 rowsep0" align="left">1.0/1.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> UVA [μM]/PIF</td><td class="colsep0 rowsep0" align="left">1.67/23</td><td class="colsep0 rowsep0" align="left">443/ 1.1</td><td class="colsep0 rowsep0" align="left">>137/1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub>/IC<sub>20</sub> μM</td><td class="colsep0 rowsep0" align="left"><2/<1</td><td class="colsep0 rowsep0" align="left">>10/4.5</td><td class="colsep0 rowsep0" align="left">2.9/>0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> Aβ42 (measured in the cell assay at least in three independent experiments), and free IC<sub>50</sub> is calculated based on the measured fu in the cell assay media containing 10% FCS.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">log <i>D</i> = logarithm of the octanol–water distribution coefficient @ pH 7.4.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Solubility expressed in μg/mL and measured in the Lysa assay.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Measured % of the free fraction unbound in mice and humans.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Clearance in human hepatocytes expressed in μL/min/million cells.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Pgp efflux. *Not measured.</p></div></div></div><div class="NLM_p">Moreover, the reduced aromaticity (as illustrated by reduced UVA absorption) abolished phototoxicity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><div class="NLM_p">Further exchange of the heterocyclic head group influences the affinity at the target while maintaining the improvement on the mentioned properties (<b>5A</b> vs <b>9A</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">Compounds <b>5A</b> and <b>9A</b> have improved solubility, lipophilicity, and human metabolic stability and a higher fraction unbound in plasma compared with compound <b>2</b>. In addition, they do not have phototoxicity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) (IC<sub>50</sub> UVA > 100 μM, PIF < 5). Both compounds also have very good metabolic stability (low Cl in hepatocytes), low Pgp efflux, and high potencies as GSMs, in particular <b>9A</b> (with the isothiazole head group with hIC<sub>50</sub> Aβ42: 4 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The novel fluoro phenyl ring bioisostere offers promising <i>in vitro</i> activity, additionally better physicochemical properties, and an improved pharmacokinetic profile, which translates into a strong <i>in vivo</i> effect on Aβ42 reduction (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">We observed that, for the new alkoxy series, the potency was improved when the thiazole group was replaced by a more lipophilic isothiazole group (<b>5A</b>, <b>8A</b> vs <b>9A</b>, <b>10A</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). A certain size of the R<sub>1</sub> alkoxy chain is needed for potency (<b>4A</b> vs <b>5A</b>, <b>6A</b>, and <b>7A</b>). The shorter methoxy group (<b>3A</b>) was not a good bioisosteric replacement as it was less potent. The OCF<sub>3</sub> group (<b>4A</b>) was not better than the methoxy in terms of properties, and it was  also weakly potent compared with the trifluoromethyl alkoxy analogues (<b>5A</b> to <b>10A</b>). With the isothiazole instead of a thiazole as the heterocyclic R<sub>2</sub> head group, the lipophilicity increased and the solubility reduced (e.g., <b>5A</b> vs <b>9A</b> and <b>8A</b> vs <b>10A</b>). Further elongations of the fluorinated alkoxy chains O-R<sup>1</sup> with the isothiazole as a head group (e.g., as <b>7A</b>) are not interesting due to high lipophilicity (log <i>D</i> > 3.9) and very low solubility (solubility < 1 μg/mL). The addition of hydrophilic R<sub>1</sub> substitutions on the OR<sup>1</sup> alkoxy chain (such as the oxetane in <b>11A</b>) improves solubility; however, it tends to reduce the potency (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison between Different Alkoxy Replacements with Thiazole and Isothiazole Heterocyclic Head Groups</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0017.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0018.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Human IC<sub>50</sub> Aβ42 (measured in the cell assay at least in three independent experiments).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">log <i>D</i> = logarithm of the octanol–water distribution coefficient @ pH 7.4.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Solubility expressed in μg/mL and measured in the Lysa assay.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Measured % of the free fraction unbound in mice and humans.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Clearance in human hepatocytes expressed in μL/min/million cells.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last"><i>K</i><sub>d</sub> measured for PIK4CB phosphatidylinositol 4-kinase, catalytic β. *IC<sub>50</sub> values are suitable for structure–activity relationship (SAR) comparison with compounds exhibiting reliable fu plasma >0.5%.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Prevention of Kinase Inhibition</h3><div class="NLM_p">We realized that some of our more interesting lead candidates such as compounds <b>5A</b> and <b>9A</b> had side activities against PIK4CB (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). PIK4CB was previously implicated in hepatitis C virus (HCV) replication. However, <i>in vitro</i> profiling of inhibitor compounds revealed a role of this kinase in lymphocyte proliferation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, we also tested compound <b>2</b>, which showed PIK4CB binding Kd of 120 nM. Although for <b>9A</b> and even <b>5A</b> we were less concerned about reaching required selectivity due to their high <i>in vitro</i> potency as modulators, we needed to eliminate kinase selectivity concerns. We decided to analyze the binding mode for our compounds by docking compound <b>2</b> into the PIK4CB binding site. In fact, the core structure fits well into the ATP binding site and we observed a possible hinge binding by the aminotriazole moiety (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hinge binding to kinase PIK4CB from the amino-triazolo pyridine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the 5-(trifluoromethyl)-8-trifluoroethoxy 2-aminotriazolo pyridine analogue <b>9B</b>, we were able to prevent the binding at the unwanted kinase. We postulated using docking (for <b>9A</b> and <b>9B</b>) into the PIK4CB binding site, in that the additional 5-CF3 group disrupts the hinge binding of the aminotriazolo pyridine moiety. All 5-trifluoromethyl 8-alkoxy aminotriazole pyridine analogues (<b>9B)</b> showed high potency as GSMs and no detectable kinase activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Disruption of the hinge binding site by substitution on the 5-position of the 8-alkoxy aminotriazole pyridine ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>5A</b> and <b>9A</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) (with thiazole and isothiazole head groups) have excellent molecular properties for brain penetration including high solubility, acceptable lipophilicity, and good metabolic stability, together with high <i>in vitro</i> and <i>in vivo</i> potencies (compound <b>9A</b> showed <i>in vivo</i> 47% remaining Aβ42 @ 3 mg/Kg, and compound <b>5A</b> showed 33% remaining Aβ42; see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For this reason, they were chosen for further profiling including covalent binding studies with radiolabeled material as we knew there was a CVB liability for compounds <b>1</b> and <b>2</b>, with a thiazole as a heterocyclic head group. Compound <b>5A</b> showed only borderline covalent binding CVB: 30 (pmoL/mg protein). Compound <b>9A</b> with the isothiazole as a head group showed higher reactivity (CVB: 96 (pmoL/mg protein)). For these two particular analogues, we were less concerned due to the significant <i>in vitro</i> potency (hIC<sub>50</sub> Aβ42 [nM] <b>5A</b>: 21 nM (total), 12 nM (free); hIC<sub>50</sub> Aβ42 [nM] <b>9A</b>: 4 nM (total), 3 nM (free)) including promising pharmacokinetics with acceptable free exposures that translated into a high <i>in vivo</i> efficacy (>50% Aβ42 reduction at 3 and 10 mg/kg p.o. as indicated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Moreover, the CVB liability is related to the efficacious human dose (which is related to potency and the fraction unbound), with compounds having <10–20 mg/Kg human dose of being no concern.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> However, it seemed likely that the undesirable compound bioactivation via the formation of GSH adducts was due to the formation of reactive metabolites through a reaction at the thiadiazole and isothiazole heterocyclic rings (paper studying the mechanism under preparation). Therefore, as we wanted to have advanced candidates without a CVB flag, we explored new heterocyclic “head” groups with lower lipophilicity and lower reactivity, compared to the thiazole and isothiazole rings.</div><div class="NLM_p">We used the 8-alkoxy-2-aminotriazolo pyridine core-substituted and the non substituted derivative with a CF<sub>3</sub> group at position 5 (cores <b>A</b> and <b>B</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<b>R</b><sub><b>2</b></sub>: explored selection of heterocycles in the order of hydrophobicity.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Explored thiazole and isothiazole heterocyclic replacements according to decreasing lipophilicity (or hydrophobicity) for cores <b>A</b> and <b>B</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analogues of compound <b>9A</b> using the most hydrophilic heteroaromatic replacements such as 1,3,4 or 1,2,4 oxadiazoles (<b>12A</b> and <b>14A</b>) lost potency (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). However, they did not have a CVB flag. We observed that when we increased the compound lipophilicity with heterocyclic head rings such as pyridine or pyrimidine devoid of CVB safety liability, we increased <i>in vitro</i> potency (<b>13A</b>). By replacing the isothiazole <b>9A</b> for more hydrophilic heterocyclic rings R<sub>2</sub> (<b>12A</b>, <b>14A</b>), we needed to balance again the compound potency by modifications on the bioisosteric replacement (<b>15A</b> vs <b>12A</b>). By introducing more hydrophobic head groups (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), we improved potency (<b>13A</b> or <b>16A</b> vs <b>12A</b> or <b>15A</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), to the detriment of solubility and lipophilicity. In this regard, we revisited a diverse combination of heterocyclic rings R<sub>2</sub> and aminotriazole pyridine alkoxy substitutions OR<sub>1</sub> for the different cores A or B type, to rebalance the compound properties and achieve desired potency ranges. A selection of key representative analogues is shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. For compounds with core type B, more hydrophilic head groups are admitted (<b>12B</b>, <b>14B</b> vs <b>12A</b>, <b>14A</b>), with solubility and lipophilicity maintained in very good ranges. To our satisfaction, all compounds without thiazole and isothiazole as heterocyclic head groups were devoid of a CVB flag.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Assessment of Key Heterocyclic Head Rings R<sub>2</sub> and Fluorinated Phenyl Ring Bioisosteric Replacements OR<sub>1</sub> for the Different Cores A or B Type</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0020.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">As we postulated, with the 5-trifluoromethyl 8-alkoxy aminotriazole pyridine core <b>B</b> analogues, we obtained the desired kinase selectivity. In addition, we maintained high potencies and acceptable compound lipophilicity, using the most hydrophilic heterocyclic head groups R<sub>2</sub> such as the oxadiazoles (<b>12B</b>, <b>14B</b>, <b>18B</b>) and the pyrimidine (<b>17B</b>) that are beneficial for solubility, do not have CVB, and offer a good metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">Three compounds <b>12B</b>, <b>17B</b>, and <b>18B</b> with good overall properties and acceptable <i>in vitro</i> total/free IC<sub>50</sub> were selected for further characterization (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Finally, compound <b>18B</b>, was selected as a promising candidate for minitox studies in rats. The three compounds and in particular <b>18B</b> with a lower hERG IC<sub>50</sub> do not have any safety flags, and they show a very promising <i>in vitro</i> profile.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Profile of Selected Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0021.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><b>12B</b> (RO7077068)</th><th class="colsep0 rowsep0" align="center"><b>17B</b> (RO7103286)</th><th class="colsep0 rowsep0" align="center"><b>18B</b> (RO7101556)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">h IC<sub>50</sub> Aβ42 total/free [nM]</td><td class="colsep0 rowsep0" align="left">33 (free 21)</td><td class="colsep0 rowsep0" align="left">21 (free 12)</td><td class="colsep0 rowsep0" align="left">30 (free 19)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse IC<sub>50</sub> total/free [nM]</td><td class="colsep0 rowsep0" align="left">20 (free 12)</td><td class="colsep0 rowsep0" align="left">11 (free 7)</td><td class="colsep0 rowsep0" align="left">21 (free 14)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">h notch IC<sub>50</sub>: [nM]</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PIK4CB <i>K</i><sub>d</sub> [μM]</td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility [μg/mL]</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i></td><td class="colsep0 rowsep0" align="left">3.79</td><td class="colsep0 rowsep0" align="left">3.90</td><td class="colsep0 rowsep0" align="left">3.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Thesa/Fassif/Fessif (mg/mL)</td><td class="colsep0 rowsep0" align="left">5, 12, 92</td><td class="colsep0 rowsep0" align="left">3, 13, 466</td><td class="colsep0 rowsep0" align="left">85, 234, 390</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pgp ER (h/m):</td><td class="colsep0 rowsep0" align="left">1.43/1.62</td><td class="colsep0 rowsep0" align="left">2.08/3.92</td><td class="colsep0 rowsep0" align="left">1.75/2.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">f.u. (h/r/m): [%]</td><td class="colsep0 rowsep0" align="left">1.7/4.6/3.1</td><td class="colsep0 rowsep0" align="left">2.8/1.0/ 1.7</td><td class="colsep0 rowsep0" align="left">5.0/5.9/4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl heps (h/r/m): [μL/min/M cells]</td><td class="colsep0 rowsep0" align="left">1/6.9/8.5</td><td class="colsep0 rowsep0" align="left">2.3/5.8/9.4</td><td class="colsep0 rowsep0" align="left">1.1/6.3/3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>20</sub>/IC<sub>50</sub> [μM]</td><td class="colsep0 rowsep0" align="left">3.5/8.75</td><td class="colsep0 rowsep0" align="left">1.4/4.5</td><td class="colsep0 rowsep0" align="left">5.4/>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Phototox IC50 UVA [μM]</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSH (CVB potential)</td><td class="colsep0 rowsep0" align="left">clean</td><td class="colsep0 rowsep0" align="left">clean</td><td class="colsep0 rowsep0" align="left">clean</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ames/MNT</td><td class="colsep0 rowsep0" align="left">clean/clean</td><td class="colsep0 rowsep0" align="left">clean/clean</td><td class="colsep0 rowsep0" align="left">clean/clean</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSH</td><td class="colsep0 rowsep0" align="left">clean</td><td class="colsep0 rowsep0" align="left">clean</td><td class="colsep0 rowsep0" align="left">clean</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EST</td><td class="colsep0 rowsep0" align="left">no flag</td><td class="colsep0 rowsep0" align="left">no flag</td><td class="colsep0 rowsep0" align="left">no flag</td></tr></tbody></table></div></div><div class="NLM_p">We evaluated <b>18B</b> in a pharmacodynamic (PD) mice model to determine its efficacy using the double transgenic APP-Swedish mice. The compound was administered orally at single doses of 10 and 20 mg/Kg, which led to strong effects on Aβ<sub>42</sub> reduction (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, with Aβ42% control in the graphic) in a time- and dose-dependent manner. An <i>in vivo</i> IC<sub>50</sub> of 40 nM was determined, fitting the time course of exposures and the Aβ42 levels (turnover model).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Time course effect of <b>18B</b> on Aβ42 reduction (expressed as % of control) in APP-swe tg mice. Dose- and time-dependent effect.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a single-dose pharmacokinetic study (SDPK) in rodents and minipig (species considered for minitox), <b>18B</b> shows acceptable oral bioavailability (F% = 33%) and good profile (such as low clearance and suitable half-life) for a single daily dose oral administration with a promising prediction (low clearance) in humans (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The detailed outcome of the minitox studies will be the subject of a dedicated subsequent paper.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vivo</i> SDPK Profile of RO7101556 (<b>18B</b>) in Rat/Minipigs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center">rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">minipigs<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AUC</b><sub><b>inf_D</b></sub> (po) (h*kg*ng/mL/mg)</td><td class="colsep0 rowsep0" align="left">1748</td><td class="colsep0 rowsep0" align="left">1383</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Cl</b> (iv) (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">3.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">terminal <i><b>t</b></i><sub><b>1/2</b></sub> (iv) (h)</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b><i>V</i><sub>ss</sub></b> (iv) (l/kg)</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">0.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i><b>F</b></i> (%)</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">27</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IV (bolus) 1 mg/kg and PO (gavage) 2 mg/kg; <i>n</i><i>=</i> 2/group (M); sampling over 24 h.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">IV (bolus) 1 mg/kg and PO (gavage) 3 mg/kg; <i>n</i><i>=</i> 3/group (M); sampling over 240 h.</p></div></div></div><div class="NLM_p">With respect to the mode of action, <b>18B</b> behaves as a potent GSM, decreasing the amount of large Aβ40/42 peptides prone to aggregation and increasing the ratio of the shorter Aβ38 peptide, which, as mentioned, are thought to be protective against the formation of aggregates. Furthermore, we confirmed that <b>18B</b> behaves as a GSM, having a clear differentiation with respect to GSIs as it does not inhibit the Notch pathway (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Mechanism of the action of <b>18B</b> as a GSM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Chemistry</h3><div class="NLM_p">To determine the influence of different fluorinated alkoxy chains OR<sup>1</sup> as phenyl ring bioisosteres (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), we explored final alkylation of an advanced common intermediate (<b>24</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Initially, for most alkoxy bioisosteric replacements. we could introduce the R<sup>1</sup> group at the beginning of the synthesis via SN<sub>2</sub> alkylation or the Mitsunobu reaction to produce (<b>20</b>), followed by the Bechamp reduction of a nitro alkoxy compound using, e.g., Fe and HCl or through hydrogenation with a Pd/C catalyst and H<sub>2</sub> to obtain the amine <b>21</b>. However, for upscaling and exploration of diverse OR1 alkoxy chains, we decided to use a modular synthesis (with OR1a = OCH<sub>3</sub>), starting with commercially available <b>20</b> and using methyl ether as a protecting group that could be removed from a common precursor (<b>23-1</b>), to prepare a variety of alkoxy analogues via alkylation of the advanced intermediate <b>24</b>. These alternatives provides an accessible route to a big range of alkoxy triazolo pyridine analogues. For OR1═OCH<sub>3</sub>, OCF<sub>3</sub>, the reaction between amine <b>21</b> (commercially available) and ethoxy carbonyl isothiocyanate, gave a suitable precursor <b>21a</b> for the synthesis of a 1,2,4-triazole (<b>22</b>) via cyclization through a concerted mechanism with the elimination of CO<sub>2</sub> using ammonia as the nitrogen source in the presence of a base such as diisopropylethylamine.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The Sandmeyer reaction was used to transform the aminotriazole <b>22</b> into a bromotriazole (<b>23</b>). Removal of the methyl group using BBr<sub>3</sub> from <b>23-1</b> gives access to the free bromo triazolo alcohol intermediate <b>24</b>, which was alkylated to give a large range of fluoro alkoxy intermediates, allowing the exploration of diverse bioisosteric replacements, <b>25-3 to 25-8</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Alternatively, the thiazole, isothiazole (<b>26, 28</b>), or a different heterocyclic BOC-protected amino-bridged piperidine (<b>30, 32, 34, 36, 38</b>; <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was prepared via alkylation, a reaction with the intermediate 4-methyl-6-thioxo-3,6-dihydro-2<i>H</i>-1,3-thiazin-2-one, or via Pd- or Cu-catalyzed couplings with the iodo, chloro, or bromo heterocycles and the BOC-protected amino-bridged piperidine (commercially available CAS 847862-26-4, or initially prepared as outlined in our patent<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>). After BOC removal under acidic conditions, the second intermediate <b>II</b> was obtained (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Cores <b>23</b>, <b>25</b> (Intermediate <b>IA</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Fe/HCl, EtOH, 90 °C, overnight, 60%; (b) EtO<sub>2</sub>CNCS (1.1 equiv), dioxane, 3 h, room temperature (r.t.), 96% (21a-1), 105% (21a-2); (c) NH<sub>2</sub>OH·HCl (5 equiv), <i>i</i>-Pr<sub>2</sub>NEt (3 equiv), MeOH/EtOH (1/1), room temperature to 60 °C, 4 h, 98.2% (22-1), 77.4% (22-2); (d) <i>tert</i>-butyl nitrite (1.5 equiv), CuBr<sub>2</sub> (1.5 equiv), acetonitrile, 75 °C, 2 h, 62% (23-1), 77.3% (23-2); (e) BBr<sub>3</sub> (5.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0–60 °C, 81%; (f) R<sup>1</sup>I (1–2 equiv), K<sub>2</sub>CO<sub>3</sub> (2–3 equiv), <i>N</i>,<i>N</i>-dimethylformamide (DMF), 120 °C, overnight, 77.4% (25-3), 90.3% (25-4), 86.8% (25-5), 39.6% (25-7), 90.1% (25-8) or 1,1,1-trifluoropropan-2-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate (1.5 equiv), K<sub>2</sub>CO<sub>3</sub> (2 equiv), DMF, 120 °C, overnight, 53.4% (25-6).</p></p></figure><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Heterocyclic Bridged Amino Piperidines (Intermediates <b>II</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-chloro-3-methyl-1,2,4-thiadiazole (1.2 equiv), Et<sub>3</sub>N (5 equiv), EtOH, 80 °C, overnight, 92%; (b) trifluoroacetic acid (TFA, 10 equiv), CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 94% (27) or HCl (10 equiv), r.t., 2 h, 55.3% (29); (c) (i) 4-methyl-6-thioxo-3,6-dihydro-2<i>H</i>-1,3-thiazin-2-one (1 equiv), 4-methylmorpholine (3 equiv), 4-dimethylaminopyridine (0.01 equiv), dioxane, 80 °C, overnight, (ii) <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 4 equiv), I<sub>2</sub> (2 equiv) in dioxane, from 0 °C to r.t overnight, 72%; (d) BrCN (1.4 equiv), Na<sub>2</sub>CO<sub>3</sub> (1.4 equiv), EtOH, 2 h, r.t. to 50 °C overnight, 92.5%; (e) (<i>z</i>)-<i>N</i>′-hydroxyacetimidamide (1 equiv), ZnCl (1.2 equiv), EtOH then HCl (3 equiv), 60 °C, 7 h, 97%; (f) 4-chloro-2-(trifluoromethyl)pyridine (1 equiv), Pd(II)OAc (0.08 equiv), Na<sup>t</sup>BuO (1.5 equiv), Hunig′s base (2 equiv), 2-(dicyclohexylphosphino)biphenyl (0.16 equiv), dioxane, microwave 140 °C, 45 min, 36.3% (32) or 5-iodo-3-methylisoxazole (1.2 equiv), CuI (0.1 equiv), K<sub>3</sub>PO<sub>4</sub> (2 equiv), <i>N</i>,<i>N</i>-diethylsalicymide (0.3 equiv), DMF, −5 °C, 6 h, 22% (36); (g) 2-bromo-5-methyl-1,3,4-oxadiazole (2 equiv), Et<sub>3</sub>N (4 equiv), EtOH, 130 °C, overnight, 68.1% (34) or 4-chloro-6- methylpyrimidine (1.2 equiv), Et<sub>3</sub>N (4 equiv), EtOH, 100 °C, overnight, 99% (38); (h) HCl (6 or 10 equiv), CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 91.9% (33), 80% (37), 94.2% (39) or TFA (10 equiv) CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 80.2% (35).</p></p></figure><div class="NLM_p">Buchwald–Hartwig coupling of the corresponding 2-bromo-[1,2,4]triazolo, 8-alkoxy pyridine intermediates <b>IA</b> (or cores <b>23</b>, <b>25</b>) with the heterocyclic amino-bridged piperidines (intermediates <b>II</b>) gave the final compounds <b>3A–16A</b> in high yield (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Final Coupling Step for Intermediates <b>IA</b> and <b>II</b> for Compounds <b>3A</b>–<b>16A</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) intermediate <b>II</b> (1 equiv), sodium phenoxide (1.1–1.6 equiv) or NaOtBu (3 equiv), xantphos (0.16 equiv), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.08 equiv), dioxane, 130–145 °C, 45–60 min in microwave, 54% (3A), 80.6% (4A), 66.9% (5A), 51.9% (6A), 63% (7A), 80,1% (8A), 60.6% (9A), 65.3% (10A), 81.2% (11A), 59.8% (13A), 63.4% (14A) or intermediate <b>II</b> (1.1 equiv), NaOtBu (2.05 equiv), bromo-(tri-<i>tert</i>-butyl)-phosphine-palladium(I) dimer (0.15 equiv), dioxane, 110–120 °C, 1–2 h, 43% (12A), 11% (15A), 27.3% (16A).</p></p></figure><div class="NLM_p">2-Bromo-5-substituted-8-alkoxy triazolo pyridine cores (intermediates <b>IB</b> from compounds <b>9B</b>, <b>12B</b>, <b>14B</b>, <b>17B</b>, and <b>18B</b>) can be prepared as described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> from 3-bromo-(trifluoromethyl)pyridin-2-amine <b>41</b> by following similar synthetic steps as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>41</b> is obtained by bromination of the 6-(trifluoromethyl) pyridin-2-amine precursor <b>40</b>. The intermediate 8-bromo-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>43</b>) undergoes Ullmann coupling with a range of OR<sub>1</sub> groups to produce several alkoxy derivatives (<b>44-1</b>, <b>44-2</b>, and <b>44-3</b>). The Sandmeyer reaction provides the 2-bromo-5-substituted-8 alkoxy triazolo-pyridine in high yields (<b>45</b>).</div><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Core B (Intermediates <b>IB</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Br<sub>2</sub> (1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, room temperature, overnight, 44%; (b) EtO<sub>2</sub>CNCS (1.1 equiv), dioxane, 100 °C, 5 h, 76.3%; (c) NH<sub>2</sub>OH·HCl (5 equiv), <i>i</i>-Pr<sub>2</sub>NEt (3 equiv), MeOH/EtOH (1/1), room temperature, 1 h to 60 °C, 3 h, 69.1%; (d) R<sup>1</sup>OH (1.5 equiv), NaH (1.3 equiv), CuBr (0.01 equiv), DMF, 155 °C, 4 h, 61.2% (44-1), 65.5% (44-2), 75.2% (44-3); (e) <i>tert</i>-butyl nitrite (1.5 equiv), CuBr<sub>2</sub> (1.5 equiv), acetonitrile, 60–75 °C, 6h, 82.9% (45-1), 85.5% (45-2), 89.6% (45-3).</p></p></figure><div class="NLM_p">Similarly, as described for the intermediate <b>IA</b>, Buchwald–Hartwig coupling of the corresponding intermediate <b>IB</b> (<b>45</b>) with the heterocyclic amino-bridged piperidines (intermediates <b>II</b> in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) gave access to compounds <b>9B</b>, <b>12B</b>, <b>14B</b>, <b>17B</b>, and <b>18B</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Final Coupling Step for Intermediates <b>IB</b> and <b>II</b> for <b>9B</b>, <b>12B</b>, <b>14B</b>, <b>17B</b>, and <b>18B</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) intermediate <b>II</b> (1.1 equiv), NaOtBu (2–3 equiv), xantphos (0.16 equiv), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.08 equiv), 125–145 °C, 30 min in microwave, 47.1% (9B), 69% (14B), 59.2% (17B), 60.1% (18B) or intermediate <b>II</b> (1.1 equiv), NaOtBu (2.05 equiv), bromo-(tri-<i>tert</i>-butyl)-phosphine-palladium(I) dimer (0.15 equiv), dioxane, 110 °C, 1 h, 54% (12B).</p></p></figure><div class="NLM_p last">The enantiomerically pure compounds, such as compound <b>18B</b>, could be obtained from the racemic precursor by chromatographic separation using a chiral column. The absolute configuration of the different enantiomers was determined using the chiral alkylating agents (step d, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) to obtain the intermediate <b>44</b> as a single enantiomer and comparing it with the different enantiomers obtained from chiral separation.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60002" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60002" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Identification of compound <b>18B</b>, an advanced GSM modulator with promising <i>in vitro</i> and <i>in vivo profiles</i>, is described starting from RO6800020 (<b>1</b>), our former lead compound. We applied sequential structural changes to RO6800020, starting on the central piperidine ring, to improve potency and increase efficacy. Also, we reduced the idiosyncratic toxicity risk window by reducing the predicted human dose, increasing potency, and balancing the free fraction. The exchange of a phenyl ring by a nonclassical alkoxy bioisosteric replacement has an enormous impact on phototoxicity and key molecular properties such as solubility and lipophilicity while maintaining potency, low Pgp efflux, and metabolic stability. The CF<sub>3</sub> alkoxy bioisosteric replacement of the phenyl ring dramatically affects the compound properties. In addition, small modifications on the fluoro alkoxy group allowed further balancing of potency and properties.</div><div class="NLM_p">A judicious structural modification introducing a 5-substituent on the core with the alkoxy bioisosteric replacement on the 8-position avoided hinge binding to PIK4CB, which improved selectivity. This modification, in combination with small changes on the bioisosteric replacement, allowed the use of alternative less lipophilic head heterocycles devoid of any CVB liability while maintaining potency.</div><div class="NLM_p last">This work also highlights the main physicochemical and safety property changes induced by this novel bioisostere. The CF<sub>3</sub> alkoxy replacement of an aromatic ring was of critical importance in achieving the desired balance between target modulation and properties such as solubility, lipophilicity, fup, Pgp, and metabolic stability and also mitigated safety liabilities (phototoxicity, CVB).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">EXPERIMENTAL SECTION</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vitro</i> Cellular Aβ Secretion Assay</h3><div class="NLM_p">Human neuroglioma H4 cells stably overexpressing the human APP695 isoform with the Swedish double mutation (K595N/M596L) were plated at 30 000 cells/well/100 μL in 96-well plates in IMDM media containing 10% FCS and 0.2 mg/L Hygromycin B and incubated at 37 °C, 5% CO<sub>2</sub>. After 3 to 4 h of plating, test compounds were diluted in culture media and 50 μL was added to the wells as a 1.5-fold concentrate to achieve the final concentration. Compound incubation was performed for 24 h. Final doses typically ranged from 4 μM down to 0.0013 μM in half-log steps, resulting in an eight-point dose–response curve. Appropriate controls using only the vehicle and reference compounds were applied to this assay. The final concentration of Me<sub>2</sub>SO was 0.4%.</div><div class="NLM_p">After incubation at 37 °C, 5% CO<sub>2</sub>, the supernatant was subjected to quantification of secreted Aβ peptides by the means of an AlphaLisa assay kits (Perkin Elmer). The cell culture supernatant (20 μL) was transferred to an assay plate. Then, 10 μL of a mixture of the AlphaLisa-coupled capture antibody and the biotinylated detection antibody was added and incubated for 3 h at room temperature while softly shaking the assay plate. After a further addition of 20 μL of the donor beads, the assay plate was incubated for 30 min at room temperature and with constant shaking without exposure to direct light. The assay plate was then read on a Paradigm AlphaLisa Reader using the build-in program with excitation at 680 nm and emission at 570 nm.</div><div class="NLM_p last">The measured signals were then used to calculate IC<sub>50</sub> values for inhibition of Aβ peptide secretion by the nonlinear regression fit analysis using the XLfit 5.3 software (IDBS).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Notch Cellular Reporter Assay</h3><div class="NLM_p last">The cellular Notch reporter assay used a stably transfected HEK293 cell line expressing the human Notch1 and luciferase reporter. Briefly, the cells were seeded in 96-well microtiter plates in cell culture medium (Iscove’s modified Dulbecco’s medium without phenol red, with 10% (v/v) fetal bovine serum) to about 80% confluency and the compounds were added at a 10× concentration in 1/10 volume of medium without FCS containing 8% dimethyl sulfoxide (DMSO) (the final concentration of DMSO was kept at 0.8% v/v). After 20 h incubation at 37 °C and 5% CO<sub>2</sub> in a humidified incubator, the microtiter plates were allowed to equilibrate to room temperature. SteadyGlo Mix (Promega, 45 μL) was added and incubated another for 20 min at room temperature. Chemoluminescence was measured in a SpectraMax Paradigm Multi-Mode Microplate Reader using a glow luminescence cartridge (Molecular Devices).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Animals and Housing Conditions</h3><div class="NLM_p last">Animals were group-housed in holding rooms at controlled temperature (20–22 °C) and humidity (55–65%) and under a 12 h light/dark cycle (lights on 0600 h). All animals were allowed ad libitum access to food and water. The experimental procedures used in this investigation received prior approval from the City of Basel Cantonal Animal Protection Committee based on adherence to federal and local regulations.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Acute Treatment of APP-Swe Transgenic Mice</h3><div class="NLM_p last">APP-Swe transgenic mice aged 2–4 months were acutely treated with different doses as indicated with group sizes ranging from 3 to 6 animals. Test compounds were applied per os once in the morning. After 4 h of dosing, animals were sacrificed and brain samples were collected. The brain tissue, one hemisphere without cerebellum, was homogenized in 1% DEA buffer (in 50 mM NaCl, 10 μL per mg brain) in a FastPrep (Bio101, Savant) with 20 s pulse at a speed of 5000 rpm in the presence of protease inhibitors and incubated for 5 h on ice. The raw extract was centrifuged for 45 min at 100 000<i>g</i>, and the supernatant was collected and stored at −80 °C for further processing. Aβ peptides were quantified in all brain samples using AlphaLISA (Perkin Elmer) or an ELISA kit (Wako), following the manufacturer’s instructions.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Docking procedure</h3><div class="NLM_p last">Compounds <b>2</b>, <b>9A</b>, and <b>9B</b> were docked into the binding pocket of PIK4CB (pdb code: 4D0L) by Gold (V5.3) with default parameters. For each molecule, 10 best docking poses were generated. After the analysis of these 10 docking poses of each molecule, the binding pose of the molecule with a reasonable conformation and a best fit to the binding pocket (judged by the modeler) were picked. the same docking procedure was used for the three compounds (pdb file provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_002.pdb" class="ext-link">Supporting Information</a>)</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Compound Synthesis and Characterization. Chemistry</h3><div class="NLM_p last">All compounds in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> are described below. Reactions were carried out under an argon atmosphere. Unless otherwise stated, the reactions were stopped when the starting material was fully consumed according to thin-layer chromatography (TLC). The solvent was then removed, and the residue was purified by column chromatography. Unless otherwise mentioned, all reagents and chemicals were obtained from commercial suppliers and used without further purification. The purity of final compounds as measured by high-performance liquid chromatography (HPLC) was at least above 95%. Column chromatography was carried out either using cartridges packed with silica gel (Isolute Columns, Telos Flash Columns) or on glass columns on silica gel 60 (32–60 mesh, 60 Å) with the eluent mixtures given for the corresponding procedures. LC high-resolution spectra were recorded with a Agilent LC system consisting of an Agilent 1290 high-pressure system, a CTC PAL auto sampler, and an Agilent 6520 QTOF. The separation was achieved on a Zorbax Eclipse Plus C18, 1.7 μm, 2.1 mm × 50 mm column at 55 °C; A = 0.01% formic acid in water; B = 0.01% formic acid in acetonitrile at a flow rate of 1 mL/min. gradient: 0 min, 5% B; 0.3 min, 5% B; 4.5 min 99% B; 5 min, 99% B. The NMR spectra were recored on a Bruker 600 MHz machine in a 5 mm TCI cryoprobe at 298 K. TMS was used for referencing. Chemical shifts are reported relative to the solvent in ppm as a reference. Coupling constants (J) are given in Hz. The resonance multiplicity is described as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), spt (septuplet), and br (broad).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Preparation of Compounds <b>3A</b> and <b>4A</b></h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Bromo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>23-1</b>, with OR1a = OMe) (Intermediate <b>IA</b>)</h4><div id="sec4_7_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Ethyl <i>N</i>-[(3-Methoxypyridin-2-yl)carbamothioyl]carbamate (<b>21a-1</b>)</h5><div class="NLM_p last">To a stirred solution of 3-methoxypyridin-2-amine (<b>21</b> with OR1a = OMe) (8 g, 64.4 mmol) in 1,4-dioxane (120 mL) was added ethoxycarbonyl Isothiocyanate (8.45 g, 7.29 mL, 64.4 mmol), and the reaction mixture was stirred 4 h. The solvent was evaporated under vacuum to yield the title compound (15.82 g, 96%) as a light yellow solid. The compound was used as crude in the next step. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.60 (br s, 1H), 11.10 (br s, 1H), 8.01 (dd, <i>J</i> = 4.7, 1.4 Hz, 1H), 7.54 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 7.33 (dd, <i>J</i> = 8.2, 4.7 Hz, 1H), 4.21 (q, <i>J</i> = 7.1 Hz, 2H), 3.84 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>13</sub> N<sub>3</sub> O<sub>3</sub> S: 256.0751, found: 256.0749, diff −0.2 mDa.</div></div><div id="sec4_7_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 8-Methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>22-1</b>, with OR1a = OMe)</h5><div class="NLM_p last">Hydroxylamine hydrochloride (21.5 g, 310 mmol) and Hunig’s base (24 g, 32.4 mL, 186 mmol) were dissolved in a mixture of MeOH (105 mL) and EtOH (105 mL). Ethyl <i>N</i>-[(3-methoxypyridin-2-yl)carbamothioyl]carbamate (<b>21a-1</b>) (15.81 g, 61.9 mmol, 1 equiv) was added, and the mixture was allowed to stir for 3 h at 60 °C. The reaction mixture was poured into 600 mL of saturated NaHCO<sub>3</sub> and extracted with dichloromethane (5 × 650 mL). The combined organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel (0–100% EtOAc in heptane, 9:1 DCM:MeOH) to yield 9.99 g (98.2%) of the title compound as a white solid. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 7.96 (dd, 1H, <i>J</i> = 5.3, 2.3 Hz), 6.7–6.7 (m, 2H), 4.43 (br s, 2H), 4.00 (s, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>7</sub> H<sub>8</sub> N<sub>4</sub> O: 165.0771, found: 165.0766, diff −0.5 mDa.</div></div><div id="sec4_7_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 2-Bromo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>23-1</b>, with OR1a = OMe)</h5><div class="NLM_p last">Copper(II) bromide (14.3 g, 64 mmol) and <i>tert</i>-butyl nitrite (6.6 g, 7.63 mL, 64 mmol) were dissolved in acetonitrile (280 mL), and the reaction mixture was heated to 60 °C. 8-Methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (7 g, 42.6 mmol) was added portion wise for 30 min, and the reaction mixture was stirred for 4 h at 60 °C. The reaction mixture was poured into 350 mL of 1 M HCl and extracted with dichloromethane (3 × 400 mL). The organic layers were dried over MgSO<sub>4</sub> and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel (solid application) (0–100% EtOAc in heptane) to yield 6.06 g (62%) of the title compound as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.10 (dd, <i>J</i> = 6.8, 0.9 Hz, 1H), 6.91–6.86 (m, 1H), 6.76 (br d, <i>J</i> = 8.1 Hz, 1H), 3.98 (s, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>7</sub> H<sub>6</sub> Br N<sub>3</sub> O: 227.9767, found: 227.9763, diff −0.4 mDa.</div></div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Preparation of Intermediate <b>II</b> (<b>27</b>)</h4><div id="sec4_7_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> <i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (<b>26</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (750 mg, 3.31 mmol) (CAS number 847862-26-4) was dissolved in ethanol (10 mL) and triethylamine (503 mg, 693 μL, 4.97 mmol, 1.5 equiv) was added, followed by 5-chloro-3-methyl-1,2,4-thiadiazole (535 mg, 395 μL, 3.98 mmol, 1.2 equiv). The reaction mixture was stirred overnight at 80 °C. The crude reaction mixture was concentrated under reduced pressure. The crude material was purified by flash chromatography (silica gel, 30–70% EtOAc in heptane) to afford the title compound as a solid (991 mg, 92% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.43 (br s, 1H), 3.7–3.8 (m, 1H), 3.64 (dd, <i>J</i> = 12.4, 3.3 Hz, 2H), 3.30 (br d, <i>J</i> = 11.9 Hz, 2H), 2.57 (s, 3H), 2.3–2.4 (m, 2H), 1.8–1.9 (m, 2H), 1.6–1.7 (m, 2H), 1.46 (s, 9H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>15</sub> H<sub>24</sub> N<sub>4</sub> O<sub>2</sub> S: 325.1693, found: 325.1693, diff 0.0 mDa.</div></div><div id="sec4_7_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>27</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)carbamate (990 mg, 3.05 mmol, 1 equiv) was disolved in dichloromethane (30 mL) and TFA (3.48 g, 2.35 mL, 30.5 mmol, 10 equiv) was added. The reaction mixture was stirred at room temp overnight. Saturated aqueous NaHCO<sub>3</sub> was added, and the aqueous phase was extracted with DCM. The organic layers were dried over MgSO<sub>4</sub> and concentrated to obtain without further purification the title compound as a white solid (644 mg, 2.87 mmol, 94% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 3.53 (dd, <i>J</i> = 11.5, 3.2 Hz, 2H), 3.26 (br d, <i>J</i> = 11.5 Hz, 2H), 3.15 (br s, 1H), 2.85 (br s, 2H, NH<sub>2</sub>), 2.28 (s, 3H), 2.08–2.06 (m, 2H), 1.98–1.96 (m, 2H), 1.44–1.39 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>16</sub> N<sub>4</sub> S: 225.1169, found: 225.1166, diff −0.3 mDa.</div></div><div id="sec4_7_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 8-Methoxy-<i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>3A</b>)</h5><div class="NLM_p last">General procedure A: (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine <b>27</b> (<b>intermediate II</b>) (40.3 mg, 180 μmol, 1 equiv) was disolved in dioxane (2 mL) in a microwawe flask. 2-Bromo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridine <b>23-1</b> (<b>intermediate IA</b>) (41 mg, 180 μmol, 1 equiv), sodium phenoxide (23 mg, 198 μmol, 1.1 equiv), and xantphos (16.6 mg, 28.8 μmol, 0.16 equiv) were added under an argon purge for 5 min. Tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (14.9 mg, 14.4 μmol, 0.08 equiv) was added afterward and the reaction mixture was heated to 130 °C in a microwawe for 45 min. The solvent was removed under vacuum and the crude material was purified by flash chromatography (silica gel, 0–100% EtOAc in heptane, followed by DCM/MeOH 9:1) to yield compound <b>3A</b> (40 mg, 54% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.14 (dd, <i>J</i> = 6.6, 1.0 Hz, 1H), 6.91 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 6.77 (dd, <i>J</i> = 7.9, 6.6 Hz, 1H,), 5.95 (br s, 1H), 3.98 (s, 3H), 3.89 (br s, 1H), 3.64 (dd, <i>J</i> = 11.8, 3.3, Hz, 2H), 3.42 (br d, <i>J</i> = 11.8 Hz, 2H), 2.6–2.5 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 2H), 1.53–1.48 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub> H<sub>21</sub> N<sub>7</sub> O S: 372.1601, found: 372.1599, diff −0.2 mDa.</div></div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Bromo-8-(trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine as intermediate <b>IA</b> (23-2 with R1a = OCF<sub>3</sub>)</h4><div id="sec4_7_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Ethyl <i>N</i>-[(3-Trifluoromethoxypyridin-2-yl)carbamothioyl]carbamate (<b>21a-2</b> with R1a = OCF<sub>3</sub>)</h5><div class="NLM_p last">The compound was prepared following the procedure described for the synthesis of <b>21a-1</b> with OR1a = OMe, using 3-(trifluoromethoxy)pyridin-2-amine (500 mg, 2.81 mmol) (<b>21-2</b> with OR1a = OCF<sub>3</sub>) and ethoxycarbonyl isothiocyanate (73.6 mg, 66.3 μL, 561 μmol) in 1,4-dioxane. The title compound (909 mg, 2.94 mmol, 105% yield) was used directly in the next step as crude. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 8.41 (br s, 1H), 7.7–7.6 (m, 2H), 4.33 (q, <i>J</i> = 7.13 Hz, 2H), 1.36 (t, <i>J</i> = 7.13 Hz, 3H) (NH is not visible).</div></div><div id="sec4_7_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 8-(Trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>22-2</b> with R1a = OCF<sub>3</sub>)</h5><div class="NLM_p last">Hydroxylamine hydrochloride (910 mg, 13.1 mmol) and Hunig’s base (1.02 g, 1.37 mL, 7.86 mmol) in MeOH (10 mL) and ethanol (10.0 mL) were used to synthesize <b>22-2</b> with R1a = OCF<sub>3</sub>, following a similar procedure as described for <b>22-1</b> with OR1a = OMe. After chromatography, the final compound was obtained as a liquid (442 mg, 2.03 mmol, 77.4% yield). <sup>1</sup>HNMR (CDCl<sub>3</sub>, 300 MHz) δ 8.27 (dd, <i>J</i> = 6.8, 0.9 Hz, 1H), 7.32 (br d, <i>J</i> = 7.9 Hz, 1H), 6.81 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H), 4.66 (br s, 2H, NH<sub>2</sub>); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>7</sub> H<sub>5</sub> F<sub>3</sub> N<sub>4</sub> O: 219.0488, found: 219.0482, diff −0.6 mDa.</div></div><div id="sec4_7_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 2-Bromo-8-(trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>23-2</b> with R1a = OCF<sub>3</sub>)</h5><div class="NLM_p last"><i>tert</i>-Butyl nitrite (280 mg, 324 μL, 2.72 mmol, 1.5 equiv), copper(II) bromide (607 mg, 2.72 mmol, 1.5 equiv), and 8-(trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (395 mg, 1.81 mmol, 1.00 equiv) in acetonitrile (20 mL) at 60 °C were used to synthesize <b>23</b> with OCF<sub>3</sub>, following a similar procedure as described for 23 with OR1a = OMe. The reaction mixture was quenched with 50 mL of 1 M HCl and extracted with EtOAc. The crude material was purified by flash chromatography (silica gel, 20 g, 0–60% EtOAc in heptane) to afford the intermediate <b>IA</b> 2-bromo-8-(trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine or <b>23-2</b> (395 mg, 1.4 mmol, 77.3% yield); <sup>1</sup>HNMR (CDCl<sub>3</sub>, 300 MHz) δ 8.50 (dd, <i>J</i> = 6.9, 1.0 Hz, 1H), 7.47 (dt, <i>J</i> = 7.9, 1.29, 1.29, 1.29 Hz, 1H), 7.07 (dd, <i>J</i> = 7.9, 6.9 Hz, 1H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>7</sub> H<sub>3</sub> Br F<sub>3</sub> N<sub>3</sub> O: 281.9485, found: 281.9483, diff −0.2 mDa.</div></div><div id="sec4_7_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-[(1S,5R,8s)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>4A</b>)</h5><div class="NLM_p last">Compound <b>4A</b> was prepared following general procedure A (similar to the preparation of compound <b>3A</b>) from 2-bromo-8-(trifluoromethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine <b>23-2</b> (33.0 mg, 112 μmol), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine <b>27</b> (<b>intermediate II</b>) (25 mg, 111 μmol), and sodium <i>tert</i>-butoxide (32.1 mg, 334 μmol, 3 equiv) instead of sodium phenoxide, xantphos (10.3 mg, 17.8 μmol), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (9.23 mg, 8.92 μmol, 0.08 equiv) in dioxane (1.2 mL) in a microwave at 145 °C for 45 min. The crude material was purified by flash chromatography (silica gel, 0–5% MeOH in DCM) to afford the title compound <b>4A</b> (38.2 mg, 89.8 μmol, 80.6% yield) as an off-white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.59 (dd, <i>J</i> = 6.7, 0.9 Hz, 1H), 7.49 (dt, <i>J</i> = 7.9, 1.2, 1.2, 1.2, Hz, 1H), 6.91 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H), 6.45 (br s, 1H), 3.90 (br s, 1H), 3.64 (dd, <i>J</i> = 12.6, 3.4 Hz, 2H), 3.42 (br d, <i>J</i> = 12.6 Hz, 2H), 2.6–2.5 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 2H), 1.51 (br d, <i>J</i> = 7.6 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub> H<sub>18</sub> F<sub>3</sub> N<sub>7</sub> O S: 426.1319, found: 426.1315, diff −0.4 mDa.</div></div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Preparation of Remaining Intermediates <b>IA</b> (<b>25-3</b>, <b>25-4</b>, <b>25-5</b>, <b>25-6</b>, <b>25-7</b>, and <b>25-8</b>)</h4><div id="sec4_7_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 2-Bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol (<b>24</b>)</h5><div class="NLM_p last">To a light yellow solution of 2-bromo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (5.0 g, 21.9 mmol, 1 equiv) (<b>23-1</b> with OR1a = OCH<sub>3</sub>) in dichloromethane (100 mL) at 0 °C was added drop wise a solution of 1 M BBr<sub>3</sub> in dichloromethane (110 mL, 110 mmol). After the addition, the reaction mixture was stirred at 0 °C for 2 h and at room temperature for 3 days. The excess of BBr<sub>3</sub> was quenched by adding methanol (around 20 mL) with a dropping funnel. The reaction mixture was poured into a solution of ammonium chloride NH<sub>4</sub>Cl and extracted with dichloromethane. The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel (solid application) (0–5% MeOH in DCM) to obtain the title compound (3.85 g, 81% yield) as an off-white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.20 (br s, 1H), 8.17 (dd, 1H, <i>J</i> = 6.7, 1.0 Hz, 1H), 7.11 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.01 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>6</sub> H<sub>4</sub> Br N<sub>3</sub> O: 213.9611, found: 213.9609, diff −0.2 mDa.</div></div><div id="sec4_7_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 2-Bromo-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-3</b>, <b>Intermediate IA</b> with OR1b = OCH<sub>2</sub>CF<sub>3</sub>)</h5><div class="NLM_p last">General procedure B: 2-bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol <b>24</b>, (1 g, 4.67 mmol, 1 equiv) was combined with DMF (20 mL) to give a light yellow solution. 1,1,1-Trifluoro-2-iodoethane (1.96 g, 921 μL, 9.34 mmol, 2 equiv) and K<sub>2</sub>CO<sub>3</sub> (1.94 g, 14 mmol, 3 equiv) were added, and the reaction mixture was stirred over night at 120 °C. DMF was removed from the brown solution under high vacuum, and the residue was dissolved in DCM, poured into 20 mL of H<sub>2</sub>O, and extracted with DCM (3 × 20 mL). The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. Chromatography (silica gel, 0–80% EtOAc in heptane) gave compound <b>25-3</b> with OR1b: OCH<sub>2</sub>CF<sub>3</sub> (1.07 g, 3.61 mmol, 77.4% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.31 (dd, <i>J</i> = 6.7, 1.0 Hz, 1H), 7.08 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H,), 6.98 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H), 4.89 (q, <i>J</i> = 8.1 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>8</sub> H<sub>5</sub> Br F<sub>3</sub> N<sub>3</sub> O: 295.9641, found: 295.9643, diff 0.2 mDa.</div></div><div id="sec4_7_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 2-Bromo-8-(3,3,3-trifluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-4</b>, <b>Intermediate IA</b> with OR1b = OCH<sub>2</sub>CH<sub>2</sub> CF<sub>3</sub>)</h5><div class="NLM_p last">This compound was prepared similarly to the intermediate <b>IA</b> (with OR1b = OCH<sub>2</sub>CF<sub>3</sub>) following procedure B and using 2-bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol (<b>24</b>) (50mg, 234 μmoL) and K<sub>2</sub>CO<sub>3</sub> (96.9 mg, 701 μmol) in DMF followed by the addition of 1,1,1-trifluoro-3-iodopropane (262 mg, 137 μL, 1.17 mmol) in this case. After chromatography, compound <b>25-4</b> with OR1b: OCH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub> was obtained as a brown solid (65.4 mg, 90.3% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.23 (dd, <i>J</i> = 6.6, 1.1 Hz, 1H), 6.97 (dd, <i>J</i> = 7.9, 6.6 Hz, 1H), 6.89 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 4.49 (t, <i>J</i> = 6.9 Hz, 2H), 2.80 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>7</sub> Br F<sub>3</sub> N<sub>3</sub> O: 309.9798, found: 309.9795, diff −0.3 mDa.</div></div><div id="sec4_7_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 2-Bromo-8-(4,4,4-trifluorobutoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-5</b>, <b>Intermediate IA</b> with OR1b = OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>)</h5><div class="NLM_p last">This compound <b>25</b> was also prepared following procedure B and using 2-bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol 24 (50mg, 234 μmoL) and K<sub>2</sub>CO<sub>3</sub> (96.9 mg, 701 μmol) in DMF followed by the addition of 1,1,1-trifluoro-4-iodobutane (111 mg, 60.7 μL, 467 μmol). After chromatography, compound <b>25-5</b> with OR1b:O(CH<sub>2</sub>)<sub>3</sub>CF<sub>3</sub> was obtained as a light brown solid (65.7 mg, 86.8% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.20 (dd, <i>J</i> = 6.7. 0.8 Hz, 1H), 6.95 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H,), 6.85 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 4.29 (t, <i>J</i> = 6.1 Hz, 2H), 2.5–2.3 (m, 2H), 2.3–2.2 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>9</sub> Br F<sub>3</sub> N<sub>3</sub> O: 323.9954, found: 323.9954, diff 0.0 mDa.</div></div><div id="sec4_7_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 2-Bromo-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-6</b>, <b>Intermediate IA</b> with OR1b = OCHCH<sub>3</sub>CF<sub>3</sub>)</h5><div class="NLM_p">Following procedure B, compound <b>25-6</b> was prepared similarly to the intermediate <b>IA</b> (<b>25-3</b> with OR<sub>1</sub> = OCH<sub>2</sub>CF<sub>3</sub>) using 2-bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol (50 mg, 234 μmol) in DMF (1 mL), freshly prepared 1,1,1-trifluoropropan-2-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate (139 mg, 350 μmol), and K<sub>2</sub>CO<sub>3</sub> (64.6 mg, 467 μmol) by stirring overnight at 120 °C in a closed vial. The crude material was purified by flash chromatography (silica gel, 0–80% EtOAc in heptane) to afford the title compound (38.7 mg, 125 μmol, 53.4% yield) as a white solid. The alkylating agent 1,1,1-trifluoropropan-2-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate was prepared from 1,1,1-trifluoropropan-2-ol with 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl fluoride and triethylamine in dichloromethane as described in <i>J. Org. Chem</i>, 1989, 54, 1432–1435. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.30 (dd, <i>J</i> = 6.7, 1.0 Hz, 1H), 7.11 (dd, <i>J</i> = 8.0. 0.9 Hz, 1H), 6.97 (dd, <i>J</i> = 7.9, 6.9 Hz, 1H), 5.54 (qq, <i>J</i> = 6.5, 6.3 Hz, 1H), 1.64 (br d, <i>J</i> = 6.5 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>7</sub> Br F<sub>3</sub> N<sub>3</sub> O: 309.9798, found: 309.9792, diff −0.6 mDa.</div><div class="NLM_p last">Chiral separation of the racemic compound by chiral HPLC (Chiralcel OD, 90% heptane/10% isopropanol, K-2979) gave the corresponding chiral intermediates <b>25-6</b> with 8.7 and 8.9 min of retention time for the different enantiomers. The absolute configuration of each enantiomer was determined by chiral synthesis of the 2-Bromo-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine intermediate using (<i>S</i>) or (<i>R</i>)-1,1,1,-trifluoropropan-2-ol. The compound with a retention time of 8.7 was the <b>25-6</b> (<i>S</i>) enantiomer with a negative optical rotation, and the second peak with retention time of 8.9 was the <b>25-6</b> (<i>R</i>) enantiomer with a positive optical rotation.</div></div><div id="sec4_7_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2-Bromo-8-(2,2,3,3,3-pentafluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-7</b>, <b>Intermediate IA</b> with OR1b = OCH<sub>2</sub>CF<sub>2</sub>CF<sub>3</sub>)</h5><div class="NLM_p last">This compound was prepared following general procedure B (similarly to the intermediate <b>IA</b><b>25-3</b> (with OR<sub>1</sub> = OCH<sub>2</sub>CF<sub>3</sub>)), using 2-bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol (500 mg, 2.34 mmol, 1 equiv), 1,1,1,2,2-pentafluoro-3-iodopropane (607 mg, 2.34 mmol), and K<sub>2</sub>CO<sub>3</sub> (646 mg, 4.67 mmol, 2 equiv) in DMF (10 mL). The reaction mixture was stirred at 120 °C overnight. The crude material was purified by flash chromatography (silica gel, 0% to 60% EtOAc in heptane) to afford 2-bromo-8-(2,2,3,3,3-pentafluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine <b>25-7</b> (320.2 mg, 925 μmol, 39.6% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ ppm 8.31 (dd, <i>J</i> = 6.7, 1.0 Hz, 1H), 7.10 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 6.98 (dd, <i>J</i> = 7.9, 6.9 Hz, 1H), 5.01 (dt, <i>J</i> = 12.6, 1.0 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>5</sub> Br F<sub>5</sub> N<sub>3</sub> O: 345.9609, found: 345.9607, diff −0.2 mDa.</div></div><div id="sec4_7_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 2-Bromo-8-(oxetan-3-ylmethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-8</b>, <b>Intermediate IA</b> with OR1b = OCH<sub>2</sub>-Oxetane)</h5><div class="NLM_p last">This compound was prepared following general procedure B (similarly to the intermediate IA <b>25-3</b> (with OR<sub>1</sub> = OCH<sub>2</sub>CF<sub>3</sub>)) from 2-bromo-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-8-ol (50 mg, 234 μmol, 1 equiv) using 3-(bromomethyl) oxetane (52.9 mg, 350 μmol, 1.5 equiv) and K<sub>2</sub>CO<sub>3</sub> (64.6 mg, 467 μmol) by stirring overnight at 120 °C in a closed vial in DMF (1 mL). The crude material was purified by flash chromatography (silica gel, 0–80% EtOAc in heptane) to afford the title compound 2-bromo-8-(oxetan-3-ylmethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine <b>25-8</b> (59.8 mg, 210 μmol, 90.1% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.20 (dd, <i>J</i> = 6.5, 1.2 Hz, 1H), 6.97 (dd, <i>J</i> = 7.9, 6.5 Hz, 1H), 6.90 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 4.95 (dd, <i>J</i> = 7.6, 6.6 Hz, 2H), 4.6–4.5 (m, 4H), 3.7–3.5 (m, 1H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>10</sub> Br N<sub>3</sub> O<sub>2</sub>: 284.0029, found: 284.0026, diff −0.3 mDa.</div></div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Preparation of Remaining Intermediates <b>II</b></h4><div id="sec4_7_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (<b>28</b>)</h5><div class="NLM_p last">4-Methyl-6-thioxo-3,6-dihydro-2<i>H</i>-1,3-thiazin-2-one (CAS 97309-82-5, 1.50 g, 9.42 mmol), (prepared as described in Schroth, Werner et al, <i>Zeitschrift fuer Chemie</i><b>1985</b>, 25(1), 20–21), <i>tert</i>-butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (CAS 847862-26-4, 2.13 g, 9.42 mmol), 4-methylmorpholine (2.86 g, 3.11 mL, 28.3 mmol), and 4-dimethylaminopyridine (11.5 mg, 94.2 μmol) were combined with dioxane (150 mL) to give a light brown solution. The reaction mixture was heated to 80 °C and stirred overnight. Diisopropylethyl amine (4.87 g, 6.58 mL, 37.7 mmol) was added, and the mixture was cooled in an icebath. Iodine (4.78 g, 18.8 mmol) in dioxane (10 mL) was added, and the reaction mixture was stirred overnight while being warmed to room temperature. The crude reaction mixture was concentrated under vacuum and purified by chromatography (silica gel–NH<sub>2</sub>, ethylacetate/heptane = 50:50 to 100:0) to yield compound <b>28</b> as light brown solid (2.1 g, 72% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 5.90 (s, 1H), 4.42 (br s, 1H), 3.75 (br d, <i>J</i> = 4.2 Hz, 1H), 3.24 (dd, <i>J</i> = 11.5, 3.0 Hz, 2H), 3.17 (br d, <i>J</i> = 11.5 Hz, 2H), 2.35–2.20 (m, 2H), 2.31 (s, 3H), 1.9–1.8 (m, 2H), 1.7–1.6 (m, 2H), 1.46 (s, 9H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>16</sub> H<sub>25</sub> N<sub>3</sub> O<sub>2</sub> S: 324.1740, found: 324.1745, diff 0.5 mDa.</div></div><div id="sec4_7_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>29</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (<b>28</b>) (110 mg, 340 μmol, 1.00 equiv) was combined with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) to give a light yellow solution. Concenrated HCl (10 dropes) was added, and stirring was continued at room temperature for 2 h. Then, the reaction mixture was cooled in an icebath and was basified with NaOH (4 N). The reaction mixture was poured into H<sub>2</sub>O and extracted with DCM. The organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum, and purified by chromatography (silica gel, ethylacetate/methanol = 100:0 to 80:20). The fractions were concentrated and dried under vacuum to yield <b>29</b> as the intermediate II (42 mg; 55.3% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ ppm 5.89 (s, 1H), 3.22 (br dd, <i>J</i> = 11.4, 3.0 Hz, 2H), 3.12 (br d, <i>J</i> = 11.5 Hz, 2H), 3.08 (br s, 1H), 2.31 (s, 3H), 2.1–2.06 (m, 2H), 2.0–1.9 (m, 2H), 1.7–1.6 (m, 2H), 1.45 (br s, 2H, NH<sub>2</sub>); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>11</sub> H<sub>17</sub> N<sub>3</sub> S: 224.1216, found: 224.1215, diff −0.1 mDa.</div></div><div id="sec4_7_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>tert</i>-Butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-Cyano-3-azabicyclo[3.2.1]octan-8-yl)carbamate (<b>30</b>)</h5><div class="NLM_p last">To a light yellow solution of <i>tert</i>-butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (4 g, 17.7 mmol) in EtOH (52 mL) was added sodium bicarbonate (2.08 g, 24.7 mmol, 1.4 equiv) followed by cyanogen bromide (2.62 g, 1.28 mL, 24.7 mmol, 1.4 equiv). The reaction mixture was stirred for 2 h at room temperature and at 50 °C overnight. The white suspension was filtered and washed with some ethanol. The crude reaction mixture was concentrated under vacuum. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, evaporated with silica gel to dryness, and transferred to a silica gel column.The crude product was purified by chromatography (silica gel, ethylacetate/heptane = 0:100 to 60:40). The fractions were combined to afford <b>30</b> (4.11 g, 16.4 mmol, 92.5% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 6.14 (br s, 1H), 3.45 (br d, <i>J</i> = 5.3 Hz, 1H), 3.28 (br d, <i>J</i> = 11.8 Hz, 2H), 3.2–3.1 (m, 2H), 2.25–2.20 (m, 2H), 1.95–1.85 (m, 2H), 1.65–1.55 (m, 2H), 1.42 (s, 9H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C1<sub>3</sub> H<sub>21</sub> N<sub>3</sub> O<sub>2</sub>: 252.1707, found: 252.1703, diff −0.4 mDa.</div></div><div id="sec4_7_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>31</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-cyano-3-azabicyclo[3.2.1]octan-8-yl)carbamate <b>30</b> (4.1 g, 16.3 mmol) was combined with ethanol (58.8 mL) to give a white suspension. (<i>Z</i>)-<i>N</i>′-hydroxyacetimidamide (1.23 g, 16.3 mmol) and zinc chloride (2.6 g, 19.6 mmol), previously dried at high vacuum with heating until it melted followed by cooling to room temperature, were added and dissolved in ethanol (19.6 mL). The reaction mixture was stirred overnight to form the intermediate that appeared as a white suspension. HCl 37% (4.08 mL, 48.9 mmol, 3 equiv) was added, and the reaction mixture was stirred at 60 °C 7 h. The reaction mixture was concentrated under vacuum, the residue was diluted with a saturated solution of NaHCO<sub>3</sub> (until pH 9), and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum. Chromatography (ethylacetate/heptane = 0:100 to 30:70) afforded the title compound (3.3 g, 15.8 mmol, 97% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 3.84 (br dd, <i>J</i> = 12.9, 3.4 Hz, 2H), 3.22 (d, <i>J</i> = 12.3 Hz, 2H), 3.14 (s, 1H), 2.21 (s, 3H), 2.15–2.05 (m, 2H), 2.0–1.9 (m, 2H), 1.7–1.4 (m, 4H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>16</sub> N<sub>4</sub> O: 209.1397, found: 209.1391, diff −0.6 mDa.</div></div><div id="sec4_7_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>tert</i>-Butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(2-(trifluoromethyl)pyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl) carbamate (<b>32</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (1.3 g, 5.74 mmol), 4-chloro-2-(trifluoromethyl)pyridine (1.04 g, 5.74 mmol, 1 equiv), palladium(II) acetate (105 mg, 460 μmol, 0.08 equiv), sodium <i>tert</i>-butoxide (845 mg, 8.62 mmol, 1.5 equiv), Hunig’s base (1.48 g, 2.01 mL, 11.5 mmol, 2 equiv), and 2-(dicyclohexylphosphino)biphenyl (332 mg, 919 μmol, 0.16 equiv) in dioxane (4 mL) were combined in a microwave vial. The reaction mixture was heated in a microwave at 140 °C for 45 min. The crude reaction mixture was concentrated under vacuum and purified by chromatography (silica gel, 50 g, ethylacetate/heptane = 0:100 to 50:50). The fractions with the pure product were concentrated and dried under vacuum to yield compound <b>32</b> (775 mg, 36.3%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.32 (br d, <i>J</i> = 6.1 Hz, 1H), 6.95 (br d, <i>J</i> = 2.5 Hz, 1H), 6.69 (br dd, <i>J</i> = 6.1, 2.5 Hz, 1H), 4.45 (br s, 1H), 3.78 (br s, 1H), 3.65 (dd, <i>J</i> = 11.9, 3.2 Hz, 2H), 3.10 (br d, <i>J</i> = 11.9 Hz, 2H), 2.5–2.4 (m, 2H), 1.9–1.8 (m, 2H), 1.7–1.6 (m, 2H), 1.47 (s, 9H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub> H<sub>24</sub> F<sub>3</sub> N<sub>3</sub> O<sub>2</sub>: 372.1894, found: 372.1888, diff −0.6 mDa.</div></div><div id="sec4_7_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(2-(Trifluoromethyl)pyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>33</b>)</h5><div class="NLM_p last">The title compound was deprotected similarly as described for compound <b>29</b> using <i>tert</i>-butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(2-(trifluoromethyl)pyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)carbamate (775 mg, 2.09 mmol, 1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) with concentrated HCl (1 mL) by stirring for 1 h at room temperature. Chromatography (silica gel, ethylacetate/methanol = 100:0 to 50:50) yielded the desired compound (520 mg; 91.9% yield) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.31 (br d, <i>J</i> = 6.1 Hz,1H), 6.95 (br d, <i>J</i> = 2.6 Hz, 1H), 6.68 (br dd, <i>J</i> = 6.1, 2.6 Hz, 1H), 3.62 (dd, <i>J</i> = 11.8, 2.9 Hz, 2H), 3.19 (s, 1H), 3.03 (br dd, <i>J</i> = 11.5, 1.2 Hz, 2H), 2.3–2.2 (m, 2H), 2.1–2.0 (m, 2H), 1.6–1.5 (m, 2H), 1.4–1.1 (br s, 2H) (NH<sub>2</sub> under the water); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>13</sub> H<sub>16</sub> F<sub>3</sub> N<sub>3</sub>: 272.1369, found: 272.1366, diff −0.3 mDa.</div></div><div id="sec4_7_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>tert</i>-Butyl <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-Methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (<b>34</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (125 mg, 552 μmol, 1.00 equiv) was combined with triethylamine (224 mg, 308 μL, 2.21 mmol, 4 equiv) in ethanol (2 mL). 2-bromo-5-methyl-1,3,4-oxadiazole (180 mg, 1.1 mmol, 2 equiv) was added and the reaction mixture was stirred at 130 °C overnight. The crude reaction mixture was concentrated under vacuum. The reaction was extracted from H<sub>2</sub>O with DCM. The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude material was purified by flash chromatography (silica gel, 0–5% MeOH in DCM) to afford the title compound <i>tert</i>-butyl (34) (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (116 mg, 376 μmol, 68.1% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.42 (br s, 1H), 3.75 (br s, 1H), 3.70 (br dd, <i>J</i> = 12.1, 3.4 Hz, 2H), 3.23 (br d, <i>J</i> = 12.1 Hz, 2H), 2.38 (s, 3H), 2.3–2.25 (m, 2H), 1.9–1.8 (m, 2H), 1.7–1.6 (m, 2H), 1.46 (s, 9H)<b>;</b> LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>15</sub> H<sub>24</sub> N<sub>4</sub> O<sub>3</sub>: 309.1921, found: 309.1919, diff −0.2 mDa.</div></div><div id="sec4_7_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (1<i>R</i>,5<i>S</i>)-3-(5-Methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>35</b>)</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (230 mg, 746 μmol, 1.00 equiv) in DCM (6 mL) was added TFA (850 mg, 575 μL, 7.46 mmol, 10 equiv), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with 20 mL of saturated NaHCO<sub>3</sub> and extracted with DCM (6 × 20 mL). The product was that was in the water phase was concentrated under vacuum. The crude material was purified by an ion-exchange column (Si-SCX-2, 10 g, washed with MeOH and liberated with MeOH (NH<sub>3</sub> 7 M)) to afford <b>35</b> (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-amine (124.5 mg, 598 μmol, 80.2% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 3.68 (br dd, <i>J</i> = 12.4, 3.5 Hz, 2H), 3.18–3.11 (br d, <i>J</i> = 12.4 Hz, 2H), 3.13 (s, 1H), 2.37 (s, 3H), 2.1–2.05 (m, 2H), 2.0–1.9 (m, 2H), 1.7–1.6 (m, 2H), 1.49–1.45 (br s, 2H) (NH<sub>2</sub> under the water); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>16</sub> N<sub>4</sub> O: 209.1397, found: 209.1392, diff −0.5 mDa.</div></div><div id="sec4_7_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>tert</i>-Butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methylisoxazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)carbamate (<b>36</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (200 mg, 884 μmol, 1 equiv), copper(I) iodide (16.8 mg, 88.4 μmol, 0.1 equiv), tripotassium phosphate (375 mg, 1.77 mmol, 2 equiv), and <i>N</i>,<i>N</i>-diethylsalicylamide (51.2 mg, 265 μmol, 0.3 equiv) were combined in DMF (5 mL). The reaction mixture was cooled down to −5 °C before 5-iodo-3-methylisoxazole (222 mg, 1.06 mmol, 1.2 equiv) was added, and the mixture was stirred for 6 h at −5 °C. The reaction mixture was poured into 50 mL of saturated NaHCO<sub>3</sub> and extracted with DCM (3 × 50 mL). The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude material was purified by flash chromatography (silica gel, 0–80% EtOAc in heptane) to afford <b>36</b> (62 mg, 22% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.76 (s, 1H), 4.42 (br s, 1H), 3.7 (br s, 1H), 3.47 (dd, <i>J</i> = 12.3, 3.6 Hz, 2H), 3.13 (br d, <i>J</i> = 12.0 Hz, 2H), 2.4–2.2 (m, 2H), 2.15 (s, 3H), 1.8–1.75 (m, 2H), 1.71–1.62 (m, 2H), 1.46 (s, 9H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>16</sub> H<sub>25</sub> N<sub>3</sub> O<sub>3</sub>: 308.1969, found: 308.1964, diff −0.5 mDa.</div></div><div id="sec4_7_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methylisoxazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>37</b>)</h5><div class="NLM_p last">Removal of the <i>N</i>-BOC protecting group was done similarly as described to obtain compound <b>29</b> starting from <i>tert</i>-butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methylisoxazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)carbamate <b>36</b> (26 mg, 84.6 μmol, 1 equiv) and using some drops of HCl (37%). After 2 h, the crude reaction mixture was poured into 10 mL of NaOH (4 N) and extracted with DCM. The organic layers were dried over MgSO<sub>4</sub>, concentrated, and dried under vacuum to yield the intermediate II (<b>37</b>) (14 mg; 80% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.74 (s, 1H), 3.5–3.4 (m, 2H), 3.2–3.0 (m, 3H), 2.18–2.1 (m, 2H), 2.15 (s, 3H), 2-0–1.9 (m, 2H), 1.7–1.6 (m, 2H), 1.6–1.5 (br s, 2H, NH<sub>2</sub> under H<sub>2</sub>O); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>11</sub> H<sub>17</sub> N<sub>3</sub> O: 208.1445, found: 208.1442, diff −0.3 mDa.</div></div><div id="sec4_7_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> <i>tert</i>-Butyl <i>N</i>-[(1<i>R</i>,5<i>S</i>)-3-(6-Methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]carbamate (<b>38</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-azabicyclo[3.2.1]octan-8-ylcarbamate (5 g, 22.1 mmol, 1 equiv), triethylamine (8.94 g, 12.3 mL, 88.4 mmol, 4 equiv), and 4-chloro-6-methylpyrimidine (3.41 g, 26.5 mmol, 1.2 equiv) were combined in ethanol (75 mL). The reaction mixture was stirred overnight at 100 °C. The crude reaction mixture was concentrated under vacuum, H<sub>2</sub>O was added, and the reaction mixture was extracted with DCM (3 × 100 mL). The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum to obtain the intermediate II (<b>38</b>) (6.96 g, 21.9 mmol, 99% yield) as a light brown solid. <sup>1</sup>H NMR (CsDCl<sub>3</sub>, 300 MHz) δ 8.50 (s, 1H), 6.33 (s, 1H), 4.5–4.4 (br s, 1H), 4.2–4.0 (m, 2H), 3.79 (br s, 1H), 3.04 (br d, <i>J</i> = 12.5 Hz, 2H), 2.4–2.3 (m, 2H), 2.35 (s, 3H), 1.81–1.7 (m, 2H), 1.6–1.5 (m, 2H), 1.46 (s, 9H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub> H<sub>26</sub> N<sub>4</sub> O<sub>2</sub>: 319.2129, found: 319.2122, diff −0.7 mDa.</div></div><div id="sec4_7_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (1<i>R</i>,5<i>S</i>)-3-(6-Methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was prepared similarly to compound <b>29</b> using <i>tert</i>-butyl ((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)carbamate (6.95 g, 21.8 mmol, 1 equiv) and HCl 37% (12.9 g, 10.8 mL, 131 mmol, 6 equiv) in dichloromethane (104 mL). The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum to obtain the intermediate II (<b>39</b>) (4.49 g, 20.6 mmol, 94.2% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ ppm 8.49 (s, 1H), 6.32 (s, 1H), 4.2–4.0 (m, 2H), 3.17 (s, 1H), 2.97 (br d, <i>J</i> = 12.7 Hz, 2H), 2.35 (s, 3H), 2.2–2.1 (m, 2H), 2.0–1.9 (m, 2H), 1.52–1.47 (m, 4H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>12</sub> H<sub>18</sub> N<sub>4</sub>: 219.1604, found: 219.1603, diff −0.1 mDa.</div></div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Preparation of type A Compounds (<b>5A</b>–<b>16A</b>)</h4><div id="sec4_7_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>5A</b>)</h5><div class="NLM_p last">Compound <b>5A</b> was prepared according to general procedure A, using Buchwald coupling from (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine <b>(27)</b> (intermediate II, 30 mg, 134 μmol, 1.00 equiv), 2-bromo-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-3</b>) as the intermediate IA (43.6 mg, 147 μmol, 1.1 equiv), sodium <i>tert</i>-butoxide (38.6 mg, 401 μmol, 3 equiv), xantphos (12.4 mg, 21.4 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (11.1 mg, 10.7 μmol, 0.08 equiv) in dioxane (1 mL) in a microwave at 145 °C for 45 min. The final compound was obtained as a white solid after chromatography (39.3 mg, 66.9% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.29 (dd, <i>J</i> = 6.6, 0.9 Hz, 1H), 7.11 (dd, <i>J</i> = 7.9. 0.9 Hz, 1H), 6.81 (dd, <i>J</i> = 7.9, 6.6 Hz, 1H), 6.16 (br s, 1H), 5.02 (q, <i>J</i> = 8.9 Hz, 2H), 3.89 (br s, 1H), 3.64 (dd, <i>J</i> = 12.6, 3.3 Hz, 2H), 3.42 (br d, <i>J</i> = 12.6 Hz, 2H), 2.6–2.5 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 2H), 1.5–1.48 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub> H<sub>20</sub> F<sub>3</sub> N<sub>7</sub> O S: 440.1475, found: 440.1475, diff 0.0 mDa.</div></div><div id="sec4_7_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(3,3,3-trifluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>6A</b>)</h5><div class="NLM_p last">Compound <b>6A</b> was prepared according to general procedure A, using Buchwald coupling following a similar procedure to prepare compound <b>3A</b>, from 2-bromo-8-(3,3,3-trifluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (122 mg, 392 μmol, 1.1 equiv) intermediate IA (<b>25-4)</b>, (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (80 mg, 357 μmol, 1.00 equiv) (<b>27</b>), sodium phenoxide (66.2 mg, 571 μmol, 1.6 equiv), xantphos (33.0 mg, 57.1 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (29.5 mg, 28.5 μmol, 0.08 equiv) in dioxane (3 mL). The crude material was purified by flash chromatography (silica gel, 0–100% EtOAc in heptan) to afford the title compound <b>6A</b> (84 mg, 51.9% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.21 (dd, <i>J</i> = 6.7. 0.9 Hz, 1H), 6.98 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 6.77 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H), 6.08 (br s, 1H), 4.54 (t, <i>J</i> = 6.1, Hz, 2H), 3.89 (br s, 1H), 3.64 (dd, <i>J</i> = 12.5, 3.3 Hz, 2H), 3.41 (d, <i>J</i> = 12.5, Hz, 2H), 2.86–2.77 (m, 2H), 2.6–2.5 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 2H), 1.52–1.48 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub> H<sub>22</sub> F<sub>3</sub> N<sub>7</sub> O S: 454.1632, found: 454.1629, diff −0.3 mDa.</div></div><div id="sec4_7_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(4,4,4-trifluorobutoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>7A</b>)</h5><div class="NLM_p last">Compound <b>7A</b> was prepared following general procedure A, similarly to compound <b>3A</b>, from 2-bromo-8-(4,4,4-trifluorobutoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (43.3 mg, 134 μmol, 1.00 equiv) (<b>25-5</b>), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>27</b>) (30 mg, 134 μmol, 1.00 equiv), sodium phenoxide (24.8 mg, 214 μmol, 1.6 equiv), xantphos (12.4 mg, 21.4 μmol, 0.16 equiv) and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (11.1 mg, 10.7 μmol, 0.08 equiv) in dioxane (2 mL). The crude material was purified by flash chromatography (silica gel, 0–100% EtOAc in heptane) to give 38.7 mg (63% yield) of the compound. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.18 (dd, <i>J</i> = 6.6, 1.0 Hz, 1H), 6.95 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 6.77 (dd, <i>J</i> = 7.8, 6.6 Hz, 1H), 6.05 (br s, 1H), 4.34 (t, <i>J</i> = 6.2 Hz, 2H), 3.88 (br s, 1H), 3.64 (dd, <i>J</i> = 12.5.3.3 Hz, 2H), 3.41 (br d, <i>J</i> = 12.5 Hz, 2H), 2.6–2.5 (m, 2H), 2.5–2.4 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 4H), 1.54–1.45 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>24</sub> F<sub>3</sub> N<sub>7</sub> O S: 468.1788, found: 468.1791, diff 0.3 mDa.</div></div><div id="sec4_7_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>8A</b>)</h5><div class="NLM_p last">The title compound was obtained by separation of racemic precursor <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine using a chiralpak OD column (8% ethanol in heptane). The most potent enantiomer <b>8A</b> is the second peak on the column with a retention time of 15.5 min, and the other enantiomer has 12.2 min of retention time. The absolute configuration was not assigned for each enantiomer. The racemic precursor was prepared by Buchwald coupling with 2-bromo-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>25-6</b>) (76.0 mg, 245 μmol, 1.1 equiv), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>27</b>) (50 mg, 223 μmol), sodium <i>tert</i>-butoxide (64.3 mg, 669 μmol), xantphos (20.6 mg, 35.7 μmol), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (18.5 mg, 17.8 μmol) in dioxane (2 mL). The crude material was purified by flash chromatography (silica gel, 0–5% MeOH in DCM) to afford racemic <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3azabicyclo[3.2.1]octan-8-yl)-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (81 mg, 179 μmol, 80.1% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.30 (dd, <i>J</i> = 6.6, 1.0 Hz, 1H), 7.11 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 6.80 (dd, <i>J</i> = 7.9, 6.6 Hz,1H), 6.20 (br s, 1H), 5.62 (spt, <i>J</i> = 6.6 Hz, 1H), 3.88 (br s, 1H), 3.64 (br dd, <i>J</i> = 12.6, 3.2 Hz, 2H), 3.42 (br d, <i>J</i> = 12.6 Hz, 2H), 2.6–2.5 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 2H), 1.53 (dq, <i>J</i> = 6.6, 0.8 Hz, 3H), 1.51 (d, <i>J</i> = 6.6 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub> H<sub>22</sub> F<sub>3</sub> N<sub>7</sub> O S: 454.1632, found: 454.1629, diff −0.3 mDa.</div></div><div id="sec4_7_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>9A</b>)</h5><div class="NLM_p last">Buchwald coupling was performed (similar to that used to prepare <b>3A</b>) using (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>29</b>) as the intermediate II (100 mg, 448 μmol, 1 equiv), 2-bromo-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (133 mg, 448 μmol, 1 equiv) as compound (<b>25-3</b>) or the intermediate I (with OR1 = OCH<sub>2</sub>CF<sub>3</sub>), xantphos (41.5 mg, 71.6 μmol, 0.16 equiv), tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (37.1 mg, 35.8 μmol, 0.08 equiv), and sodium <i>tert</i>-butoxide (90.4 mg, 940 μmol, 2.1 equiv) in dioxane (5 mL) by heating in a microwave at 150 °C for 45 min. After chromatography in (ethylacetate/heptane = 50:50 to 100:0), compound <b>9A</b> (119 mg; 60.6% yield) was obtained as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.29 (dd, 1H, <i>J</i> = 6.6, 0.9 Hz), 7.10 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 6.80 (dd, <i>J</i> = 7.9, 6.7 Hz,1H), 6.06 (s, 1H), 6.12 (br s, 1H), 5.02 (q, <i>J</i> = 8.8 Hz, 2H), 3.82 (br s, 1H), 3.30 (dd, <i>J</i> = 11.5, 3.0 Hz, 2H), 3.23 (dd, <i>J</i> = 11.5, 1.0 Hz), 2.6–2.5 (m, 2H), 2.23 (s, 3H), 2.1–2.0 (m, 2H), 1.6–1.5 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub> H<sub>21</sub> F<sub>3</sub> N<sub>6</sub> O S: 439.1523, found: 439.1517, diff −0.6 mDa.</div></div><div id="sec4_7_6_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2-thiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>10A</b>)</h5><div class="NLM_p last">The chiral intermediate IA or (<i>S</i>)-2-bromo-8-((1,1,1-trifluoropropan-2-yl)oxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (36.4 mg, 118 μmol, 1.05 equiv) (<b>25-6S</b>) and (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>29</b>) (25 mg, 112 μmol, 1 equiv) were reacted in a Buchwald coupling similarly to compound <b>3A</b> with sodium <i>tert</i>-butoxide (32.3 mg, 336 μmol, 3 equiv), xantphos (10.4 mg, 17.9 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (9.27 mg, 8.96 μmol, 0.08 equiv) in 1,4-dioxane (1.5 mL). The crude material was purified by flash chromatography (silica gel, 12 g, 0–80% EtOAc in heptan) to afford the title compound <b>10A</b> (33.1 mg, 73.1 μmol, 65.3% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.30 (dd, <i>J</i> = 6.6. 1.0 Hz, 1H), 7.11 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 6.80 (dd, <i>J</i> = 7.9, 6.6 Hz, 1H), 6.06 (s, 1H), 6.07 (br s, 1H), 5.62 (spt, <i>J</i> = 6.6 Hz, 1H), 3.81 (br s, 1H), 3.30 (dd, <i>J</i> = 11.6, 3.6 Hz, 2H), 3.23 (br dd, <i>J</i> = 11.6, 1.6 Hz, 2H), 2.6–2.5 (m, 2H), 2.23 (s, 3H), 2.1–2.05 (m, 2H), 1.6–1.56 (m, 2H), 1.53 (dq, <i>J</i> = 6.6, 0.9 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>23</sub> F<sub>3</sub> N<sub>6</sub> O S: 453.1679, found: 453.1672, diff −0.7 mDa.</div></div><div id="sec4_7_6_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(oxetan-3-ylmethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>11A</b>)</h5><div class="NLM_p last">Similar to the preparation of compound <b>3A</b>, 2-bromo-8-(oxetan-3-ylmethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (22.8 mg, 80.2 μmol, 1.2 equiv) (<b>25-8</b>), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-thiadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (15 mg, 66.9 μmol, 1 equiv) <b>27</b>, sodium <i>tert</i>-butoxide (19.3 mg, 201 μmol, 3 equiv), xantphos (6.19 mg, 10.7 μmol, 0.16 equiv) and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (5.54 mg, 5.35 μmol, 0.08 equiv) were combined in 1,4-dioxane (1 mL) and heated in a microwave. The crude material was purified by flash chromatography (silica gel, 12 g, 0–5% MeOH in DCM) to afford the title compound <b>11A</b> (23.2 mg, 54.3 μmol, 81.2% yield) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.18 (dd, <i>J</i> = 6.6, 1.0 Hz, 1H), 6.97 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 6.77 (dd, <i>J</i> = 7.8, 6.6 Hz, 1H), 6.07 (br s, 1H), 4.73 (dd, <i>J</i> = 7.9, 5.9 Hz, 2H), 4.55–4.45 (m, 4H), 3.88 (br s, 1H), 3.63 (dd, <i>J</i> = 12.6, 3.3 Hz, 2H), 3.46 (m, 1H), 3.42 (br d, <i>J</i> = 12.6 Hz, 2H), 2.6–2.5 (m, 2H), 2.30 (s, 3H), 2.1–2.0 (m, 2H), 1.55–1.45 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>25</sub> N<sub>7</sub> O<sub>2</sub> S: 428.1863, found: 428.1860, diff −0.3 mDa.</div></div><div id="sec4_7_6_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>12A</b>)</h5><div class="NLM_p last">Similar to the preparation of <b>3A</b>, compound <b>12A</b> was obtained using (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (40 mg, 192 μmol, 1 equiv), <b>31</b> (40 mg, 192 μmol, 1.00 equiv), and 2-bromo-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (56.8 mg, 192 μmol, 1 equiv) (<b>25-3</b>) in 1,4-dioxane (1.5 mL) with dibromo-bis-(tri-<i>tert</i>-butyl)-phosphine-palladium or [Pd(C<sub>4</sub>H<sub>9</sub>)<sub>3</sub>PBr]<sub>2</sub> (14.9 mg, 19.2 μmol, 0.1 equiv) and sodium <i>tert</i>-butoxide (37.8 mg, 394 μmol, 2.05 equiv) in a closed vial at 110 °C for 60 min. The mixture was purified by flash chromatography (silica gel, 12 g, 0–80% EtOAc in heptane) to afford <b>12A</b> as a white solid (35 mg, 43% yield). <sup>1</sup>HNMR (CDCl<sub>3</sub>, 300 MHz) δ ppm 8.11 (dd, <i>J</i> = 6.8, 0.9 Hz, 1H), 6.92 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 6.73 (dd, <i>J</i> = 7.9, 6.8 Hz, 1H), 4.76 (q, <i>J</i> = 8.3 Hz, 2H), 4.49 (br d, <i>J</i> = 6.3 Hz,1H), 4.0–3.9 (m, 3H), 3.40 (br d, <i>J</i> = 12.5 Hz, 2H), 2.6–2.5 (m, 2H), 2.23 (s, 3H), 2.0–1.9 (m, 2H), 1.7–1.6 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub> H<sub>20</sub> F<sub>3</sub> N<sub>7</sub> O<sub>2</sub>: 424.1704, found: 424.1705, diff 0.1 mDa.</div></div><div id="sec4_7_6_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 8-(2,2,2-Trifluoroethoxy)-<i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(2-(trifluoromethyl)pyridin-4-yl)-3azabicyclo [3.2.1]octan-8-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>13A</b>)</h5><div class="NLM_p last">The compound was prepared similarly to <b>3A</b> using Buchwald coupling. In this case, (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(2-(trifluoromethyl)pyridin-4-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>33</b>) (70 mg, 258 μmol, 1 equiv), 2-bromo-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (76.4 mg, 258 μmol, 1 equiv) (<b>25-3</b>), xantphos (23.9 mg, 41.3 μmol, 0.16 equiv), tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (21.4 mg, 20.6 μmol, 0.08 equiv), and sodium <i>tert</i>-butoxide (52.1 mg, 542 μmol, 2.1 equiv) were mixed in dioxane (10 mL) and heated in a microwave at 145 °C for 30 min.The crude reaction mixture was concentrated in vacuo and purified by chromatography (silica gel, 12 g, ethylacetate/heptane = 50:50 to 100:0). The fractions were concentrated under vacuum and triturated using diethyl ether (0.5/2 mL). The solid was filtered through sintered glass and dried under vacuum to yield <b>13A</b> (75 mg, 59.8%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.29 (dd, <i>J</i> = 6.6. 0.9 Hz, 1H), 8.26 (d, <i>J</i> = 5.9 Hz, 1H), 7.11 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 7.08 (d, <i>J</i> = 2.6 Hz, 1H), 6.93 (dd, <i>J</i> = 5.9, 2.6 Hz, 1H), 6.81 (dd, <i>J</i> = 7.9, 6.6 Hz, 1H), 6.15 (br s, 1H), 5.02 (q, <i>J</i> = 8.8 Hz, 2H), 3.85 (br s, 1H), 3.78 (dd, <i>J</i> = 12.2, 3.3 Hz, 2H), 3.15 (br dd, <i>J</i> = 12.2 Hz, 2H), 2.6–2.5 (m, 2H), 2.1–2.0 (m, 2H), 1.6–1.5 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub> H<sub>20</sub> F<sub>6</sub> N<sub>6</sub> O: 487.1676, found: 487.1677, diff 0.1 mDa.</div></div><div id="sec4_7_6_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> <i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-Methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-yl)-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>14A</b>)</h5><div class="NLM_p last">The compound was prepared similarly to <b>3A</b> using (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-amine (25 mg, 120 μmol, 1.00 equiv) (<b>35</b>), 2-bromo-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (40.9 mg, 132 μmol, 1.1 equiv) (<b>25-6</b>), sodium <i>tert</i>-butoxide (34.6 mg, 360 μmol, 3 equiv), xantphos (11.1 mg, 19.2 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (9.94 mg, 9.6 μmol, 0.08 equiv) in dioxane (1 mL). The crude material was purified by flash chromatography (silica gel, 0–10% CH<sub>2</sub>Cl<sub>2</sub>/MeOH) to yield <b>14A</b> (33.3 mg, 63.4%) as an off-white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.30 (dd, <i>J</i> = 6.6, 0.9 Hz, 1H), 7.11 (dd, <i>J</i> = 7.8, 0.9 Hz, 1H), 6.80 (dd, <i>J</i> = 7.8, 6.6 Hz, 1H), 6.15 (br s, 1H), 5.62 (qq, <i>J</i> = 6.5, 6.4 Hz, 1H), 3.80 (br s, 1H), 3.65 (br dd, <i>J</i> = 12.5, 3.6 Hz, 2H), 3.27 (br d, <i>J</i> = 12.5 Hz, 2H), 2.6–2.5 (m, 2H), 2.32 (s, 3H), 2.1–1.9 (m, 2H), 1.56 (br s, 2H), 1.53 (dq, <i>J</i> = 6.4, 0.8, 0.8, 0.8 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub> H<sub>22</sub> F<sub>3</sub> N<sub>7</sub> O<sub>2</sub>: 438.1860, found: 438.1855, diff −0.5 mDa.</div></div><div id="sec4_7_6_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(2,2,3,3,3-pentafluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>15A</b>)</h5><div class="NLM_p last">The compound was prepared similarly to <b>3A</b> using Buchwald coupling of 2-bromo-8-(2,2,3,3,3-pentafluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (150 mg, 433 μmol, 1 equiv) (<b>25-7</b>) and (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (99.3 mg, 477 μmol, 1.1 equiv) (<b>31</b>) in 1,4-dioxane (1.5 mL) with sodium <i>tert</i>-butoxide (85.4 mg, 889 μmol, 2.05 equiv). The reaction was degassed for 2 min before dibromo-bis-(tri-<i>tert</i>-butyl)-phosphine-palladium (50.5 mg, 65 μmol, 0.15 equiv) was added, and the mixture was stirred at 110 °C for 2 h. The reaction mixture was diluted with 25 mL of saturated NaHCO<sub>3</sub> and extracted with DCM. The crude material was purified by flash chromatography (silica gel, 0–10% MeOH in DCM) to afford <b>15A</b> (22.2 mg, 46.9 μmol, 11% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.30 (dd, <i>J</i> = 6.7, 0.9 Hz, 1H), 7.12 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 6.81 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H), 6.19 (br s, 1H), 5.11 (td, <i>J</i> = 13.5, 13.5, 1.1 Hz, 2H), 3.83 (br s, 1H), 3.81 (br dd, <i>J</i> = 12.9, 3.2 Hz, 2H), 3.37 (br d, <i>J</i> = 12.9 Hz, 2H), 2.6–2.5 (m, 2H), 2.11 (s, 3H), 2.05–1.9 (m, 2H), 1.55–1.45 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub> H<sub>20</sub> F<sub>5</sub> N<sub>7</sub> O<sub>2</sub>: 474.1672, found: 474.1666, diff −0.6 mDa.</div></div><div id="sec4_7_6_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> <i>N</i>-[(1<i>S</i>,5<i>R</i>)-3-(3-Methyl-1,2-oxazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(2,2,3,3,3-pentafluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>16A</b>)</h5><div class="NLM_p last">The compound was prepared similarly to compound <b>3A</b> using 2-bromo-8-(2,2,3,3,3-pentafluoropropoxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (142 mg, 409 μmol, 1.6 equiv) (<b>25-7</b>), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methylisoxazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (53 mg, 256 μmol, 1 equiv) (<b>37</b>), and sodium <i>tert</i>-butoxide (50.4 mg, 524 μmol, 2.05 equiv) in 1,4-dioxane (5 mL), with the addition of dibromo-bis-(tri-<i>tert</i>-butyl)-phosphine-palladium (39.8 mg, 51.2 μmol, 0.2 equiv). The reaction mixture was stirred at 110 °C for 2 h.The crude was purified by chromatography using DCM:MeOH 100:0 to 95:5 and then heptane:EtOAc 50:50 to 100:0 to afford <b>16A</b> (33 mg, 69.9 μmol, 27.3% yield) as a white foam. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.30 (dd, <i>J</i> = 6.7, 1.0 Hz, 1H), 7.11 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 6.80 (dd, <i>J</i> = 7.9, 6.7 Hz, 1H), 6.16 (br s, 1H), 5.12 (tq, <i>J</i> = 13.4,1.2, Hz, 2H), 4.96 (s, 1H), 3.78 (br s, 1H), 3.49 (dd, <i>J</i> = 12.1, 3.6 Hz, 2H), 3.18 (br d, <i>J</i> = 12.1 Hz, 2H), 2.6–2.5 (m, 2H), 2.07 (s, 3H), 2.0–1.9 (m, 2H), 1.6–1.5 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>21</sub> F<sub>5</sub> N<sub>6</sub> O<sub>2</sub>: 473.1719, found: 473.1713, diff −0.6 mDa.</div></div></div><div id="sec4_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Preparation of Intermediates <b>IB</b></h4><div id="sec4_7_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 3-Bromo-6-(trifluoromethyl)pyridin-2-amine (<b>41</b>)</h5><div class="NLM_p last">6-(Trifluoromethyl)pyridin-2-amine <b>41</b> (2.5 g, 15.4 mmol, 1.00 equiv) was combined with dichloromethane (30 mL) to give a colorless solution. The mixture was cooled to 0 °C, and bromine (2.46 g, 792 μL, 15.4 mmol, 1.00 equiv) was added slowly for 20 min. The reaction mixture was stirred overnight at room temperature. The reaction mixture was extracted with a 3% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution and water. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. Chromatography using heptane to heptane:ethyl acetate 6:1 gave the final compound (1.65 g, 44% yield). <sup>1</sup>HNMR (CDCl<sub>3</sub>, 300 MHz) δ 7.79 (br d, <i>J</i> = 7.9 Hz, 1H), 6.90 (br d, <i>J</i> = 7.9 Hz, 1H), 5.21 (br s, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>6</sub> H<sub>4</sub> Br F<sub>3</sub> N<sub>2</sub>: 240.9583, found: 240.9585, diff 0.2 mDa.</div></div><div id="sec4_7_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Ethyl <i>N</i>-[[3-Bromo-6-(trifluoromethyl)pyridin-2-yl]carbamothioyl]carbamate (<b>42</b>)</h5><div class="NLM_p last">3-Bromo-6-(trifluoromethyl)pyridin-2-amine (5 g, 20.7 mmol, 1.00 equiv) and ethoxy carbonyl isothiocyanate (2.99 g, 22.8 mmol, 1.10 equiv) were combined with dioxane (55 mL) to give a yellow solution. The reaction mixture was stirred for 5 min at room temperature and then heated to 100 °C and stirred for 5 h. The crude reaction mixture was concentrated and dried under vacuum to yield the intermediate <b>42</b> (5.89 g, 76.3%), which was used as a crude in the next step. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ ppm 8.15 (br d, <i>J</i> = 8.1 Hz, 1H), 7.45 (br d, <i>J</i> = 8.1 Hz, 1H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H) (NHs not visible); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>9</sub> Br F<sub>3</sub> N<sub>3</sub> O<sub>2</sub> S: 371.9624, found: 371.9620, diff −0.4 mDa.</div></div><div id="sec4_7_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 8-Bromo-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>43</b>)</h5><div class="NLM_p last">Hydroxylamine hydrochloride (1.75 g, 25.1 mmol, 5.00 equiv) and diisopropylethylamine (1.95 g, 2.63 mL, 15.1 mmol, 3.00 equiv) were combined with ethanol (20 mL) and methanol (20 mL) to give a light yellow solution. Ethyl <i>N</i>-[[3-bromo-6-(trifluoromethyl)pyridin-2-yl]carbamothioyl]carbamate (1.87 g, 5.02 mmol, 1.00 equiv) was added, and the mixture was stirred at room temperature for 1 h and then heated to 60 °C for 3 h. After being cooled, the mixture was concentrated under vacuum, poured into 25 mL of saturated NaHCO<sub>3</sub>, and extracted with DCM. The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude material was purified by chromatography (silica gel, ethylacetate/heptane = 50:50 to 100:0) to yield the title compound (976 mg, 69.1% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.70 (br d, <i>J</i> = 8.0 Hz, 1H), 7.12 (br d, <i>J</i> = 8.0 Hz, 1H), 4.89 (br s, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>7</sub> H<sub>4</sub> Br F<sub>3</sub> N<sub>4</sub>: 280.9644, found: 280.9644, diff 0.0 mDa.</div></div><div id="sec4_7_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 8-(2,2,2-Trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>44-1</b>)</h5><div class="NLM_p last">General procedure C: NaH (30.3 mg, 694 μmol, 1.3 equiv) was suspended in DMF (1 mL) and cooled to 0 °C in an ice bath. 2,2,2-Trifluoroethanol (80.1 mg, 57.6 μL, 801 μmol, 1.5 equiv) dissolved in DMF (1 mL) was added dropwise over 10 min. After the addition, the ice bath was removed and the reaction mixture was stirred 20 min. 8-Bromo-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (150 mg, 534 μmol, 1 equiv) (<b>43</b>) dissolved in DMF (1 mL) was added dropwise afterward followed by copper(I) bromide (766 μg, 5.34 μmol, 0.01 equiv) and the mixture was heated to 155 °C for 4 h. After being cooled, the mixture was poured into saturated NaHCO<sub>3</sub> and extracted with DCM. The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. Chromatography (silica gel, 25 g, 0–80% EtOAc in heptane) afforded the title compound 8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (98 mg, 61.2% yield). <sup>1</sup>HNMR (CDCl<sub>3</sub>, 300 MHz) δ 7.18 (br d, <i>J</i> = 8.3 Hz, 1H), 6.94 (br d, <i>J</i> = 8.3 Hz, 1H), 4.88 (q, <i>J</i> = 8.1 Hz, 2H), 4.68 (br s, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>6</sub> F<sub>6</sub> N<sub>4</sub> O: 301.0519, found: 301.0517, diff −0.2 mDa.</div></div><div id="sec4_7_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 2-Bromo-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>45-1</b>)</h5><div class="NLM_p last">General procedure D<b>:</b> To a dark green solution of <i>tert</i>-butyl nitrite (388 mg, 449 μL, 3.76 mmol, 1.5 equiv) and copper(II) bromide (839 mg, 3.76 mmol, 1.5 equiv) in acetonitrile (24 mL) at 60 °C was added dropwise a solution of 8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (752 mg, 2.51 mmol, 1 equiv) in acetonitrile (2.0 mL). After addition the reaction was warmed to 75 °C and stirred for 6 h. HCl (10 mL of 1 M) was added to stop the reaction that was diluted with 5 mL of H<sub>2</sub>O and extracted with DCM. The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. The crude material was purified by flash chromatography (silica gel, 12 g, 0–80% EtOAc in heptane) to afford the title compound 2-bromo-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (756.4 mg, 82.9% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.42 (br d, <i>J</i> = 8.3 Hz, 1H), 7.11 (br d, <i>J</i> = 8.3 Hz, 1H), 4.99 (q, <i>J</i> = 7.9 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>4</sub> Br F<sub>6</sub> N<sub>3</sub> O: 363.9515, found: 363.9520, diff 0.5 mDa.</div></div><div id="sec4_7_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 5-(Trifluoromethyl)-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>44-2</b>)</h5><div class="NLM_p last">The compound was prepared similarly to compound (<b>44-1</b>) following general procedure C using NaH (202 mg, 4.63 mmol, 1.3 equiv), 1,1,1-trifluoro-2-propanol (609 mg, 484 μL, 5.34 mmol, 1.5 equiv), 8-bromo-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (1 g, 3.56 mmol, 1 equiv), and copper(I) bromide (5.1 mg, 35.6 μmol, 0.01 equiv) in DMF (24 mL). The crude material was purified by flash chromatography (silica gel, 0–40% EtOAc in heptane) to afford 5-(trifluoromethyl)-8-((1,1,1-trifluoropropan-2-yl)oxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine <b>44-2</b> (732 mg, 65.5% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.17 (d, <i>J</i> = 8.3 Hz, 1H), 6.98 (d, <i>J</i> = 8.3 Hz, 1H), 5.58 (qq, <i>J</i> = 6.4, 6.3 Hz, 1H), 4.66 (br s, 2H), 1.63 (dq, <i>J</i> = 6.4, 0.7 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>8</sub> F<sub>6</sub> N<sub>4</sub> O: 315.0675, found: 315.0672, diff −0.3 mDa.</div></div><div id="sec4_7_7_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 5-(Trifluoromethyl)-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>44-2</b>) (<i>S</i>)</h5><div class="NLM_p">The (<i>S</i>) and (<i>R</i>) enantiomers were initially obtained from chiral separation of racemic 5-(trifluoromethyl)-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine <b>44-2</b> using as column Chiralpak AD as a column and heptane/isopropanol (90/10) as a solvent. The retention time of the (<i>S</i>) enantiomer was 7.400 min (with a negative optical rotation). The retention time of the (<i>R</i>) enantiomer was 8.483 min (with a positive optical rotation).</div><div class="NLM_p last">The absolute configuration for the chiral 5-(trifluoromethyl)-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine was determined by chiral synthesis. The enantiomers were prepared according to the same procedure used to synthesize racemic (<b>44-2</b>) using chiral (<i>R</i>) or (<i>S</i>) 1,1,1-trifluoro-propan-2-ol instead of racemic 1,1,1-trifluoro-propan-2-ol. Coinjection in the column Chiralpak AD determined the absolute configuration according to the mentioned retention times. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.17 (d, <i>J</i> = 8.5 Hz, 1H), 6.98 (d, <i>J</i> = 8.1 Hz, 1H), 5.59 (qq, <i>J</i> = 6.5, 6.3 Hz, 1H), 4.66 (br s, 2H), 1.63 (dq, <i>J</i> = 6.5, 0.6, 0.6,0.6 Hz,3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>8</sub> F<sub>6</sub> N<sub>4</sub> O: 315.0675, found: 315.0673, diff −0.2 mDa.</div></div><div id="sec4_7_7_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 2-Bromo-5-(trifluoromethyl)-8-(1,1,1-trifluoropropan-2-yloxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>45-2</b>)</h5><div class="NLM_p last">The title compound was prepared following a similar procedure to synthesize <b>45-1</b>, using <i>tert</i>-butyl-nitrite (207 mg, 239 μL, 2.01 mmol) and 5-(trifluoromethyl)-8-[(2)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (420 mg, 1.34 mmol) (<b>44-2</b>) in acetonitrile (1.12 mL) at 60 °C. The crude material was purified by flash chromatography (silica gel, 25 g, 0–50% EtOAc in heptane) to afford the title compound 2-bromo-5-(trifluoromethyl)-8-((1,1,1-trifluoropropan-2-yl)oxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (432 mg, 1.14 mmol, 85.5% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.41 (d, <i>J</i> = 8.7 Hz, 1H), 7.13 (d, <i>J</i> = 8.3 Hz, 1H), 5.70 (qq, <i>J</i> = 6.5, 6.2 Hz, 1H), 1.67 (dq, <i>J</i> = 6.5, 0.6, 0.6, 0.6 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>6</sub> Br F<sub>6</sub> N<sub>3</sub> O: 377.9671, found: 377.9667, diff −0.4mDa.</div></div><div id="sec4_7_7_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 2-Bromo-5-(trifluoromethyl)-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>45-2</b>) <b>(<i>S</i>)</b></h5><div class="NLM_p last">Similar to the preparation of <b>45-1</b>, the title compound was prepared using <i>tert</i>-butyl-nitrite (79.6 mg, 92.1 μL, 772 μmol), copper(II) bromide (172 mg, 772 μmol), and chiral 5-(trifluoromethyl)-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (161.6 mg, 514 μmol) <b>(44-2) (<i>S</i>)</b> in acetonitrile (4.8 mL) at 60 °C. The compound was obtained as a white solid (190.3 mg, 503 μmol, 97.9% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ ppm 7.41 (d, <i>J</i> = 8.3 Hz, 1H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 5.70 (qq, <i>J</i> = 6.5, 6.3 Hz, 1H), 1.67 (dq. <i>J</i> = 6,5, 0.6 Hz, 3H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>10</sub> H<sub>6</sub> Br F<sub>6</sub> N<sub>3</sub> O: 377.9671, found: 377.9669, diff −0.2 mDa.</div></div><div id="sec4_7_7_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 8-(2,2-Difluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>44-3</b>)</h5><div class="NLM_p last">The compound was prepared following a similar procedure for the preparation of (<b>44-1</b>) using NaH (404 mg, 9.25 mmol, 1.3 equiv), 2-difluoroethanol (876 mg, 676 μL, 10.7 mmol, 1.5 equiv), 8-bromo-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (2 g, 7.12 mmol, 1 equiv) (<b>45-3</b>), and copper(I) bromide (10.2 mg, 71.2 μmol, 0.01 equiv) in DMF (3 × 13 mL). The organic layers were dried over MgSO<sub>4</sub> and concentrated under vacuum. Chromatography (silica gel, 80 g, 0–80% EtOAc in heptane) afforded the final compound <b>44-3</b> (1.51 g, 5.35 mmol, 75.2% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.18 (d, <i>J</i> = 8.3 Hz, 1H), 6.84 (d, <i>J</i> = 8.3 Hz, 1H), 6.23 (tt, <i>J</i> = 54.7, 4.1 Hz, 1H), 4.68 (br s, 2H), 4.53 (td, <i>J</i> = 12.7, 4.1 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>7</sub> F<sub>5</sub> N<sub>4</sub> O: 283.0613, found: 283.0609, diff −0.4 mDa.</div></div><div id="sec4_7_7_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 2-Bromo-8-(2,2-difluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>45-3</b>)</h5><div class="NLM_p last">Similar to the preparation of <b>45-1</b>, the compound was obtained using <i>tert</i>-butyl-nitrite (828 mg, 958 μL, 8.03 mmol, 1.5 equiv), copper(II) bromide (1.79 g, 8.03 mmol, 1.5 equiv), and 8-(2,2-difluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (1.51 g, 5.35 mmol, 1 equiv) (<b>46-3</b>) in acetonitrile (40 mL) from 60–75 °C. The title compound 2-bromo-8-(2,2-difluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (1.66 g, 4.8 mmol, 89.6% yield) was obtained as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ pppm 7.41 (d, <i>J</i> = 8.3 Hz, 1H), 6.99 (d, <i>J</i> = 8.3 Hz, 1H), 6.23 (tt, <i>J</i> = 54.7, 4.0 Hz, 1H), 4.63 (td, <i>J</i> = 12.7, 4.0 Hz, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub> H<sub>5</sub> Br F<sub>5</sub> N<sub>3</sub> O: 345.9609, found: 345.9610, diff 0.1 mDa.</div></div></div><div id="sec4_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Preparation of Compounds Type B (<b>9B</b>, <b>12B</b>, <b>14B</b>, <b>17B</b>, and <b>18B</b>)</h4><div id="sec4_7_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> <i>N</i>-[(1<i>R</i>,5<i>S</i>)-3-(3-Methyl-1,2-thiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>9B</b>)</h5><div class="NLM_p last">Following a similar procedure described to prepare compound <b>3A</b>, 2-bromo-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (27.4 mg, 75.2 μmol, 1.05 equiv) (<b>45-1</b>), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (<b>29</b>) (16 mg, 71.6 μmol, 1 equiv), sodium <i>tert</i>-butoxide (20.7 mg, 215 μmol, 3 equiv), xantphos (6.63 mg, 11.5 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (5.93 mg, 5.73 μmol, 0.08 equiv) were combined in 1,4-dioxane (1 mL) and the mixture was heated in a microwave at 145 °C for 30 min. Chromatography (silica gel, 0–100% EtOAc in heptane) afforded the title compound <b>9B</b> (17.1 mg, 33.8 μmol, 47.1% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 7.36 (d, <i>J</i> = 8.6 Hz, 1H), 7.23 (d, <i>J</i> = 8.6 Hz, 1H), 6.59 (br s, 1H), 6.07 (s, 1H), 5.12 (q, <i>J</i> = 8.8 Hz, 2H), 3.8 (br s, 1H), 3.31 (dd, <i>J</i> = 11.8, 3.4 Hz, 2H), 3.23 (br d, <i>J</i> = 11.8 Hz, 2H), 2.6–2.5 (m, 2H), 2.23 (s, 3H), 2.1–2.0 (m, 2H), 1.65–1.5 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>20</sub> F<sub>6</sub> N<sub>6</sub> O S: 507.1396, found: 507.1401, diff 0.5 mDa.</div></div><div id="sec4_7_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-Methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl]-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>12B</b>)</h5><div class="NLM_p last">2-Bromo-8-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (29 mg, 79.4 μmol, 1 equiv) (<b>45-1</b>), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-amine (18.2 mg, 87.3 μmol, 1.1 equiv) (<b>31</b>), and sodium <i>tert</i>-butoxide (15.6 mg, 163 μmol, 2.05 equiv) were degassed with argon in an ultra sound bath. Dibromo-bis-(tri-<i>tert</i>-butyl)-phosphine-palladium (or Bromo(tri-<i>tert</i>-butylphosphine)palladium(I)dimer) (6.17 mg, 7.94 μmol, 0.1 equiv) was added to the reaction mixture under argon, and the reaction mixture was heated to 110 °C for 1 h. The residue was dissolved in 25 mL of saturated NaHCO<sub>3</sub> and extracted with DCM. The organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The crude material was purified by flash chromatography (silica gel, 0–80% EtOAc in heptane) to afford the title compound (<b>12B</b>) as a white solid (21 mg, 54% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 7.37 (d, <i>J</i> = 8.3 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 6.60 (br s, 1H), 5.12 (q, <i>J</i> = 8.7 Hz, 2H), 3.88 (br s, 1H), 3.81 (dd, <i>J</i> = 12.9, 3.6 Hz, 2H), 3.38 (br d, <i>J</i> = 12.9 Hz, 2H), 2.6–2.5 (m, 2H), 2.12 (s, 3H), 2.05–1.98 (m, 2H), 1.53–1.46 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub> H<sub>19</sub> F<sub>6</sub> N<sub>7</sub> O<sub>2</sub>: 492.1577, found: 492.1576, diff −0.1 mDa.</div></div><div id="sec4_7_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> <i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-Methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]-5-(trifluoromethyl)-8-[1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>14B</b>)</h5><div class="NLM_p last">Following a similar procedure described to prepare compound <b>3A</b>, 2-bromo-5-(trifluoromethyl)-8-((1,1,1-trifluoropropan-2-yl)oxy)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>45-2</b>) (50 mg, 132 μmol, 1 equiv), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-amine (33.1 mg, 159 μmol, 1.2 equiv) (<b>35</b>), sodium <i>tert</i>-butoxide (25.4 mg, 265 μmol, 2 equiv), xantphos (12.2 mg, 21.2 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (11 mg, 10.6 μmol, 0.08 equiv) were solved in 1,4-dioxane (1 mL), and the mixture was heated in a microwave at 125 °C for 30 min. Flash chromatography (silica gel, 0–100% EtOAc in heptane) yielded the title compound <b>14B</b> (46.1 mg, 91.2 μmol, 69% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 7.35 (d, <i>J</i> = 8.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 6.60 (br s, 1H), 5.75 (qq, <i>J</i> = 6.5, 6.4 Hz, 1H), 3.83 (br s, 1H), 3.66 (dd, <i>J</i> = 12.4, 3.5 Hz, 2H), 3.28 (br d, <i>J</i> = 12.4 Hz, 2H), 2.6–2.5 (m, 2H), 2.32 (s, 3H), 2.03–1.9 (m, 2H), 1.58 (dq, <i>J</i> = 6.4. 0.8 Hz, 3H), 1.6–1.5 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>21</sub> F<sub>6</sub> N<sub>7</sub> O<sub>2</sub>: 506.1734, found: 506.1732, diff −0.2 mDa.</div></div><div id="sec4_7_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 8-(2,2-Difluoroethoxy)-<i>N</i>-[(1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>17B</b>)</h5><div class="NLM_p last">Following a similar procedure described to prepare compound <b>3A</b>, 2-bromo-8-(2,2-difluoroethoxy)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (1.5 g, 4.33 mmol, 1 equiv), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-amine (1.14 g, 5.2 mmol, 1.2 equiv) (<b>39</b>), sodium <i>tert</i>-butoxide (833 mg, 8.67 mmol, 2 equiv), xantphos (401 mg, 694 μmol, 0.16 equiv), and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (359 mg, 347 μmol, 0.08 equiv) were combined in 1,4-dioxane (30 mL). The final compound was purified by flash chromatography (silica gel, 80 g, 0–5% MeOH in DCM). After chromotography, 1.24 g of 8-(2,2-difluoroethoxy)-<i>N</i>-((1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-5-(trifluoromethyl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine <b>17B</b> was obtained (59.2% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 8.38 (s, 1H), 7.34 (d, <i>J</i> = 8.3 Hz, 1H), 7.16 (d, <i>J</i> = 8.3 Hz, 1H), 6.60 (s, 1H), (6.54-6.4-6.37) 6.41 (tt, <i>J</i> = 54.5, 3.6Hz, 1H), 6.49 (br s, 1H, NH), 4.72 (td, <i>J</i> = 14.5, 3.6 Hz, 2H), 4.18 (dd, <i>J</i> = 12.1, 3.4 Hz, 2H), 3.89 (br s, 1H), 3.10 (br d, <i>J</i> = 12.1 Hz, 2H), 2.6–2.5 (m, 2H), 2.29 (s, 3H), 2.0–1.9 (m, 2H), 1.5–1.4 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub> H<sub>22</sub> F<sub>5</sub> N<sub>7</sub> O: 484.1879, found: 484.1875, diff −0.4 mDa.</div></div><div id="sec4_7_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> <i>N</i>-[(1<i>R</i>,5<i>S</i>)-3-(5-Methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]-5-(trifluoromethyl)-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (18B) (S Enantiomer of <b>14B</b>)</h5><div class="NLM_p last">Following the similar procedure to prepare compound <b>3A</b>, 2-bromo-5-(trifluoromethyl)-8-[(2<i>S</i>)-1,1,1-trifluoropropan-2-yl]oxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridine <b>(45-2) (<i>S</i>)</b> (30 mg, 79.4 μmol), (1<i>R</i>,5<i>S</i>,8<i>s</i>)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-3-azabicyclo[3.2.1]octan-8-amine (19.8 mg, 95.2 μmol, 1.2 equiv) (<b>35</b>), and sodium <i>tert</i>-butoxide (15.3 mg, 159 μmol, 2 equiv) in 1,4-dioxane (1 mL) were degassed with argon in an ultra sound bath for 5 min. Xantphos (7.35 mg, 12.7 μmol, 0.16 equiv) and tris(dibenzylideneacetone)dipalladium (0) chloroform adduct (6.57 mg, 6.35 μmol, 0.08 equiv) were added, and the reaction mixture was heated in a microwave at 130 °C for 30 min. After extraction, the crude material was purified by flash chromatography (silica gel, 25 g, 0–100% EtOAc in heptane) to afford <b>18B</b> (24.1 mg, 47.7 μmol, 60.1% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ ppm 7.35 (d, <i>J</i> = 8.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 6.61 (br s, 1H, NH), 5.75 (qq, <i>J</i> = 6.5. 6.49 Hz, 1H), 3.83 (br s, 1H), 3.66 (dd, <i>J</i> = 12.4, 3.5 Hz, 2H), 3.28 (br d, <i>J</i> = 12.4 Hz, 2H), 2.5–2.6 (m, 2H), 2.32 (s, 3H), 2.05–1.95 (m, 2H), 1.58 (dq, <i>J</i> = 6.5, 0.9 Hz, 3H), 1.5–1.6 (m, 2H); LC-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub> H<sub>21</sub> F<sub>6</sub> N<sub>7</sub> O<sub>2</sub>: 506.1734, found: 506.1731, diff −0.3 mDa. [α]<sub class="stack">D</sub><sup class="stack">20</sup> (<i>c</i>1 CH<sub>3</sub>OH) <i>=</i> −11.43 for the described chiral <i>S</i> enantiomer.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00909" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16437" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16437" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00909?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00909</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC of the described chiral intermediates, HPLC chromatograms of the key compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Corresponding pdb-formatted file of the PIK4CB docking model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_001.pdf">jm0c00909_si_001.pdf (957.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_002.pdb">jm0c00909_si_002.pdb (636.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_003.csv">jm0c00909_si_003.csv (1.62 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00909" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosa María Rodríguez
Sarmiento</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0737-8885" title="Orcid link">http://orcid.org/0000-0003-0737-8885</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#94e6fbe7f5cbf9f5e6fdf5bae6fbf0e6fdf3e1f1eecbe7f5e6f9fdf1fae0fbd4e6fbf7fcf1baf7fbf9"><span class="__cf_email__" data-cfemail="25574a56447a4844574c440b574a41574c4250405f7a564457484c404b514a65574a464d400b464a48">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caterina Bissantz</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Bylund</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anja Limberg</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Werner Neidhart</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roland Jakob-Roetne</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisha Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karlheinz Baumann</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research and
Early Development, F. Hoffmann-La Roche
AG, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are employees of F. Hoffmann-La Roche AG.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7476-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank to Stefan Berchtold, Danny Krumm, Patrick Boisson, Katharine Locke, and Markus Bender for the preparation of the compounds described. The authors also thank Erwin Gotschi, Andrew Thomas, Luke Green, and Thomas Luebbers for previous work on diverse series of the GSM projects. The authors also thank Hasane Ratni for discussions on the manuscript. The research described in the manuscript was funded by F. Hoffmann-La Roche AG.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid β</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">GSM</td><td class="NLM_def"><p class="first last">γ-secretase modulator</p></td></tr><tr><td class="NLM_term">CVB</td><td class="NLM_def"><p class="first last">covalent binding</p></td></tr><tr><td class="NLM_term">PBB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">fup</td><td class="NLM_def"><p class="first last">fraction unbound in plasma</p></td></tr><tr><td class="NLM_term">PKPD</td><td class="NLM_def"><p class="first last">pharmacokinetics and pharmacodynamics</p></td></tr><tr><td class="NLM_term">PIF</td><td class="NLM_def"><p class="first last">photoirritancy factor</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brayne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodaty, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fratiglioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scazufca, M.</span></span> <span> </span><span class="NLM_article-title">Global prevalence of dementia: a Delphi consensus study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2112</span>– <span class="NLM_lpage">2117</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)67889-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1016%2FS0140-6736%2805%2967889-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=16360788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A280%3ADC%252BD2MnnsVSiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2005&pages=2112-2117&author=C.+P.+Ferriauthor=M.+Princeauthor=C.+Brayneauthor=H.+Brodatyauthor=L.+Fratiglioniauthor=M.+Ganguliauthor=K.+Hallauthor=K.+Hasegawaauthor=H.+Hendrieauthor=Y.+Huangauthor=A.+Jormauthor=C.+Mathersauthor=P.+R.+Menezesauthor=E.+Rimmerauthor=M.+Scazufca&title=Global+prevalence+of+dementia%3A+a+Delphi+consensus+study&doi=10.1016%2FS0140-6736%2805%2967889-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global prevalence of dementia: a Delphi consensus study</span></div><div class="casAuthors">Ferri Cleusa P; Prince Martin; Brayne Carol; Brodaty Henry; Fratiglioni Laura; Ganguli Mary; Hall Kathleen; Hasegawa Kazuo; Hendrie Hugh; Huang Yueqin; Jorm Anthony; Mathers Colin; Menezes Paulo R; Rimmer Elizabeth; Scazufca Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9503</span>),
    <span class="NLM_cas:pages">2112-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  100 years after the first description, Alzheimer's disease is one of the most disabling and burdensome health conditions worldwide.  We used the Delphi consensus method to determine dementia prevalence for each world region.  METHODS:  12 international experts were provided with a systematic review of published studies on dementia and were asked to provide prevalence estimates for every WHO world region, for men and women combined, in 5-year age bands from 60 to 84 years, and for those aged 85 years and older.  UN population estimates and projections were used to estimate numbers of people with dementia in 2001, 2020, and 2040.  We estimated incidence rates from prevalence, remission, and mortality.  FINDINGS:  Evidence from well-planned, representative epidemiological surveys is scarce in many regions.  We estimate that 24.3 million people have dementia today, with 4.6 million new cases of dementia every year (one new case every 7 seconds).  The number of people affected will double every 20 years to 81.1 million by 2040.  Most people with dementia live in developing countries (60% in 2001, rising to 71% by 2040).  Rates of increase are not uniform; numbers in developed countries are forecast to increase by 100% between 2001 and 2040, but by more than 300% in India, China, and their south Asian and western Pacific neighbours.  INTERPRETATION:  We believe that the detailed estimates in this paper constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw6_2C-aXsbczK395ZObgVfW6udTcc2eYc7LDO8pOol7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnnsVSiug%253D%253D&md5=97f7f4cb7dfaa55dbdd6be23a7439efe</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2967889-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252967889-0%26sid%3Dliteratum%253Aachs%26aulast%3DFerri%26aufirst%3DC.%2BP.%26aulast%3DPrince%26aufirst%3DM.%26aulast%3DBrayne%26aufirst%3DC.%26aulast%3DBrodaty%26aufirst%3DH.%26aulast%3DFratiglioni%26aufirst%3DL.%26aulast%3DGanguli%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DHendrie%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJorm%26aufirst%3DA.%26aulast%3DMathers%26aufirst%3DC.%26aulast%3DMenezes%26aufirst%3DP.%2BR.%26aulast%3DRimmer%26aufirst%3DE.%26aulast%3DScazufca%26aufirst%3DM.%26atitle%3DGlobal%2520prevalence%2520of%2520dementia%253A%2520a%2520Delphi%2520consensus%2520study%26jtitle%3DLancet%26date%3D2005%26volume%3D366%26spage%3D2112%26epage%3D2117%26doi%3D10.1016%2FS0140-6736%2805%2967889-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzinger, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santacruz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossor, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1056%2FNEJMoa1202753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=22784036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=795-804&author=R.+J.+Batemanauthor=C.+Xiongauthor=T.+L.+Benzingerauthor=A.+M.+Faganauthor=A.+Goateauthor=N.+C.+Foxauthor=D.+S.+Marcusauthor=N.+J.+Cairnsauthor=X.+Xieauthor=T.+M.+Blazeyauthor=D.+M.+Holtzmanauthor=A.+Santacruzauthor=V.+Bucklesauthor=A.+Oliverauthor=K.+Moulderauthor=P.+S.+Aisenauthor=B.+Ghettiauthor=W.+E.+Klunkauthor=E.+McDadeauthor=R.+N.+Martinsauthor=C.+L.+Mastersauthor=R.+Mayeuxauthor=J.+M.+Ringmanauthor=M.+N.+Rossorauthor=P.+R.+Schofieldauthor=R.+A.+Sperlingauthor=S.+Sallowayauthor=J.+C.+Morris&title=Clinical+and+biomarker+changes+in+dominantly+inherited+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1202753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker changes in dominantly inherited Alzheimer's disease</span></div><div class="casAuthors">Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The order and magnitude of pathol. processes in Alzheimer's disease are not well understood, partly because the disease develops over many years.  Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to det. the sequence and magnitude of pathol. changes that culminate in symptomatic disease.  METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clin. and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests.  We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calc. the estd. years from expected symptom onset (age of the participant minus parent's age at symptom onset).  We conducted cross-sectional analyses of baseline data in relation to estd. years from expected symptom onset in order to det. the relative order and magnitude of pathophysiol. changes.  RESULTS: Concns. of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before expected symptom onset.  Aβ deposition, as measured by positron-emission tomog. with the use of Pittsburgh compd. B, was detected 15 years before expected symptom onset.  Increased concns. of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset.  Cerebral hypometabolism and impaired episodic memory were obsd. 10 years before expected symptom onset.  Global cognitive impairment, as measured by the Mini-Mental State Examn. and the Clin. Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an av. of 3 years after expected symptom onset.  CONCLUSIONS: We found that autosomal dominant Alzheimer's disease was assocd. with a series of pathophysiol. changes over decades in CSF biochem. markers of Alzheimer's disease, brain amyloid deposition, and brain metab. as well as progressive cognitive impairment.  Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJNV9eDXBCLVg90H21EOLACvtfcHk0liMwqsm8ZjyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J&md5=c4f999ea3401af9651a2770724757bed</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202753%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DC.%26aulast%3DBenzinger%26aufirst%3DT.%2BL.%26aulast%3DFagan%26aufirst%3DA.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DN.%2BC.%26aulast%3DMarcus%26aufirst%3DD.%2BS.%26aulast%3DCairns%26aufirst%3DN.%2BJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBlazey%26aufirst%3DT.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DSantacruz%26aufirst%3DA.%26aulast%3DBuckles%26aufirst%3DV.%26aulast%3DOliver%26aufirst%3DA.%26aulast%3DMoulder%26aufirst%3DK.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DGhetti%26aufirst%3DB.%26aulast%3DKlunk%26aufirst%3DW.%2BE.%26aulast%3DMcDade%26aufirst%3DE.%26aulast%3DMartins%26aufirst%3DR.%2BN.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DMayeux%26aufirst%3DR.%26aulast%3DRingman%26aufirst%3DJ.%2BM.%26aulast%3DRossor%26aufirst%3DM.%2BN.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DClinical%2520and%2520biomarker%2520changes%2520in%2520dominantly%2520inherited%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D795%26epage%3D804%26doi%3D10.1056%2FNEJMoa1202753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachurin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovina, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustyugov, A. A.</span></span> <span> </span><span class="NLM_article-title">Drugs in Clinical Trials for Alzheimer’s Disease: The Major Trends</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1186</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1002/med.21434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1002%2Fmed.21434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=28084618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yktbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1186-1225&author=S.+O.+Bachurinauthor=E.+V.+Bovinaauthor=A.+A.+Ustyugov&title=Drugs+in+Clinical+Trials+for+Alzheimer%E2%80%99s+Disease%3A+The+Major+Trends&doi=10.1002%2Fmed.21434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends</span></div><div class="casAuthors">Bachurin, Sergey O.; Bovina, Elena V.; Ustyugov, Aleksey A.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1186-1225</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by a chronic and progressive neurodegenerative process resulting from the intracellular and extracellular accumulation of fibrillary proteins: beta-amyloid and hyperphosphorylated Tau.  Overaccumulation of these aggregates leads to synaptic dysfunction and subsequent neuronal loss.  The precise mol. mechanisms of AD are still not fully understood but it is clear that AD is a multifactorial disorder and that advanced age is the main risk factor.  Over the last decade, more than 50 drug candidates have successfully passed phase II clin. trials, but none has passed phase III.  Here, we summarize data on current "anti-Alzheimer's" agents currently in clin. trials based on findings available in the Thomson Reuters 'Integrity' database, on the public website, and on database of the website .  As a result, it was possible to outline some major trends in AD drug discovery: (i) the development of compds. acting on the main stages of the pathogenesis of the disease (the so-called "disease-modifying agents") - these drugs could potentially slow the development of structural and functional abnormalities in the central nervous system providing sustainable improvements of cognitive functions, which persist even after drug withdrawal; (ii) focused design of multitargeted drugs acting on multiple mol. targets involved in the pathogenesis of the disease; (3) finally, the repositioning of old drugs for new (anti-Alzheimer's) application offers a very attractive approach to facilitate the completion of clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgLGjGuc0iLVg90H21EOLACvtfcHk0lgquhbxXeNXlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yktbvO&md5=a5659940c428ecd50892d80e0c1baa7d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.21434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21434%26sid%3Dliteratum%253Aachs%26aulast%3DBachurin%26aufirst%3DS.%2BO.%26aulast%3DBovina%26aufirst%3DE.%2BV.%26aulast%3DUstyugov%26aufirst%3DA.%2BA.%26atitle%3DDrugs%2520in%2520Clinical%2520Trials%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520The%2520Major%2520Trends%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1186%26epage%3D1225%26doi%3D10.1002%2Fmed.21434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzi, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertram, L.</span></span> <span> </span><span class="NLM_article-title">Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2005.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1016%2Fj.cell.2005.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=15734686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVWnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2005&pages=545-555&author=R.+E.+Tanziauthor=L.+Bertram&title=Twenty+years+of+the+Alzheimer%E2%80%99s+disease+amyloid+hypothesis%3A+a+genetic+perspective&doi=10.1016%2Fj.cell.2005.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective</span></div><div class="casAuthors">Tanzi, Rudolph E.; Bertram, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  From Alois Alzheimer's description of Auguste D.'s brain in 1907 to George Glenner's biochem. dissection of β-amyloid in 1984, the "amyloid hypothesis" of Alzheimer's disease has continued to gain support over the past two decades, particularly from genetic studies.  Here we assess the amyloid hypothesis based on both known and putative Alzheimer's disease genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPVQvwUmMmXrVg90H21EOLACvtfcHk0lgquhbxXeNXlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVWnu7k%253D&md5=3f88dc7dda6b726429789c61d5992493</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DTanzi%26aufirst%3DR.%2BE.%26aulast%3DBertram%26aufirst%3DL.%26atitle%3DTwenty%2520years%2520of%2520the%2520Alzheimer%25E2%2580%2599s%2520disease%2520amyloid%2520hypothesis%253A%2520a%2520genetic%2520perspective%26jtitle%3DCell%26date%3D2005%26volume%3D120%26spage%3D545%26epage%3D555%26doi%3D10.1016%2Fj.cell.2005.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, F.</span></span> <span> </span><span class="NLM_article-title">Dementia: What pharmacists need to know</span>. <i>Can. Pharm. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1177/1715163517690745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1177%2F1715163517690745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnsVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2017&pages=118-129&author=S.+Duongauthor=T.+Patelauthor=F.+Chang&title=Dementia%3A+What+pharmacists+need+to+know&doi=10.1177%2F1715163517690745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dementia: What pharmacists need to know</span></div><div class="casAuthors">Duong Silvia; Patel Tejal; Chang Feng</div><div class="citationInfo"><span class="NLM_cas:title">Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-129</span>
        ISSN:<span class="NLM_cas:issn">1715-1635</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsLLKKFDIcAL7NkxioyDXTfW6udTcc2eYx085EuRiBq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnsVSjsQ%253D%253D&md5=6b214901f72daec435e91c86f7fa0898</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1177%2F1715163517690745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1715163517690745%26sid%3Dliteratum%253Aachs%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DF.%26atitle%3DDementia%253A%2520What%2520pharmacists%2520need%2520to%2520know%26jtitle%3DCan.%2520Pharm.%2520J.%26date%3D2017%26volume%3D150%26spage%3D118%26epage%3D129%26doi%3D10.1177%2F1715163517690745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">a004457</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a004457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1101%2Fcshperspect.a004457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21576255" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=D.+J.+Selkoe&title=Alzheimer%E2%80%99s+disease&doi=10.1101%2Fcshperspect.a004457"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a004457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a004457%26sid%3Dliteratum%253Aachs%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2011%26volume%3D3%26doi%3D10.1101%2Fcshperspect.a004457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease at 25 years</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.15252/emmm.201606210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.15252%2Femmm.201606210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=27025652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=595-608&author=D.+J.+Selkoeauthor=J.+Hardy&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease+at+25+years&doi=10.15252%2Femmm.201606210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease at 25 years</span></div><div class="casAuthors">Selkoe, Dennis J.; Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">595-608</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Despite continuing debate about the amyloid β-protein or Aβ hypothesis, new lines of evidence from labs. and clinics worldwide support the concept that an imbalance between prodn. and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease AD.  Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate amyloid precursor protein, APP or the protease presenilin of the reaction that generates Aβ.  Duplication of the wild-type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD.  Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain.  Sol. oligomers of Aβ42 isolated from AD patients' brains can decrease synapse no., inhibit long-term potentiation, and enhance long-term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory.  The human oligomers also induce hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in cultured neurons.  Crossing human APP with human tau transgenic mice enhances tau-pos. neurotoxicity.  In humans, new studies show that low cerebrospinal fluid CSF Aβ42 and amyloid-PET positivity precede other AD manifestations by many years.  Most importantly, recent trials of three different Aβ antibodies solanezumab, crenezumab, and aducanumab have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects.  Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyGo1qmyvVtbVg90H21EOLACvtfcHk0lh3e_KjKd7O5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D&md5=b7a2003ba5d341f5eef5c7e9454235ce</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.15252%2Femmm.201606210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201606210%26sid%3Dliteratum%253Aachs%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520at%252025%2520years%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D595%26epage%3D608%26doi%3D10.15252%2Femmm.201606210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suemoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleegers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Broeckhoven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saido, T. C.</span></span> <span> </span><span class="NLM_article-title">Potent amyloidogenicity and pathogenicity of Abeta43</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1038/nn.2858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1038%2Fnn.2858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21725313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlClsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=1023-1032&author=T.+Saitoauthor=T.+Suemotoauthor=N.+Brouwersauthor=K.+Sleegersauthor=S.+Funamotoauthor=N.+Mihiraauthor=Y.+Matsubaauthor=K.+Yamadaauthor=P.+Nilssonauthor=J.+Takanoauthor=M.+Nishimuraauthor=N.+Iwataauthor=C.+Van+Broeckhovenauthor=Y.+Iharaauthor=T.+C.+Saido&title=Potent+amyloidogenicity+and+pathogenicity+of+Abeta43&doi=10.1038%2Fnn.2858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potent amyloidogenicity and pathogenicity of Aβ43</span></div><div class="casAuthors">Saito, Takashi; Suemoto, Takahiro; Brouwers, Nathalie; Sleegers, Kristel; Funamoto, Satoru; Mihira, Naomi; Matsuba, Yukio; Yamada, Kazuyuki; Nilsson, Per; Takano, Jiro; Nishimura, Masaki; Iwata, Nobuhisa; Van Broeckhoven, Christine; Ihara, Yasuo; Saido, Takaomi C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1023-1032</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The amyloid-β peptide Aβ42 is known to be a primary amyloidogenic and pathogenic agent in Alzheimer's disease.  However, the role of Aβ43, which is found just as frequently in the brains of affected individuals, remains unresolved.  We generated knock-in mice contg. a pathogenic presenilin-1 R278I mutation that causes overprodn. of Aβ43.  Homozygosity was embryonic lethal, indicating that the mutation involves a loss of function.  Crossing amyloid precursor protein transgenic mice with heterozygous mutant mice resulted in elevated Aβ43, impairment of short-term memory and acceleration of amyloid-β pathol., which accompanied pronounced accumulation of Aβ43 in plaque cores similar in biochem. compn. to those obsd. in the brains of affected individuals.  Consistently, Aβ43 showed a higher propensity to aggregate and was more neurotoxic than Aβ42.  Other pathogenic presenilin mutations also caused overprodn. of Aβ43 in a manner correlating with Aβ42 and with the age of disease onset.  These findings indicate that Aβ43, an overlooked species, is potently amyloidogenic, neurotoxic and abundant in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1wc1KTo7vbVg90H21EOLACvtfcHk0lh3e_KjKd7O5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlClsLs%253D&md5=fcf07320891e8948f6368c0f698ef957</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnn.2858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2858%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DSuemoto%26aufirst%3DT.%26aulast%3DBrouwers%26aufirst%3DN.%26aulast%3DSleegers%26aufirst%3DK.%26aulast%3DFunamoto%26aufirst%3DS.%26aulast%3DMihira%26aufirst%3DN.%26aulast%3DMatsuba%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DNilsson%26aufirst%3DP.%26aulast%3DTakano%26aufirst%3DJ.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DIwata%26aufirst%3DN.%26aulast%3DVan%2BBroeckhoven%26aufirst%3DC.%26aulast%3DIhara%26aufirst%3DY.%26aulast%3DSaido%26aufirst%3DT.%2BC.%26atitle%3DPotent%2520amyloidogenicity%2520and%2520pathogenicity%2520of%2520Abeta43%26jtitle%3DNat.%2520Neurosci.%26date%3D2011%26volume%3D14%26spage%3D1023%26epage%3D1032%26doi%3D10.1038%2Fnn.2858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1126/science.1072994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1126%2Fscience.1072994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=12130773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=353-356&author=J.+Hardyauthor=D.+J.+Selkoe&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease%3A+progress+and+problems+on+the+road+to+therapeutics&doi=10.1126%2Fscience.1072994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</span></div><div class="casAuthors">Hardy, John; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5580</span>),
    <span class="NLM_cas:pages">353-356</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  It has been more than 10 yr since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide (Aβ) in plaques in brain tissue.  According to the amyloid hypothesis, accumulation of Aβ in the brain is the primary influence driving AD pathogenesis.  The rest of the disease process, including formation of neurofibrillary tangles contg. tau protein, is proposed to result from an imbalance between Aβ prodn. and Aβ clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9G5omTHR6cbVg90H21EOLACvtfcHk0lhGAAcvG_ZYxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D&md5=f7b8db1bc6f13e85f887b73f3042e86e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1072994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1072994%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520progress%2520and%2520problems%2520on%2520the%2520road%2520to%2520therapeutics%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D353%26epage%3D356%26doi%3D10.1126%2Fscience.1072994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1038/nrd3505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1038%2Fnrd3505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21852788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVelsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=698-712&author=E.+Karranauthor=M.+Merckenauthor=B.+De+Strooper&title=The+amyloid+cascade+hypothesis+for+Alzheimer%E2%80%99s+disease%3A+an+appraisal+for+the+development+of+therapeutics&doi=10.1038%2Fnrd3505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics</span></div><div class="casAuthors">Karran, Eric; Mercken, Marc; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">698-712</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathol., has dominated research for the past twenty years.  Several therapeutics that were purported to reduce amyloid-β prodn. or aggregation have failed in Phase III clin. testing, and many others are in various stages of development.  Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clin. trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_-zjcfHaQ87Vg90H21EOLACvtfcHk0lhGAAcvG_ZYxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVelsL3L&md5=cf2824a56a4c3df6e265d8788970729d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd3505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3505%26sid%3Dliteratum%253Aachs%26aulast%3DKarran%26aufirst%3DE.%26aulast%3DMercken%26aufirst%3DM.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DThe%2520amyloid%2520cascade%2520hypothesis%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520appraisal%2520for%2520the%2520development%2520of%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D698%26epage%3D712%26doi%3D10.1038%2Fnrd3505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bursavich, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blain, J. F.</span></span> <span> </span><span class="NLM_article-title">Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7389</span>– <span class="NLM_lpage">7409</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01960</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01960" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVajsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7389-7409&author=M.+G.+Bursavichauthor=B.+A.+Harrisonauthor=J.+F.+Blain&title=Gamma+Secretase+Modulators%3A+New+Alzheimer%E2%80%99s+Drugs+on+the+Horizon%3F&doi=10.1021%2Facs.jmedchem.5b01960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?</span></div><div class="casAuthors">Bursavich, Matthew G.; Harrison, Bryce A.; Blain, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7389-7409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rapidly aging population desperately requires new therapies for Alzheimer's disease.  Despite years of pharmaceutical research, limited clin. success has been realized, with several failed disease modification therapies in recent years.  On the basis of compelling genetic evidence, the pharmaceutical industry has put a large emphasis on brain beta amyloid (Aβ) either through its removal via antibodies or by targeting the proteases responsible for its prodn.  In this Perspective, we focus on the development of small mols. that improve the activity of one such protease, gamma secretase, through an allosteric binding site to preferentially increase the concn. of the shorter non-amyloidogenic Aβ species.  After a few early failures due to poor drug-like properties, the industry is now on the cusp of delivering gamma secretase modulators for clin. proof-of-mechanism studies that combine potency and efficacy with improved drug-like properties such as lower cLogP, high central nervous system multiparameter optimization scores, and high sp3 character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEjGJ5oHdrrVg90H21EOLACvtfcHk0lhcHMHq608Yiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVajsbk%253D&md5=8ba1b7de2ce64903c296b7cb63c1c5d3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01960%26sid%3Dliteratum%253Aachs%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DHarrison%26aufirst%3DB.%2BA.%26aulast%3DBlain%26aufirst%3DJ.%2BF.%26atitle%3DGamma%2520Secretase%2520Modulators%253A%2520New%2520Alzheimer%25E2%2580%2599s%2520Drugs%2520on%2520the%2520Horizon%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7389%26epage%3D7409%26doi%3D10.1021%2Facs.jmedchem.5b01960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Mena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceballos-Diaz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levites, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukar, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchelt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon-Limas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Funez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golde, T. E.</span></span> <span> </span><span class="NLM_article-title">Short Abeta peptides attenuate Abeta42 toxicity in vivo</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1084/jem.20170600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1084%2Fjem.20170600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=29208777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2rt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2018&pages=283-301&author=B.+D.+Mooreauthor=J.+Martinauthor=L.+de+Menaauthor=J.+Sanchezauthor=P.+E.+Cruzauthor=C.+Ceballos-Diazauthor=T.+B.+Laddauthor=Y.+Ranauthor=Y.+Levitesauthor=T.+L.+Kukarauthor=J.+J.+Kurianauthor=R.+McKennaauthor=E.+H.+Kooauthor=D.+R.+Borcheltauthor=C.+Janusauthor=D.+Rincon-Limasauthor=P.+Fernandez-Funezauthor=T.+E.+Golde&title=Short+Abeta+peptides+attenuate+Abeta42+toxicity+in+vivo&doi=10.1084%2Fjem.20170600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Short Aβ peptides attenuate Aβ42 toxicity in vivo</span></div><div class="casAuthors">Moore, Brenda D.; Martin, Jason; de Mena, Lorena; Sanchez, Jonatan; Cruz, Pedro E.; Ceballos-Diaz, Carolina; Ladd, Thomas B.; Ran, Yong; Levites, Yona; Kukar, Thomas L.; Kurian, Justin J.; McKenna, Robert; Koo, Edward H.; Borchelt, David R.; Janus, Christopher; Rincon-Limas, Diego; Fernandez-Funez, Pedro; Golde, Todd E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-301</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Processing of amyloid-β (Aβ) precursor protein (APP) by γ-secretase produces multiple species of Aβ: Aβ40, short Aβ peptides (Aβ37-39), and longer Aβ peptides (Aβ42-43). γ-Secretase modulators, a class of Alzheimer's disease therapeutics, reduce prodn. of the pathogenic Aβ42 but increase the relative abundance of short Aβ peptides.  To evaluate the pathol. relevance of these peptides, we expressed Aβ36-40 and Aβ42-43 in Drosophila melanogaster to evaluate inherent toxicity and potential modulatory effects on Aβ42 toxicity.  In contrast to Aβ42, the short Aβ peptides were not toxic and, when coexpressed with Aβ42, were protective in a dose-dependent fashion.  In parallel, we explored the effects of recombinant adeno- assocd. virus-mediated expression of Aβ38 and Aβ40 in mice.  When expressed in nontransgenic mice at levels sufficient to drive Aβ42 deposition, Aβ38 and Aβ40 did not deposit or cause behavioral alterations.  These studies indicate that treatments that lower Aβ42 by raising the levels of short Aβ peptides could attenuate the toxic effects of Aβ42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5jiOyGX0VmrVg90H21EOLACvtfcHk0lhcHMHq608Yiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2rt73J&md5=8fcdb12f8c4dc72b835f64dc93ebb18d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1084%2Fjem.20170600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20170600%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DB.%2BD.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3Dde%2BMena%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DP.%2BE.%26aulast%3DCeballos-Diaz%26aufirst%3DC.%26aulast%3DLadd%26aufirst%3DT.%2BB.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DLevites%26aufirst%3DY.%26aulast%3DKukar%26aufirst%3DT.%2BL.%26aulast%3DKurian%26aufirst%3DJ.%2BJ.%26aulast%3DMcKenna%26aufirst%3DR.%26aulast%3DKoo%26aufirst%3DE.%2BH.%26aulast%3DBorchelt%26aufirst%3DD.%2BR.%26aulast%3DJanus%26aufirst%3DC.%26aulast%3DRincon-Limas%26aufirst%3DD.%26aulast%3DFernandez-Funez%26aufirst%3DP.%26aulast%3DGolde%26aufirst%3DT.%2BE.%26atitle%3DShort%2520Abeta%2520peptides%2520attenuate%2520Abeta42%2520toxicity%2520in%2520vivo%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2018%26volume%3D215%26spage%3D283%26epage%3D301%26doi%3D10.1084%2Fjem.20170600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haapasalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, D. M.</span></span> <span> </span><span class="NLM_article-title">The many substrates of presenilin/gamma-secretase</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.3233/JAD-2011-101065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.3233%2FJAD-2011-101065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21335653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=3-28&author=A.+Haapasaloauthor=D.+M.+Kovacs&title=The+many+substrates+of+presenilin%2Fgamma-secretase&doi=10.3233%2FJAD-2011-101065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Substrates of Presenilin/γ-Secretase</span></div><div class="casAuthors">Haapasalo, Annakaisa; Kovacs, Dora M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-28</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  The Alzheimer's disease (AD)-assocd. amyloid-β protein precursor (AβPP) is cleaved by α-, β-, and presenilin (PS)/γ-secretases through sequential regulated proteolysis.  These proteolytic events control the generation of the pathogenic amyloid-β (Aβ) peptide, which excessively accumulates in the brains of individuals afflicted by AD.  A growing no. of addnl. proteins cleaved by PS/γ-secretase continue to be discovered.  Similarly to AβPP, most of these proteins are type-I transmembrane proteins involved in vital signaling functions regulating cell fate, adhesion, migration, neurite outgrowth, or synaptogenesis.  All the identified proteins share common structural features, which are typical for their proteolysis.  The consequences of the PS/γ-secretase-mediated cleavage on the function of many of these proteins are largely unknown.  Here, we review the current literature on the proteolytic processing mediated by the versatile PS/γ-secretase complex.  We begin by discussing the steps of AβPP processing and PS/γ-secretase complex compn. and localization, which give clues to how and where the processing of other PS/γ-secretase substrates may take place.  Then we summarize the typical features of PS/γ-secretase-mediated protein processing.  Finally, we recapitulate the current knowledge on the possible physiol. function of PS/γ-secretase-mediated cleavage of specific substrate proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphYizFVw4_A7Vg90H21EOLACvtfcHk0lhKwhfV_V8itg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSisbY%253D&md5=22ce56939b97019e5c130556f9db7d5f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3233%2FJAD-2011-101065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2011-101065%26sid%3Dliteratum%253Aachs%26aulast%3DHaapasalo%26aufirst%3DA.%26aulast%3DKovacs%26aufirst%3DD.%2BM.%26atitle%3DThe%2520many%2520substrates%2520of%2520presenilin%252Fgamma-secretase%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2011%26volume%3D25%26spage%3D3%26epage%3D28%26doi%3D10.3233%2FJAD-2011-101065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beel, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, C. R.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity of gamma-secretase and other intramembrane proteases</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1311</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1007/s00018-008-7462-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1007%2Fs00018-008-7462-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=18239854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFyhurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=1311-1334&author=A.+J.+Beelauthor=C.+R.+Sanders&title=Substrate+specificity+of+gamma-secretase+and+other+intramembrane+proteases&doi=10.1007%2Fs00018-008-7462-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate specificity of γ-secretase and other intramembrane proteases</span></div><div class="casAuthors">Beel, A. J.; Sanders, C. R.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1311-1334</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  γ-Secretase (I) is a promiscuous protease that cleaves bitopic membrane proteins within the lipid bilayer.  Elucidating both the mechanistic basis of I proteolysis and the precise factors regulating substrate identification is important because modulation of this biochem. degradative process can have important consequences in a physiol. and pathophysiol. context.  Here, the authors briefly review such information for all major classes of intramembrane-cleaving proteases (I-CLiPs), with an emphasis on I, an I-CLiP closely linked to the etiol. of Alzheimer's disease.  A large body of emerging data allows the authors to survey the substrates of I to ascertain the conformational features that predispose a peptide to cleavage by this enigmatic protease.  Because substrate specificity in vivo is closely linked to the relative subcellular compartmentalization of I and its substrates, the authors also survey the voluminous body of literature concerning the traffic of I and its most prominent substrate, the amyloid precursor protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1_vPRH_d3rVg90H21EOLACvtfcHk0lhs6jxHHxay5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFyhurc%253D&md5=b4ab798610a0a26396ee65a92652e0e9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00018-008-7462-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-008-7462-2%26sid%3Dliteratum%253Aachs%26aulast%3DBeel%26aufirst%3DA.%2BJ.%26aulast%3DSanders%26aufirst%3DC.%2BR.%26atitle%3DSubstrate%2520specificity%2520of%2520gamma-secretase%2520and%2520other%2520intramembrane%2520proteases%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2008%26volume%3D65%26spage%3D1311%26epage%3D1334%26doi%3D10.1007%2Fs00018-008-7462-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Novel gamma-secretase modulators for the treatment of Alzheimer’s disease: a review focusing on patents from 2010 to 2012</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1349</span>– <span class="NLM_lpage">1366</span>, <span class="refDoi"> DOI: 10.1517/13543776.2013.821465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1517%2F13543776.2013.821465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=23875696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1349-1366&author=M.+Petterssonauthor=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=D.+S.+Johnson&title=Novel+gamma-secretase+modulators+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+a+review+focusing+on+patents+from+2010+to+2012&doi=10.1517%2F13543776.2013.821465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012</span></div><div class="casAuthors">Pettersson, Martin; Stepan, Antonia F.; Kauffman, Gregory W.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1349-1366</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: γ-Secretase is the enzyme responsible for the final step of amyloid precursor protein proteolysis to generate Aβ peptides including Aβ42 which is believed to be a toxic species involved in Alzheimer's disease (AD) progression. γ-Secretase modulators (GSMs) have been shown to selectively lower Aβ42 prodn. without affecting total Aβ levels or the formation of γ-secretase substrate intracellular domains such as APP intracellular domain and Notch intracellular domain.  Therefore, GSMs have emerged as an important therapeutic strategy for the treatment of AD.  Areas covered: The literature covering novel GSMs will be reviewed focusing on patents from 2010 to 2012.  Expert opinion: During the last review period (2008 - 2010) considerable progress was made developing GSMs with improved potency for lowering Aβ42 levels, but most of the compds. resided in unfavorable central nervous system (CNS) drug space.  In this review period (2010 - 2012), there is a higher percentage of potent GSM chem. matter that resides in favorable CNS drug space.  It is anticipated that clin. candidates will emerge out of this cohort that will be able to test the GSM mechanism of action in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFLi5hAAdKc7Vg90H21EOLACvtfcHk0lhs6jxHHxay5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7fP&md5=6b43a8feb210fa87ded92a26397b754f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.821465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.821465%26sid%3Dliteratum%253Aachs%26aulast%3DPettersson%26aufirst%3DM.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DNovel%2520gamma-secretase%2520modulators%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520focusing%2520on%2520patents%2520from%25202010%2520to%25202012%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D1349%26epage%3D1366%26doi%3D10.1517%2F13543776.2013.821465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, Y.</span></span> <span> </span><span class="NLM_article-title">Gamma-secretase modulators do not induce Abeta-rebound and accumulation of beta-C-terminal fragment</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2011.07560.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1111%2Fj.1471-4159.2011.07560.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=22035227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2012&pages=277-286&author=T.+Liauthor=Y.+Huangauthor=S.+Jinauthor=L.+Yeauthor=N.+Rongauthor=X.+Yangauthor=Y.+Dingauthor=Z.+Chengauthor=J.+Zhangauthor=Z.+Wanauthor=D.+C.+Harrisonauthor=I.+Hussainauthor=A.+Hallauthor=D.+H.+Leeauthor=L.+F.+Lauauthor=Y.+Matsuoka&title=Gamma-secretase+modulators+do+not+induce+Abeta-rebound+and+accumulation+of+beta-C-terminal+fragment&doi=10.1111%2Fj.1471-4159.2011.07560.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment</span></div><div class="casAuthors">Li, Ting; Huang, Yunhong; Jin, Shiyi; Ye, Liang; Rong, Na; Yang, Xiujuan; Ding, Yu; Cheng, Ziqiang; Zhang, Jinqiang; Wan, Zehong; Harrison, David C.; Hussain, Ishrut; Hall, Adrian; Lee, Daniel Hong Seng; Lau, Lit-Fui; Matsuoka, Yasuji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1 & 2</span>),
    <span class="NLM_cas:pages">277-286</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">γ-Secretase inhibitors (GSIs) have been developed to reduce amyloid-β (Aβ) prodn. for the treatment of Alzheimer's disease by inhibiting the cleavage of amyloid precursor protein (APP).  However, cross-inhibitory activity on the processing of Notch can cause adverse reactions.  To avoid these undesirable effects, γ-secretase modulators (GSMs) are being developed to selectively reduce toxic Aβ prodn. without perturbing Notch signaling.  As it is also known that GSIs can cause a paradoxical increase of plasma Aβ over the baseline after a transient redn. (known as Aβ-rebound), we asked if GSMs would cause a similar rebound and what the potential mechanism might be.  Our studies were performed with one GSI (LY-450139) and two chem. distinct GSMs.  Although LY-450139 caused Aβ-rebound as expected in rat plasma, the two GSMs did not.  Inhibition of APP processing by LY-450139 induced an accumulation of γ-secretase substrates, α- and β-C-terminal fragments of APP, but neither GSM caused such an accumulation.  In conclusion, we discover that GSMs, unlike GSIs, do not cause Aβ-rebound, possibly because of the lack of accumulation of β-C-terminal fragments.  GSMs may be superior to GSIs in the treatment of Alzheimer's disease not only by sparing Notch signaling but also by avoiding Aβ-rebound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbNSd_Jes7MrVg90H21EOLACvtfcHk0ljZCuY8tCeL0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKlt7s%253D&md5=a5c6183ca9a10de3aef6ac83cb770325</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07560.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07560.x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DHarrison%26aufirst%3DD.%2BC.%26aulast%3DHussain%26aufirst%3DI.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLau%26aufirst%3DL.%2BF.%26aulast%3DMatsuoka%26aufirst%3DY.%26atitle%3DGamma-secretase%2520modulators%2520do%2520not%2520induce%2520Abeta-rebound%2520and%2520accumulation%2520of%2520beta-C-terminal%2520fragment%26jtitle%3DJ.%2520Neurochem.%26date%3D2012%26volume%3D121%26spage%3D277%26epage%3D286%26doi%3D10.1111%2Fj.1471-4159.2011.07560.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span>; <span class="NLM_string-name">Goetschi, E.</span>; <span class="NLM_string-name">Green, L.</span>; <span class="NLM_string-name">Jolydon, S.</span>; <span class="NLM_string-name">Knust, H.</span>; <span class="NLM_string-name">Limberg, A.</span>; <span class="NLM_string-name">Luebbers, T.</span>; <span class="NLM_string-name">Thomas, A.</span></span> <span> </span><span class="NLM_article-title">Gamma-secretase modulators</span>. <span class="NLM_patent">WO2011/092272A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Baumann&author=E.+Goetschi&author=L.+Green&author=S.+Jolydon&author=H.+Knust&author=A.+Limberg&author=T.+Luebbers&author=A.+Thomas&title=Gamma-secretase+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DK.%26atitle%3DGamma-secretase%2520modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span> <span> </span><span class="NLM_article-title">Analytical studies on the prediction of photosensitive/phototoxic potential of pharmaceutical substances</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1007/s11095-005-8497-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1007%2Fs11095-005-8497-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=16308671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Clsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=156-164&author=S.+Onoueauthor=Y.+Tsuda&title=Analytical+studies+on+the+prediction+of+photosensitive%2Fphototoxic+potential+of+pharmaceutical+substances&doi=10.1007%2Fs11095-005-8497-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Analytical Studies on the Prediction of Photosensitive/Phototoxic Potential of Pharmaceutical Substances</span></div><div class="casAuthors">Onoue, Satomi; Tsuda, Yoshiko</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Phototoxic responses after administration of photosensitive pharmaceutics were recognized as undesirable side effects, and predicting potential hazardous side effects is gaining importance as new drugs are introduced to the market.  In this work, the authors characterize the photochem./photobiol. properties of model compds. to develop an effective screening method for the prediction of phototoxic/photosensitive potential.  Twenty-one known photosensitive/phototoxic compds. and 5 weak/nonphototoxic compds. were subjected to UV spectral analyses and photochem. evaluation including the detn. of produced reactive oxygen species (ROS) and photostability study.  The photooxidn. of linoleic acid was also monitored in the presence of tested compds., guided on the formation of thiobarbituric acid reactive substances.  Most photosensitive/phototoxic drugs tested, even weak UV absorbers, at a concn. of 200 μM showed significant prodn. of ROS under 18 h light exposure (30,000 lx).  On the other hand, ROS generated from weak/nonphototoxic compds., including strong UV absorber benzocaine, were low or negligible.  Although exposure of quinine to light resulted in significant degrdn. (half-life, t1/2 = 6.4 h), it was dramatically attenuated by the addn. of ROS scavengers, esp. sodium azide (t1/2 = 122.6 h).  Furthermore, concomitant exposure of photosensitive/phototoxic compds. (200 μM) and linoleic acid (1 mM) for 18 h led to the marked formation of lipoperoxide.  Results indicated that known photosensitive/phototoxic compds. tested have the ability to generate ROS under light exposure, and this photochem. reaction could be assocd. with their photoinstability and/or phototoxic responses.  Based on these findings, detn. of ROS, generated from photoirradiated compds., may be an effective predictive model in recognizing their photosensitive/phototoxic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3y9IB1PPBYrVg90H21EOLACvtfcHk0ljZCuY8tCeL0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Clsbc%253D&md5=2a477fc426e92b1cd5a0b7f465db7445</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs11095-005-8497-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-005-8497-9%26sid%3Dliteratum%253Aachs%26aulast%3DOnoue%26aufirst%3DS.%26aulast%3DTsuda%26aufirst%3DY.%26atitle%3DAnalytical%2520studies%2520on%2520the%2520prediction%2520of%2520photosensitive%252Fphototoxic%2520potential%2520of%2520pharmaceutical%2520substances%26jtitle%3DPharm.%2520Res.%26date%3D2006%26volume%3D23%26spage%3D156%26epage%3D164%26doi%3D10.1007%2Fs11095-005-8497-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, S.</span></span> <span> </span><span class="NLM_article-title">Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development</span>. <i>Curr. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.2174/157488609788173044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.2174%2F157488609788173044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=19442106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OqtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=123-136&author=S.+Onoueauthor=Y.+Setoauthor=G.+Gandyauthor=S.+Yamada&title=Drug-induced+phototoxicity%3B+an+early+in+vitro+identification+of+phototoxic+potential+of+new+drug+entities+in+drug+discovery+and+development&doi=10.2174%2F157488609788173044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced phototoxicity; An early in vitro identification of phototoxic potential of new drug entities in drug discovery and development</span></div><div class="casAuthors">Onoue, Satomi; Seto, Yoshiki; Gandy, Graham; Yamada, Shizuo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-136</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-induced photoirritation can be defined as an inflammatory reaction of the skin after topical or systemic administration of pharmaceutical substances.  In many cases of drug-induced phototoxicity, skin reactions can be triggered by doses of sunlight regarded as harmless and most often in the UV A (320-400 nm).  Several classes of drugs including antibacterials, thiazide diuretics, non-steroidal anti-inflammatory drugs, quinolones, and tricyclic antidepressants, even though nontoxic by themselves, may become reactive under exposure to environmental light, leading to undesired side effects.  At least three types of drug-induced phototoxic skin reactions, including the photoirritant, photogenotoxic and photoallergic skin responses, have been recognized, and their mechanisms and pathol. features are quite different.  The development of effective methodol. to evaluate the photochem./biol. properties has been attempted over the past few years, since it would be a key consideration to predict and avoid the phototoxic risk in the early phase of the drug discovery process.  The aim of this review is to describe the clin. features, pathogenesis and photochem. characteristics of drug-induced phototoxicity, and the current developments in research tools for predicting phototoxic potential of new drug entities are also addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzhnEKB9Mw7Vg90H21EOLACvtfcHk0ljt9VskW-uosA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OqtLnK&md5=2ef8638811b1e1e519adc15a92fd5f43</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F157488609788173044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488609788173044%26sid%3Dliteratum%253Aachs%26aulast%3DOnoue%26aufirst%3DS.%26aulast%3DSeto%26aufirst%3DY.%26aulast%3DGandy%26aufirst%3DG.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DDrug-induced%2520phototoxicity%253B%2520an%2520early%2520in%2520vitro%2520identification%2520of%2520phototoxic%2520potential%2520of%2520new%2520drug%2520entities%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DCurr.%2520Drug%2520Saf.%26date%3D2009%26volume%3D4%26spage%3D123%26epage%3D136%26doi%3D10.2174%2F157488609788173044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacci-Daniel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennehy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drumm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedmann, B.</span></span> <span> </span><span class="NLM_article-title">Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5149</span>– <span class="NLM_lpage">5156</span>, <span class="refDoi"> DOI: 10.1128/AAC.00946-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1128%2FAAC.00946-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=22825118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5149-5156&author=M.+J.+Lamarcheauthor=J.+Borawskiauthor=A.+Boseauthor=C.+Capacci-Danielauthor=R.+Colvinauthor=M.+Dennehyauthor=J.+Dingauthor=M.+Doblerauthor=J.+Drummauthor=L.+A.+Gaitherauthor=J.+Gaoauthor=X.+Jiangauthor=K.+Linauthor=U.+McKeeverauthor=X.+Puyangauthor=P.+Ramanauthor=S.+Thohanauthor=R.+Tommasiauthor=K.+Wagnerauthor=X.+Xiongauthor=T.+Zabawaauthor=S.+Zhuauthor=B.+Wiedmann&title=Anti-hepatitis+C+virus+activity+and+toxicity+of+type+III+phosphatidylinositol-4-kinase+beta+inhibitors&doi=10.1128%2FAAC.00946-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors</span></div><div class="casAuthors">LaMarche, M. J.; Borawski, J.; Bose, A.; Capacci-Daniel, C.; Colvin, R.; Dennehy, M.; Ding, J.; Dobler, M.; Drumm, J.; Gaither, L. A.; Gao, J.; Jiang, X.; Lin, K.; McKeever, U.; Puyang, X.; Raman, P.; Thohan, S.; Tommasi, R.; Wagner, K.; Xiong, X.; Zabawa, T.; Zhu, S.; Wiedmann, B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5149-5156</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Type III phosphatidylinositol-4-kinase beta (PI4KIIIβ) was previously implicated in hepatitis C virus (HCV) replication by small interfering RNA (siRNA) depletion and was therefore proposed as a novel cellular target for the treatment of hepatitis C.  Medicinal chem. efforts identified highly selective PI4KIIIβ inhibitors that potently inhibited the replication of genotype 1a and 1b HCV replicons and genotype 2a virus in vitro.  Replicon cells required more than 5 wk to reach low levels of 3- to 5-fold resistance, suggesting a high resistance barrier to these cellular targets.  Extensive in vitro profiling of the compds. revealed a role of PI4KIIIβ in lymphocyte proliferation.  Previously proposed functions of PI4KIIIβ in insulin secretion and the regulation of several ion channels were not perturbed with these inhibitors.  Moreover, PI4KIIIβ inhibitors were not generally cytotoxic as demonstrated across hundreds of cell lines and primary cells.  However, an unexpected antiproliferative effect in lymphocytes precluded their further development for the treatment of hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg3G6T2U7Lv7Vg90H21EOLACvtfcHk0ljt9VskW-uosA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7jK&md5=fd7a50d1813d04862e5d8fa549c73da5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.00946-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00946-12%26sid%3Dliteratum%253Aachs%26aulast%3DLamarche%26aufirst%3DM.%2BJ.%26aulast%3DBorawski%26aufirst%3DJ.%26aulast%3DBose%26aufirst%3DA.%26aulast%3DCapacci-Daniel%26aufirst%3DC.%26aulast%3DColvin%26aufirst%3DR.%26aulast%3DDennehy%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDobler%26aufirst%3DM.%26aulast%3DDrumm%26aufirst%3DJ.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DMcKeever%26aufirst%3DU.%26aulast%3DPuyang%26aufirst%3DX.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DThohan%26aufirst%3DS.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DXiong%26aufirst%3DX.%26aulast%3DZabawa%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWiedmann%26aufirst%3DB.%26atitle%3DAnti-hepatitis%2520C%2520virus%2520activity%2520and%2520toxicity%2520of%2520type%2520III%2520phosphatidylinositol-4-kinase%2520beta%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5149%26epage%3D5156%26doi%3D10.1128%2FAAC.00946-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span> <span> </span><span class="NLM_article-title">Plasma protein binding: from discovery to development</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2953</span>– <span class="NLM_lpage">2994</span>, <span class="refDoi"> DOI: 10.1002/jps.23614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1002%2Fjps.23614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=23798314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2013&pages=2953-2994&author=T.+Bohnertauthor=L.+S.+Gan&title=Plasma+protein+binding%3A+from+discovery+to+development&doi=10.1002%2Fjps.23614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma protein binding: From discovery to development</span></div><div class="casAuthors">Bohnert, Tonika; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2953-2994</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The importance of plasma protein binding (PPB) in modulating the effective drug concn. at pharmacol. target sites has been the topic of significant discussion and debate amongst drug development groups over the past few decades.  Free drug theory, which states that in absence of energy-dependent processes, after steady state equil. has been attained, free drug concn. in plasma is equal to free drug concn. at the pharmacol. target receptor(s) in tissues, has been used to explain pharmacokinetics/pharmacodynamics relationships in a large no. of cases.  Any sudden increase in free concn. of a drug could potentially cause toxicity and may need dose adjustment.  Free drug concn. is also helpful to est. the effective concn. of drugs that potentially can ppt. metab. (or transporter)-related drug-drug interactions.  Disease models are extensively validated in animals to progress a compd. into development.  Unbound drug concn., and therefore PPB information across species is very informative in establishing safety margins and guiding selection of First in Human (FIH) dose and human efficacious dose.  The scope of this review is to give an overview of reported role of PPB in several therapeutic areas, highlight cases where PPB changes are clin. relevant, and provide drug metab. and pharmacokinetics recommendations in discovery and development settings. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqobJp8eG98XrVg90H21EOLACvtfcHk0lgp8MFQfRhEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D&md5=d676f7490c6e0f09c8acf7cce5183b17</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjps.23614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23614%26sid%3Dliteratum%253Aachs%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DGan%26aufirst%3DL.%2BS.%26atitle%3DPlasma%2520protein%2520binding%253A%2520from%2520discovery%2520to%2520development%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D102%26spage%3D2953%26epage%3D2994%26doi%3D10.1002%2Fjps.23614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">When PPB ≪1% and unspecific binding is high/extreme, it makes difficult the interpretation of the <i>in vitro</i> potency and the <i>in vitro</i> stability data (there is a 10% of serum in the potency assay media and the hepatocytes stability assay), also predictions become innacurate.</p></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span>; <span class="NLM_string-name">Green, L.</span>; <span class="NLM_string-name">Limberg, A.</span>; <span class="NLM_string-name">Luebbers, T.</span>; <span class="NLM_string-name">Thomas, A.</span></span> <span> </span><span class="NLM_article-title">Bridged piperidine derivatives for use as amyloid beta modulators</span>. <span class="NLM_patent">WO2012/116965A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Baumann&author=L.+Green&author=A.+Limberg&author=T.+Luebbers&author=A.+Thomas&title=Bridged+piperidine+derivatives+for+use+as+amyloid+beta+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DK.%26atitle%3DBridged%2520piperidine%2520derivatives%2520for%2520use%2520as%2520amyloid%2520beta%2520modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrecht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lave, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span> <span> </span><span class="NLM_article-title">PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1684</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1016%2Fj.bcp.2013.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=23454189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlKrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=1684-1699&author=A.+Carusoauthor=R.+Alvarez-Sanchezauthor=A.+Hillebrechtauthor=A.+Poirierauthor=F.+Schulerauthor=T.+Laveauthor=C.+Funkauthor=S.+Belli&title=PK%2FPD+assessment+in+CNS+drug+discovery%3A+Prediction+of+CSF+concentration+in+rodents+for+P-glycoprotein+substrates+and+application+to+in+vivo+potency+estimation&doi=10.1016%2Fj.bcp.2013.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation</span></div><div class="casAuthors">Caruso, Antonello; Alvarez-Sanchez, Ruben; Hillebrecht, Alexander; Poirier, Agnes; Schuler, Franz; Lave, Thierry; Funk, Christoph; Belli, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1684-1699</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The unbound drug concn. in brain parenchyma is considered to be the relevant driver for interaction with central nervous system (CNS) biol. targets.  Drug levels in cerebrospinal fluid (C_CSF) are frequently used surrogates for the unbound concns. in brain.  For drugs actively transported across the blood-brain barrier (BBB), C_CSF differs from unbound plasma concn. (Cu_p) to an extent that is commonly unknown.  In this study, the relationship between CSF-to-unbound plasma drug partitioning in rats and the mouse Pgp (Mdr1a) efflux ratio (ER) obtained from in vitro transcellular studies has been investigated for a set of 61 CNS compds. exhibiting substantial diversity in chem. structure and physico-chem. properties.  In order to understand the in vitro-in vivo extrapolation of Pgp efflux, a mechanistic model was derived relating in vivo CNS distribution kinetics to in vitro active transport.  The model was applied to predict C_CSF from Cu_p and ER data for 19 proprietary Roche CNS drug candidates.  The calcd. CSF concns. were correlated with CNS pharmacodynamic responses obsd. in rodent models.  The correlation between in vitro and in vivo potency for different pharmacol. endpoints indicated that the predicted C_CSF is a valuable surrogate of the concn. at the target site.  Overall, C_CSF proved superior description of PK/PD data than unbound plasma or total brain concn. for Mdr1a substrates.  Predicted C_CSF can be used as a default approach to understand the PK/PD relationships in CNS efficacy models and can support the extrapolation of efficacious brain exposure for new drug candidates from rodent to man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruK6k0mONiBbVg90H21EOLACvtfcHk0lgp8MFQfRhEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlKrs70%253D&md5=76fec0e52a881f894ed01836bba27db6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DPoirier%26aufirst%3DA.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DLave%26aufirst%3DT.%26aulast%3DFunk%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26atitle%3DPK%252FPD%2520assessment%2520in%2520CNS%2520drug%2520discovery%253A%2520Prediction%2520of%2520CSF%2520concentration%2520in%2520rodents%2520for%2520P-glycoprotein%2520substrates%2520and%2520application%2520to%2520in%2520vivo%2520potency%2520estimation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D1684%26epage%3D1699%26doi%3D10.1016%2Fj.bcp.2013.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.027797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding&doi=10.1124%2Fdmd.109.027797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0liKUZJ9Cl3BhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977%26doi%3D10.1124%2Fdmd.109.027797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/tx034170b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development&doi=10.1021%2Ftx034170b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0liKUZJ9Cl3BhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16%26doi%3D10.1021%2Ftx034170b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0liKUZJ9Cl3BhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nettekoven, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic access to 2-amido-5-aryl-8-methoxy-triazolopyridine and 2-amido-5-morpholino-8-methoxy-triazolopyridine derivatives as potential inhibitors of the adenosine receptor subtypes</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2003</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1652</span>, <span class="refDoi"> DOI: 10.1055/s-2003-40874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1055%2Fs-2003-40874" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2003&publication_year=2003&pages=1649-1652&author=M.+Nettekovenauthor=B.+Pullmannauthor=S.+Schmitt&title=Synthetic+access+to+2-amido-5-aryl-8-methoxy-triazolopyridine+and+2-amido-5-morpholino-8-methoxy-triazolopyridine+derivatives+as+potential+inhibitors+of+the+adenosine+receptor+subtypes&doi=10.1055%2Fs-2003-40874"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1055%2Fs-2003-40874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2003-40874%26sid%3Dliteratum%253Aachs%26aulast%3DNettekoven%26aufirst%3DM.%26aulast%3DPullmann%26aufirst%3DB.%26aulast%3DSchmitt%26aufirst%3DS.%26atitle%3DSynthetic%2520access%2520to%25202-amido-5-aryl-8-methoxy-triazolopyridine%2520and%25202-amido-5-morpholino-8-methoxy-triazolopyridine%2520derivatives%2520as%2520potential%2520inhibitors%2520of%2520the%2520adenosine%2520receptor%2520subtypes%26jtitle%3DSynthesis%26date%3D2003%26volume%3D2003%26spage%3D1649%26epage%3D1652%26doi%3D10.1055%2Fs-2003-40874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xian-Ting  Cao</span>, <span class="hlFld-ContribAuthor ">Su-Ning  Wei</span>, <span class="hlFld-ContribAuthor ">Hao-Tian  Sun</span>, <span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Zuo-Ling  Zheng</span>, <span class="hlFld-ContribAuthor ">Guannan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Iridium-catalyzed regioselective C–H sulfonamidation of 1,2,4-thiadiazoles with sulfonyl azides in water. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (36)
                                     , 22000-22004. <a href="https://doi.org/10.1039/D1RA04450H" title="DOI URL">https://doi.org/10.1039/D1RA04450H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1RA04450H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1RA04450H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIridium-catalyzed%252Bregioselective%252BC%2525E2%252580%252593H%252Bsulfonamidation%252Bof%252B1%25252C2%25252C4-thiadiazoles%252Bwith%252Bsulfonyl%252Bazides%252Bin%252Bwater%26aulast%3DCao%26aufirst%3DXian-Ting%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D36%26spage%3D22000%26epage%3D22004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabian H.  Knaup</span>, <span class="hlFld-ContribAuthor ">Christian  Meyners</span>, <span class="hlFld-ContribAuthor ">Anna  Charalampidou</span>, <span class="hlFld-ContribAuthor ">Patryk  Krajczy</span>, <span class="hlFld-ContribAuthor ">Patrick L.  Purder</span>, <span class="hlFld-ContribAuthor ">Tatjana  Ross</span>, <span class="hlFld-ContribAuthor ">Felix  Hausch</span>. </span><span class="cited-content_cbyCitation_article-title">Med Chem Remote: The Frontiers in Medicinal Chemistry 2021. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>157 </em><a href="https://doi.org/10.1002/cmdc.202100355" title="DOI URL">https://doi.org/10.1002/cmdc.202100355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100355%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMed%252BChem%252BRemote%25253A%252BThe%252BFrontiers%252Bin%252BMedicinal%252BChemistry%252B2021%26aulast%3DKnaup%26aufirst%3DFabian%2BH.%26date%3D2021%26date%3D2021%26volume%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Ratni</span>, <span class="hlFld-ContribAuthor ">K.  Baumann</span>, <span class="hlFld-ContribAuthor ">P.  Bellotti</span>, <span class="hlFld-ContribAuthor ">X. A.  Cook</span>, <span class="hlFld-ContribAuthor ">L. G.  Green</span>, <span class="hlFld-ContribAuthor ">T.  Luebbers</span>, <span class="hlFld-ContribAuthor ">M.  Reutlinger</span>, <span class="hlFld-ContribAuthor ">A. F.  Stepan</span>, <span class="hlFld-ContribAuthor ">W.  Vifian</span>. </span><span class="cited-content_cbyCitation_article-title">Phenyl bioisosteres in medicinal chemistry: discovery of novel γ-secretase modulators as a potential treatment for Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 758-766. <a href="https://doi.org/10.1039/D1MD00043H" title="DOI URL">https://doi.org/10.1039/D1MD00043H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00043H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00043H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPhenyl%252Bbioisosteres%252Bin%252Bmedicinal%252Bchemistry%25253A%252Bdiscovery%252Bof%252Bnovel%252B%2525CE%2525B3-secretase%252Bmodulators%252Bas%252Ba%252Bpotential%252Btreatment%252Bfor%252BAlzheimer%252527s%252Bdisease%26aulast%3DRatni%26aufirst%3DH.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D5%26spage%3D758%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Sequential improvement of the potency and properties of <b>1</b>. Increase of potency and free fraction (<b>2</b>). Improvement in the physicochemical properties and elimination of phototoxic liability upon the introduction of a phenyl ring bioisostere (<b>5A</b>). Reduction of PIK4CB side activity by disturbing the kinase hinge binding (<b>9B</b>). Elimination of covalent binding liability with new heterocyclic head rings and properties–potency rebalance with modifications on the alkoxy bioisosteric replacement (<b>18B</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Correlation between estimated free <i>in vitro</i> IC<sub>50</sub> (Aβ42) and <i>in vivo</i> free brain IC<sub>50</sub> concentrations for <b>5A</b> and compounds from the same chemical series (side A). Effects of potency (IC<sub>50</sub>) and predicted human pharmacokinetic property improvement, with a more balanced plasma protein binding, lowering efficacious human doses (side B and table). Human/mice free IC<sub>50</sub> predictions and initial human dose estimations for 50% of Aβ42 reduction at steady state for compounds <b>1</b> and <b>2</b> (see table).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Conformational differences between compounds <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vitro</i> phototoxicity of compound <b>2</b> measured with cells exposed to the compound in the presence (+Irr) or absence (−Irr) of UVA light. The phototoxic potential (indicated by high UVA absorption) is expressed through the use of the photoirritancy fFactor (PIF) by comparing the IC<sub>50</sub> +Irr to the IC<sub>50</sub> −Irr. PIF > 5 indicates phototoxicity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Fluoro phenyl ring bioisostere. Reduced UV absorption, resulting in no phototoxicity risk.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hinge binding to kinase PIK4CB from the amino-triazolo pyridine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Disruption of the hinge binding site by substitution on the 5-position of the 8-alkoxy aminotriazole pyridine ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Explored thiazole and isothiazole heterocyclic replacements according to decreasing lipophilicity (or hydrophobicity) for cores <b>A</b> and <b>B</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Time course effect of <b>18B</b> on Aβ42 reduction (expressed as % of control) in APP-swe tg mice. Dose- and time-dependent effect.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Mechanism of the action of <b>18B</b> as a GSM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Cores <b>23</b>, <b>25</b> (Intermediate <b>IA</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Fe/HCl, EtOH, 90 °C, overnight, 60%; (b) EtO<sub>2</sub>CNCS (1.1 equiv), dioxane, 3 h, room temperature (r.t.), 96% (21a-1), 105% (21a-2); (c) NH<sub>2</sub>OH·HCl (5 equiv), <i>i</i>-Pr<sub>2</sub>NEt (3 equiv), MeOH/EtOH (1/1), room temperature to 60 °C, 4 h, 98.2% (22-1), 77.4% (22-2); (d) <i>tert</i>-butyl nitrite (1.5 equiv), CuBr<sub>2</sub> (1.5 equiv), acetonitrile, 75 °C, 2 h, 62% (23-1), 77.3% (23-2); (e) BBr<sub>3</sub> (5.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0–60 °C, 81%; (f) R<sup>1</sup>I (1–2 equiv), K<sub>2</sub>CO<sub>3</sub> (2–3 equiv), <i>N</i>,<i>N</i>-dimethylformamide (DMF), 120 °C, overnight, 77.4% (25-3), 90.3% (25-4), 86.8% (25-5), 39.6% (25-7), 90.1% (25-8) or 1,1,1-trifluoropropan-2-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate (1.5 equiv), K<sub>2</sub>CO<sub>3</sub> (2 equiv), DMF, 120 °C, overnight, 53.4% (25-6).</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Heterocyclic Bridged Amino Piperidines (Intermediates <b>II</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-chloro-3-methyl-1,2,4-thiadiazole (1.2 equiv), Et<sub>3</sub>N (5 equiv), EtOH, 80 °C, overnight, 92%; (b) trifluoroacetic acid (TFA, 10 equiv), CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 94% (27) or HCl (10 equiv), r.t., 2 h, 55.3% (29); (c) (i) 4-methyl-6-thioxo-3,6-dihydro-2<i>H</i>-1,3-thiazin-2-one (1 equiv), 4-methylmorpholine (3 equiv), 4-dimethylaminopyridine (0.01 equiv), dioxane, 80 °C, overnight, (ii) <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 4 equiv), I<sub>2</sub> (2 equiv) in dioxane, from 0 °C to r.t overnight, 72%; (d) BrCN (1.4 equiv), Na<sub>2</sub>CO<sub>3</sub> (1.4 equiv), EtOH, 2 h, r.t. to 50 °C overnight, 92.5%; (e) (<i>z</i>)-<i>N</i>′-hydroxyacetimidamide (1 equiv), ZnCl (1.2 equiv), EtOH then HCl (3 equiv), 60 °C, 7 h, 97%; (f) 4-chloro-2-(trifluoromethyl)pyridine (1 equiv), Pd(II)OAc (0.08 equiv), Na<sup>t</sup>BuO (1.5 equiv), Hunig′s base (2 equiv), 2-(dicyclohexylphosphino)biphenyl (0.16 equiv), dioxane, microwave 140 °C, 45 min, 36.3% (32) or 5-iodo-3-methylisoxazole (1.2 equiv), CuI (0.1 equiv), K<sub>3</sub>PO<sub>4</sub> (2 equiv), <i>N</i>,<i>N</i>-diethylsalicymide (0.3 equiv), DMF, −5 °C, 6 h, 22% (36); (g) 2-bromo-5-methyl-1,3,4-oxadiazole (2 equiv), Et<sub>3</sub>N (4 equiv), EtOH, 130 °C, overnight, 68.1% (34) or 4-chloro-6- methylpyrimidine (1.2 equiv), Et<sub>3</sub>N (4 equiv), EtOH, 100 °C, overnight, 99% (38); (h) HCl (6 or 10 equiv), CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 91.9% (33), 80% (37), 94.2% (39) or TFA (10 equiv) CH<sub>2</sub>Cl<sub>2</sub>, r.t., overnight, 80.2% (35).</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Final Coupling Step for Intermediates <b>IA</b> and <b>II</b> for Compounds <b>3A</b>–<b>16A</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) intermediate <b>II</b> (1 equiv), sodium phenoxide (1.1–1.6 equiv) or NaOtBu (3 equiv), xantphos (0.16 equiv), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.08 equiv), dioxane, 130–145 °C, 45–60 min in microwave, 54% (3A), 80.6% (4A), 66.9% (5A), 51.9% (6A), 63% (7A), 80,1% (8A), 60.6% (9A), 65.3% (10A), 81.2% (11A), 59.8% (13A), 63.4% (14A) or intermediate <b>II</b> (1.1 equiv), NaOtBu (2.05 equiv), bromo-(tri-<i>tert</i>-butyl)-phosphine-palladium(I) dimer (0.15 equiv), dioxane, 110–120 °C, 1–2 h, 43% (12A), 11% (15A), 27.3% (16A).</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Core B (Intermediates <b>IB</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Br<sub>2</sub> (1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, room temperature, overnight, 44%; (b) EtO<sub>2</sub>CNCS (1.1 equiv), dioxane, 100 °C, 5 h, 76.3%; (c) NH<sub>2</sub>OH·HCl (5 equiv), <i>i</i>-Pr<sub>2</sub>NEt (3 equiv), MeOH/EtOH (1/1), room temperature, 1 h to 60 °C, 3 h, 69.1%; (d) R<sup>1</sup>OH (1.5 equiv), NaH (1.3 equiv), CuBr (0.01 equiv), DMF, 155 °C, 4 h, 61.2% (44-1), 65.5% (44-2), 75.2% (44-3); (e) <i>tert</i>-butyl nitrite (1.5 equiv), CuBr<sub>2</sub> (1.5 equiv), acetonitrile, 60–75 °C, 6h, 82.9% (45-1), 85.5% (45-2), 89.6% (45-3).</p></p></figure><figure data-id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/medium/jm0c00909_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Final Coupling Step for Intermediates <b>IB</b> and <b>II</b> for <b>9B</b>, <b>12B</b>, <b>14B</b>, <b>17B</b>, and <b>18B</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00909/20200806/images/large/jm0c00909_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00909&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) intermediate <b>II</b> (1.1 equiv), NaOtBu (2–3 equiv), xantphos (0.16 equiv), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.08 equiv), 125–145 °C, 30 min in microwave, 47.1% (9B), 69% (14B), 59.2% (17B), 60.1% (18B) or intermediate <b>II</b> (1.1 equiv), NaOtBu (2.05 equiv), bromo-(tri-<i>tert</i>-butyl)-phosphine-palladium(I) dimer (0.15 equiv), dioxane, 110 °C, 1 h, 54% (12B).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brayne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodaty, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fratiglioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scazufca, M.</span></span> <span> </span><span class="NLM_article-title">Global prevalence of dementia: a Delphi consensus study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2112</span>– <span class="NLM_lpage">2117</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)67889-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1016%2FS0140-6736%2805%2967889-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=16360788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A280%3ADC%252BD2MnnsVSiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2005&pages=2112-2117&author=C.+P.+Ferriauthor=M.+Princeauthor=C.+Brayneauthor=H.+Brodatyauthor=L.+Fratiglioniauthor=M.+Ganguliauthor=K.+Hallauthor=K.+Hasegawaauthor=H.+Hendrieauthor=Y.+Huangauthor=A.+Jormauthor=C.+Mathersauthor=P.+R.+Menezesauthor=E.+Rimmerauthor=M.+Scazufca&title=Global+prevalence+of+dementia%3A+a+Delphi+consensus+study&doi=10.1016%2FS0140-6736%2805%2967889-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global prevalence of dementia: a Delphi consensus study</span></div><div class="casAuthors">Ferri Cleusa P; Prince Martin; Brayne Carol; Brodaty Henry; Fratiglioni Laura; Ganguli Mary; Hall Kathleen; Hasegawa Kazuo; Hendrie Hugh; Huang Yueqin; Jorm Anthony; Mathers Colin; Menezes Paulo R; Rimmer Elizabeth; Scazufca Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9503</span>),
    <span class="NLM_cas:pages">2112-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  100 years after the first description, Alzheimer's disease is one of the most disabling and burdensome health conditions worldwide.  We used the Delphi consensus method to determine dementia prevalence for each world region.  METHODS:  12 international experts were provided with a systematic review of published studies on dementia and were asked to provide prevalence estimates for every WHO world region, for men and women combined, in 5-year age bands from 60 to 84 years, and for those aged 85 years and older.  UN population estimates and projections were used to estimate numbers of people with dementia in 2001, 2020, and 2040.  We estimated incidence rates from prevalence, remission, and mortality.  FINDINGS:  Evidence from well-planned, representative epidemiological surveys is scarce in many regions.  We estimate that 24.3 million people have dementia today, with 4.6 million new cases of dementia every year (one new case every 7 seconds).  The number of people affected will double every 20 years to 81.1 million by 2040.  Most people with dementia live in developing countries (60% in 2001, rising to 71% by 2040).  Rates of increase are not uniform; numbers in developed countries are forecast to increase by 100% between 2001 and 2040, but by more than 300% in India, China, and their south Asian and western Pacific neighbours.  INTERPRETATION:  We believe that the detailed estimates in this paper constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRw6_2C-aXsbczK395ZObgVfW6udTcc2ebWQc2pltdSybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnnsVSiug%253D%253D&md5=97f7f4cb7dfaa55dbdd6be23a7439efe</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2967889-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252967889-0%26sid%3Dliteratum%253Aachs%26aulast%3DFerri%26aufirst%3DC.%2BP.%26aulast%3DPrince%26aufirst%3DM.%26aulast%3DBrayne%26aufirst%3DC.%26aulast%3DBrodaty%26aufirst%3DH.%26aulast%3DFratiglioni%26aufirst%3DL.%26aulast%3DGanguli%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DHendrie%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJorm%26aufirst%3DA.%26aulast%3DMathers%26aufirst%3DC.%26aulast%3DMenezes%26aufirst%3DP.%2BR.%26aulast%3DRimmer%26aufirst%3DE.%26aulast%3DScazufca%26aufirst%3DM.%26atitle%3DGlobal%2520prevalence%2520of%2520dementia%253A%2520a%2520Delphi%2520consensus%2520study%26jtitle%3DLancet%26date%3D2005%26volume%3D366%26spage%3D2112%26epage%3D2117%26doi%3D10.1016%2FS0140-6736%2805%2967889-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzinger, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santacruz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossor, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1056%2FNEJMoa1202753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=22784036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=795-804&author=R.+J.+Batemanauthor=C.+Xiongauthor=T.+L.+Benzingerauthor=A.+M.+Faganauthor=A.+Goateauthor=N.+C.+Foxauthor=D.+S.+Marcusauthor=N.+J.+Cairnsauthor=X.+Xieauthor=T.+M.+Blazeyauthor=D.+M.+Holtzmanauthor=A.+Santacruzauthor=V.+Bucklesauthor=A.+Oliverauthor=K.+Moulderauthor=P.+S.+Aisenauthor=B.+Ghettiauthor=W.+E.+Klunkauthor=E.+McDadeauthor=R.+N.+Martinsauthor=C.+L.+Mastersauthor=R.+Mayeuxauthor=J.+M.+Ringmanauthor=M.+N.+Rossorauthor=P.+R.+Schofieldauthor=R.+A.+Sperlingauthor=S.+Sallowayauthor=J.+C.+Morris&title=Clinical+and+biomarker+changes+in+dominantly+inherited+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1202753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker changes in dominantly inherited Alzheimer's disease</span></div><div class="casAuthors">Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The order and magnitude of pathol. processes in Alzheimer's disease are not well understood, partly because the disease develops over many years.  Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to det. the sequence and magnitude of pathol. changes that culminate in symptomatic disease.  METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clin. and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests.  We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calc. the estd. years from expected symptom onset (age of the participant minus parent's age at symptom onset).  We conducted cross-sectional analyses of baseline data in relation to estd. years from expected symptom onset in order to det. the relative order and magnitude of pathophysiol. changes.  RESULTS: Concns. of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before expected symptom onset.  Aβ deposition, as measured by positron-emission tomog. with the use of Pittsburgh compd. B, was detected 15 years before expected symptom onset.  Increased concns. of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset.  Cerebral hypometabolism and impaired episodic memory were obsd. 10 years before expected symptom onset.  Global cognitive impairment, as measured by the Mini-Mental State Examn. and the Clin. Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an av. of 3 years after expected symptom onset.  CONCLUSIONS: We found that autosomal dominant Alzheimer's disease was assocd. with a series of pathophysiol. changes over decades in CSF biochem. markers of Alzheimer's disease, brain amyloid deposition, and brain metab. as well as progressive cognitive impairment.  Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJNV9eDXBCLVg90H21EOLACvtfcHk0lgne8hcOCiTNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J&md5=c4f999ea3401af9651a2770724757bed</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202753%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DC.%26aulast%3DBenzinger%26aufirst%3DT.%2BL.%26aulast%3DFagan%26aufirst%3DA.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DN.%2BC.%26aulast%3DMarcus%26aufirst%3DD.%2BS.%26aulast%3DCairns%26aufirst%3DN.%2BJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBlazey%26aufirst%3DT.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DSantacruz%26aufirst%3DA.%26aulast%3DBuckles%26aufirst%3DV.%26aulast%3DOliver%26aufirst%3DA.%26aulast%3DMoulder%26aufirst%3DK.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DGhetti%26aufirst%3DB.%26aulast%3DKlunk%26aufirst%3DW.%2BE.%26aulast%3DMcDade%26aufirst%3DE.%26aulast%3DMartins%26aufirst%3DR.%2BN.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DMayeux%26aufirst%3DR.%26aulast%3DRingman%26aufirst%3DJ.%2BM.%26aulast%3DRossor%26aufirst%3DM.%2BN.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DClinical%2520and%2520biomarker%2520changes%2520in%2520dominantly%2520inherited%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D795%26epage%3D804%26doi%3D10.1056%2FNEJMoa1202753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachurin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovina, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustyugov, A. A.</span></span> <span> </span><span class="NLM_article-title">Drugs in Clinical Trials for Alzheimer’s Disease: The Major Trends</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1186</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1002/med.21434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1002%2Fmed.21434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=28084618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yktbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1186-1225&author=S.+O.+Bachurinauthor=E.+V.+Bovinaauthor=A.+A.+Ustyugov&title=Drugs+in+Clinical+Trials+for+Alzheimer%E2%80%99s+Disease%3A+The+Major+Trends&doi=10.1002%2Fmed.21434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends</span></div><div class="casAuthors">Bachurin, Sergey O.; Bovina, Elena V.; Ustyugov, Aleksey A.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1186-1225</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by a chronic and progressive neurodegenerative process resulting from the intracellular and extracellular accumulation of fibrillary proteins: beta-amyloid and hyperphosphorylated Tau.  Overaccumulation of these aggregates leads to synaptic dysfunction and subsequent neuronal loss.  The precise mol. mechanisms of AD are still not fully understood but it is clear that AD is a multifactorial disorder and that advanced age is the main risk factor.  Over the last decade, more than 50 drug candidates have successfully passed phase II clin. trials, but none has passed phase III.  Here, we summarize data on current "anti-Alzheimer's" agents currently in clin. trials based on findings available in the Thomson Reuters 'Integrity' database, on the public website, and on database of the website .  As a result, it was possible to outline some major trends in AD drug discovery: (i) the development of compds. acting on the main stages of the pathogenesis of the disease (the so-called "disease-modifying agents") - these drugs could potentially slow the development of structural and functional abnormalities in the central nervous system providing sustainable improvements of cognitive functions, which persist even after drug withdrawal; (ii) focused design of multitargeted drugs acting on multiple mol. targets involved in the pathogenesis of the disease; (3) finally, the repositioning of old drugs for new (anti-Alzheimer's) application offers a very attractive approach to facilitate the completion of clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUgLGjGuc0iLVg90H21EOLACvtfcHk0lgne8hcOCiTNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yktbvO&md5=a5659940c428ecd50892d80e0c1baa7d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.21434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21434%26sid%3Dliteratum%253Aachs%26aulast%3DBachurin%26aufirst%3DS.%2BO.%26aulast%3DBovina%26aufirst%3DE.%2BV.%26aulast%3DUstyugov%26aufirst%3DA.%2BA.%26atitle%3DDrugs%2520in%2520Clinical%2520Trials%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520The%2520Major%2520Trends%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1186%26epage%3D1225%26doi%3D10.1002%2Fmed.21434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanzi, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertram, L.</span></span> <span> </span><span class="NLM_article-title">Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2005.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1016%2Fj.cell.2005.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=15734686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVWnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2005&pages=545-555&author=R.+E.+Tanziauthor=L.+Bertram&title=Twenty+years+of+the+Alzheimer%E2%80%99s+disease+amyloid+hypothesis%3A+a+genetic+perspective&doi=10.1016%2Fj.cell.2005.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective</span></div><div class="casAuthors">Tanzi, Rudolph E.; Bertram, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  From Alois Alzheimer's description of Auguste D.'s brain in 1907 to George Glenner's biochem. dissection of β-amyloid in 1984, the "amyloid hypothesis" of Alzheimer's disease has continued to gain support over the past two decades, particularly from genetic studies.  Here we assess the amyloid hypothesis based on both known and putative Alzheimer's disease genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPVQvwUmMmXrVg90H21EOLACvtfcHk0lgkxw5oSOSXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVWnu7k%253D&md5=3f88dc7dda6b726429789c61d5992493</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DTanzi%26aufirst%3DR.%2BE.%26aulast%3DBertram%26aufirst%3DL.%26atitle%3DTwenty%2520years%2520of%2520the%2520Alzheimer%25E2%2580%2599s%2520disease%2520amyloid%2520hypothesis%253A%2520a%2520genetic%2520perspective%26jtitle%3DCell%26date%3D2005%26volume%3D120%26spage%3D545%26epage%3D555%26doi%3D10.1016%2Fj.cell.2005.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, F.</span></span> <span> </span><span class="NLM_article-title">Dementia: What pharmacists need to know</span>. <i>Can. Pharm. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1177/1715163517690745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1177%2F1715163517690745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnsVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2017&pages=118-129&author=S.+Duongauthor=T.+Patelauthor=F.+Chang&title=Dementia%3A+What+pharmacists+need+to+know&doi=10.1177%2F1715163517690745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dementia: What pharmacists need to know</span></div><div class="casAuthors">Duong Silvia; Patel Tejal; Chang Feng</div><div class="citationInfo"><span class="NLM_cas:title">Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-129</span>
        ISSN:<span class="NLM_cas:issn">1715-1635</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsLLKKFDIcAL7NkxioyDXTfW6udTcc2eY9nggrDZ1SVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnsVSjsQ%253D%253D&md5=6b214901f72daec435e91c86f7fa0898</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1177%2F1715163517690745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1715163517690745%26sid%3Dliteratum%253Aachs%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DF.%26atitle%3DDementia%253A%2520What%2520pharmacists%2520need%2520to%2520know%26jtitle%3DCan.%2520Pharm.%2520J.%26date%3D2017%26volume%3D150%26spage%3D118%26epage%3D129%26doi%3D10.1177%2F1715163517690745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">a004457</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a004457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1101%2Fcshperspect.a004457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21576255" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=D.+J.+Selkoe&title=Alzheimer%E2%80%99s+disease&doi=10.1101%2Fcshperspect.a004457"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a004457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a004457%26sid%3Dliteratum%253Aachs%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2011%26volume%3D3%26doi%3D10.1101%2Fcshperspect.a004457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease at 25 years</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.15252/emmm.201606210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.15252%2Femmm.201606210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=27025652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=595-608&author=D.+J.+Selkoeauthor=J.+Hardy&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease+at+25+years&doi=10.15252%2Femmm.201606210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease at 25 years</span></div><div class="casAuthors">Selkoe, Dennis J.; Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">595-608</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Despite continuing debate about the amyloid β-protein or Aβ hypothesis, new lines of evidence from labs. and clinics worldwide support the concept that an imbalance between prodn. and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer's disease AD.  Confirmation that presenilin is the catalytic site of γ-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate amyloid precursor protein, APP or the protease presenilin of the reaction that generates Aβ.  Duplication of the wild-type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD.  Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain.  Sol. oligomers of Aβ42 isolated from AD patients' brains can decrease synapse no., inhibit long-term potentiation, and enhance long-term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory.  The human oligomers also induce hyperphosphorylation of tau at AD-relevant epitopes and cause neuritic dystrophy in cultured neurons.  Crossing human APP with human tau transgenic mice enhances tau-pos. neurotoxicity.  In humans, new studies show that low cerebrospinal fluid CSF Aβ42 and amyloid-PET positivity precede other AD manifestations by many years.  Most importantly, recent trials of three different Aβ antibodies solanezumab, crenezumab, and aducanumab have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects.  Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyGo1qmyvVtbVg90H21EOLACvtfcHk0lhHd-d9rB6lQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVOhtL8%253D&md5=b7a2003ba5d341f5eef5c7e9454235ce</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.15252%2Femmm.201606210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201606210%26sid%3Dliteratum%253Aachs%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520at%252025%2520years%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D595%26epage%3D608%26doi%3D10.15252%2Femmm.201606210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suemoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleegers, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Broeckhoven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saido, T. C.</span></span> <span> </span><span class="NLM_article-title">Potent amyloidogenicity and pathogenicity of Abeta43</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1038/nn.2858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1038%2Fnn.2858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21725313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlClsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=1023-1032&author=T.+Saitoauthor=T.+Suemotoauthor=N.+Brouwersauthor=K.+Sleegersauthor=S.+Funamotoauthor=N.+Mihiraauthor=Y.+Matsubaauthor=K.+Yamadaauthor=P.+Nilssonauthor=J.+Takanoauthor=M.+Nishimuraauthor=N.+Iwataauthor=C.+Van+Broeckhovenauthor=Y.+Iharaauthor=T.+C.+Saido&title=Potent+amyloidogenicity+and+pathogenicity+of+Abeta43&doi=10.1038%2Fnn.2858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potent amyloidogenicity and pathogenicity of Aβ43</span></div><div class="casAuthors">Saito, Takashi; Suemoto, Takahiro; Brouwers, Nathalie; Sleegers, Kristel; Funamoto, Satoru; Mihira, Naomi; Matsuba, Yukio; Yamada, Kazuyuki; Nilsson, Per; Takano, Jiro; Nishimura, Masaki; Iwata, Nobuhisa; Van Broeckhoven, Christine; Ihara, Yasuo; Saido, Takaomi C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1023-1032</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The amyloid-β peptide Aβ42 is known to be a primary amyloidogenic and pathogenic agent in Alzheimer's disease.  However, the role of Aβ43, which is found just as frequently in the brains of affected individuals, remains unresolved.  We generated knock-in mice contg. a pathogenic presenilin-1 R278I mutation that causes overprodn. of Aβ43.  Homozygosity was embryonic lethal, indicating that the mutation involves a loss of function.  Crossing amyloid precursor protein transgenic mice with heterozygous mutant mice resulted in elevated Aβ43, impairment of short-term memory and acceleration of amyloid-β pathol., which accompanied pronounced accumulation of Aβ43 in plaque cores similar in biochem. compn. to those obsd. in the brains of affected individuals.  Consistently, Aβ43 showed a higher propensity to aggregate and was more neurotoxic than Aβ42.  Other pathogenic presenilin mutations also caused overprodn. of Aβ43 in a manner correlating with Aβ42 and with the age of disease onset.  These findings indicate that Aβ43, an overlooked species, is potently amyloidogenic, neurotoxic and abundant in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1wc1KTo7vbVg90H21EOLACvtfcHk0lhHd-d9rB6lQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlClsLs%253D&md5=fcf07320891e8948f6368c0f698ef957</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnn.2858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.2858%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DSuemoto%26aufirst%3DT.%26aulast%3DBrouwers%26aufirst%3DN.%26aulast%3DSleegers%26aufirst%3DK.%26aulast%3DFunamoto%26aufirst%3DS.%26aulast%3DMihira%26aufirst%3DN.%26aulast%3DMatsuba%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DNilsson%26aufirst%3DP.%26aulast%3DTakano%26aufirst%3DJ.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DIwata%26aufirst%3DN.%26aulast%3DVan%2BBroeckhoven%26aufirst%3DC.%26aulast%3DIhara%26aufirst%3DY.%26aulast%3DSaido%26aufirst%3DT.%2BC.%26atitle%3DPotent%2520amyloidogenicity%2520and%2520pathogenicity%2520of%2520Abeta43%26jtitle%3DNat.%2520Neurosci.%26date%3D2011%26volume%3D14%26spage%3D1023%26epage%3D1032%26doi%3D10.1038%2Fnn.2858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1126/science.1072994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1126%2Fscience.1072994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=12130773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=353-356&author=J.+Hardyauthor=D.+J.+Selkoe&title=The+amyloid+hypothesis+of+Alzheimer%E2%80%99s+disease%3A+progress+and+problems+on+the+road+to+therapeutics&doi=10.1126%2Fscience.1072994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</span></div><div class="casAuthors">Hardy, John; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5580</span>),
    <span class="NLM_cas:pages">353-356</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  It has been more than 10 yr since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide (Aβ) in plaques in brain tissue.  According to the amyloid hypothesis, accumulation of Aβ in the brain is the primary influence driving AD pathogenesis.  The rest of the disease process, including formation of neurofibrillary tangles contg. tau protein, is proposed to result from an imbalance between Aβ prodn. and Aβ clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9G5omTHR6cbVg90H21EOLACvtfcHk0lgyqlIoaFQA5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Cju7s%253D&md5=f7b8db1bc6f13e85f887b73f3042e86e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1072994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1072994%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520progress%2520and%2520problems%2520on%2520the%2520road%2520to%2520therapeutics%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D353%26epage%3D356%26doi%3D10.1126%2Fscience.1072994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1038/nrd3505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1038%2Fnrd3505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21852788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVelsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=698-712&author=E.+Karranauthor=M.+Merckenauthor=B.+De+Strooper&title=The+amyloid+cascade+hypothesis+for+Alzheimer%E2%80%99s+disease%3A+an+appraisal+for+the+development+of+therapeutics&doi=10.1038%2Fnrd3505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics</span></div><div class="casAuthors">Karran, Eric; Mercken, Marc; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">698-712</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathol., has dominated research for the past twenty years.  Several therapeutics that were purported to reduce amyloid-β prodn. or aggregation have failed in Phase III clin. testing, and many others are in various stages of development.  Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clin. trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_-zjcfHaQ87Vg90H21EOLACvtfcHk0lgyqlIoaFQA5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVelsL3L&md5=cf2824a56a4c3df6e265d8788970729d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd3505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3505%26sid%3Dliteratum%253Aachs%26aulast%3DKarran%26aufirst%3DE.%26aulast%3DMercken%26aufirst%3DM.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DThe%2520amyloid%2520cascade%2520hypothesis%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520appraisal%2520for%2520the%2520development%2520of%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D698%26epage%3D712%26doi%3D10.1038%2Fnrd3505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bursavich, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blain, J. F.</span></span> <span> </span><span class="NLM_article-title">Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7389</span>– <span class="NLM_lpage">7409</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01960</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01960" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVajsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7389-7409&author=M.+G.+Bursavichauthor=B.+A.+Harrisonauthor=J.+F.+Blain&title=Gamma+Secretase+Modulators%3A+New+Alzheimer%E2%80%99s+Drugs+on+the+Horizon%3F&doi=10.1021%2Facs.jmedchem.5b01960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?</span></div><div class="casAuthors">Bursavich, Matthew G.; Harrison, Bryce A.; Blain, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7389-7409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rapidly aging population desperately requires new therapies for Alzheimer's disease.  Despite years of pharmaceutical research, limited clin. success has been realized, with several failed disease modification therapies in recent years.  On the basis of compelling genetic evidence, the pharmaceutical industry has put a large emphasis on brain beta amyloid (Aβ) either through its removal via antibodies or by targeting the proteases responsible for its prodn.  In this Perspective, we focus on the development of small mols. that improve the activity of one such protease, gamma secretase, through an allosteric binding site to preferentially increase the concn. of the shorter non-amyloidogenic Aβ species.  After a few early failures due to poor drug-like properties, the industry is now on the cusp of delivering gamma secretase modulators for clin. proof-of-mechanism studies that combine potency and efficacy with improved drug-like properties such as lower cLogP, high central nervous system multiparameter optimization scores, and high sp3 character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEjGJ5oHdrrVg90H21EOLACvtfcHk0ljLPXnnF4MawA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVajsbk%253D&md5=8ba1b7de2ce64903c296b7cb63c1c5d3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01960%26sid%3Dliteratum%253Aachs%26aulast%3DBursavich%26aufirst%3DM.%2BG.%26aulast%3DHarrison%26aufirst%3DB.%2BA.%26aulast%3DBlain%26aufirst%3DJ.%2BF.%26atitle%3DGamma%2520Secretase%2520Modulators%253A%2520New%2520Alzheimer%25E2%2580%2599s%2520Drugs%2520on%2520the%2520Horizon%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7389%26epage%3D7409%26doi%3D10.1021%2Facs.jmedchem.5b01960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Mena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceballos-Diaz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levites, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukar, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchelt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon-Limas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Funez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golde, T. E.</span></span> <span> </span><span class="NLM_article-title">Short Abeta peptides attenuate Abeta42 toxicity in vivo</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1084/jem.20170600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1084%2Fjem.20170600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=29208777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2rt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2018&pages=283-301&author=B.+D.+Mooreauthor=J.+Martinauthor=L.+de+Menaauthor=J.+Sanchezauthor=P.+E.+Cruzauthor=C.+Ceballos-Diazauthor=T.+B.+Laddauthor=Y.+Ranauthor=Y.+Levitesauthor=T.+L.+Kukarauthor=J.+J.+Kurianauthor=R.+McKennaauthor=E.+H.+Kooauthor=D.+R.+Borcheltauthor=C.+Janusauthor=D.+Rincon-Limasauthor=P.+Fernandez-Funezauthor=T.+E.+Golde&title=Short+Abeta+peptides+attenuate+Abeta42+toxicity+in+vivo&doi=10.1084%2Fjem.20170600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Short Aβ peptides attenuate Aβ42 toxicity in vivo</span></div><div class="casAuthors">Moore, Brenda D.; Martin, Jason; de Mena, Lorena; Sanchez, Jonatan; Cruz, Pedro E.; Ceballos-Diaz, Carolina; Ladd, Thomas B.; Ran, Yong; Levites, Yona; Kukar, Thomas L.; Kurian, Justin J.; McKenna, Robert; Koo, Edward H.; Borchelt, David R.; Janus, Christopher; Rincon-Limas, Diego; Fernandez-Funez, Pedro; Golde, Todd E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-301</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Processing of amyloid-β (Aβ) precursor protein (APP) by γ-secretase produces multiple species of Aβ: Aβ40, short Aβ peptides (Aβ37-39), and longer Aβ peptides (Aβ42-43). γ-Secretase modulators, a class of Alzheimer's disease therapeutics, reduce prodn. of the pathogenic Aβ42 but increase the relative abundance of short Aβ peptides.  To evaluate the pathol. relevance of these peptides, we expressed Aβ36-40 and Aβ42-43 in Drosophila melanogaster to evaluate inherent toxicity and potential modulatory effects on Aβ42 toxicity.  In contrast to Aβ42, the short Aβ peptides were not toxic and, when coexpressed with Aβ42, were protective in a dose-dependent fashion.  In parallel, we explored the effects of recombinant adeno- assocd. virus-mediated expression of Aβ38 and Aβ40 in mice.  When expressed in nontransgenic mice at levels sufficient to drive Aβ42 deposition, Aβ38 and Aβ40 did not deposit or cause behavioral alterations.  These studies indicate that treatments that lower Aβ42 by raising the levels of short Aβ peptides could attenuate the toxic effects of Aβ42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5jiOyGX0VmrVg90H21EOLACvtfcHk0ljLPXnnF4MawA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2rt73J&md5=8fcdb12f8c4dc72b835f64dc93ebb18d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1084%2Fjem.20170600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20170600%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DB.%2BD.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3Dde%2BMena%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DP.%2BE.%26aulast%3DCeballos-Diaz%26aufirst%3DC.%26aulast%3DLadd%26aufirst%3DT.%2BB.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DLevites%26aufirst%3DY.%26aulast%3DKukar%26aufirst%3DT.%2BL.%26aulast%3DKurian%26aufirst%3DJ.%2BJ.%26aulast%3DMcKenna%26aufirst%3DR.%26aulast%3DKoo%26aufirst%3DE.%2BH.%26aulast%3DBorchelt%26aufirst%3DD.%2BR.%26aulast%3DJanus%26aufirst%3DC.%26aulast%3DRincon-Limas%26aufirst%3DD.%26aulast%3DFernandez-Funez%26aufirst%3DP.%26aulast%3DGolde%26aufirst%3DT.%2BE.%26atitle%3DShort%2520Abeta%2520peptides%2520attenuate%2520Abeta42%2520toxicity%2520in%2520vivo%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2018%26volume%3D215%26spage%3D283%26epage%3D301%26doi%3D10.1084%2Fjem.20170600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haapasalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, D. M.</span></span> <span> </span><span class="NLM_article-title">The many substrates of presenilin/gamma-secretase</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.3233/JAD-2011-101065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.3233%2FJAD-2011-101065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=21335653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=3-28&author=A.+Haapasaloauthor=D.+M.+Kovacs&title=The+many+substrates+of+presenilin%2Fgamma-secretase&doi=10.3233%2FJAD-2011-101065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Substrates of Presenilin/γ-Secretase</span></div><div class="casAuthors">Haapasalo, Annakaisa; Kovacs, Dora M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-28</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  The Alzheimer's disease (AD)-assocd. amyloid-β protein precursor (AβPP) is cleaved by α-, β-, and presenilin (PS)/γ-secretases through sequential regulated proteolysis.  These proteolytic events control the generation of the pathogenic amyloid-β (Aβ) peptide, which excessively accumulates in the brains of individuals afflicted by AD.  A growing no. of addnl. proteins cleaved by PS/γ-secretase continue to be discovered.  Similarly to AβPP, most of these proteins are type-I transmembrane proteins involved in vital signaling functions regulating cell fate, adhesion, migration, neurite outgrowth, or synaptogenesis.  All the identified proteins share common structural features, which are typical for their proteolysis.  The consequences of the PS/γ-secretase-mediated cleavage on the function of many of these proteins are largely unknown.  Here, we review the current literature on the proteolytic processing mediated by the versatile PS/γ-secretase complex.  We begin by discussing the steps of AβPP processing and PS/γ-secretase complex compn. and localization, which give clues to how and where the processing of other PS/γ-secretase substrates may take place.  Then we summarize the typical features of PS/γ-secretase-mediated protein processing.  Finally, we recapitulate the current knowledge on the possible physiol. function of PS/γ-secretase-mediated cleavage of specific substrate proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphYizFVw4_A7Vg90H21EOLACvtfcHk0ljLPXnnF4MawA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSisbY%253D&md5=22ce56939b97019e5c130556f9db7d5f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3233%2FJAD-2011-101065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2011-101065%26sid%3Dliteratum%253Aachs%26aulast%3DHaapasalo%26aufirst%3DA.%26aulast%3DKovacs%26aufirst%3DD.%2BM.%26atitle%3DThe%2520many%2520substrates%2520of%2520presenilin%252Fgamma-secretase%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2011%26volume%3D25%26spage%3D3%26epage%3D28%26doi%3D10.3233%2FJAD-2011-101065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beel, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, C. R.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity of gamma-secretase and other intramembrane proteases</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1311</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1007/s00018-008-7462-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1007%2Fs00018-008-7462-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=18239854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFyhurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=1311-1334&author=A.+J.+Beelauthor=C.+R.+Sanders&title=Substrate+specificity+of+gamma-secretase+and+other+intramembrane+proteases&doi=10.1007%2Fs00018-008-7462-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate specificity of γ-secretase and other intramembrane proteases</span></div><div class="casAuthors">Beel, A. J.; Sanders, C. R.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1311-1334</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  γ-Secretase (I) is a promiscuous protease that cleaves bitopic membrane proteins within the lipid bilayer.  Elucidating both the mechanistic basis of I proteolysis and the precise factors regulating substrate identification is important because modulation of this biochem. degradative process can have important consequences in a physiol. and pathophysiol. context.  Here, the authors briefly review such information for all major classes of intramembrane-cleaving proteases (I-CLiPs), with an emphasis on I, an I-CLiP closely linked to the etiol. of Alzheimer's disease.  A large body of emerging data allows the authors to survey the substrates of I to ascertain the conformational features that predispose a peptide to cleavage by this enigmatic protease.  Because substrate specificity in vivo is closely linked to the relative subcellular compartmentalization of I and its substrates, the authors also survey the voluminous body of literature concerning the traffic of I and its most prominent substrate, the amyloid precursor protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1_vPRH_d3rVg90H21EOLACvtfcHk0li6j4gHRNSWDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFyhurc%253D&md5=b4ab798610a0a26396ee65a92652e0e9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00018-008-7462-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-008-7462-2%26sid%3Dliteratum%253Aachs%26aulast%3DBeel%26aufirst%3DA.%2BJ.%26aulast%3DSanders%26aufirst%3DC.%2BR.%26atitle%3DSubstrate%2520specificity%2520of%2520gamma-secretase%2520and%2520other%2520intramembrane%2520proteases%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2008%26volume%3D65%26spage%3D1311%26epage%3D1334%26doi%3D10.1007%2Fs00018-008-7462-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Novel gamma-secretase modulators for the treatment of Alzheimer’s disease: a review focusing on patents from 2010 to 2012</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1349</span>– <span class="NLM_lpage">1366</span>, <span class="refDoi"> DOI: 10.1517/13543776.2013.821465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1517%2F13543776.2013.821465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=23875696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1349-1366&author=M.+Petterssonauthor=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=D.+S.+Johnson&title=Novel+gamma-secretase+modulators+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+a+review+focusing+on+patents+from+2010+to+2012&doi=10.1517%2F13543776.2013.821465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012</span></div><div class="casAuthors">Pettersson, Martin; Stepan, Antonia F.; Kauffman, Gregory W.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1349-1366</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: γ-Secretase is the enzyme responsible for the final step of amyloid precursor protein proteolysis to generate Aβ peptides including Aβ42 which is believed to be a toxic species involved in Alzheimer's disease (AD) progression. γ-Secretase modulators (GSMs) have been shown to selectively lower Aβ42 prodn. without affecting total Aβ levels or the formation of γ-secretase substrate intracellular domains such as APP intracellular domain and Notch intracellular domain.  Therefore, GSMs have emerged as an important therapeutic strategy for the treatment of AD.  Areas covered: The literature covering novel GSMs will be reviewed focusing on patents from 2010 to 2012.  Expert opinion: During the last review period (2008 - 2010) considerable progress was made developing GSMs with improved potency for lowering Aβ42 levels, but most of the compds. resided in unfavorable central nervous system (CNS) drug space.  In this review period (2010 - 2012), there is a higher percentage of potent GSM chem. matter that resides in favorable CNS drug space.  It is anticipated that clin. candidates will emerge out of this cohort that will be able to test the GSM mechanism of action in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFLi5hAAdKc7Vg90H21EOLACvtfcHk0li6j4gHRNSWDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7fP&md5=6b43a8feb210fa87ded92a26397b754f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.821465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.821465%26sid%3Dliteratum%253Aachs%26aulast%3DPettersson%26aufirst%3DM.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DNovel%2520gamma-secretase%2520modulators%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520focusing%2520on%2520patents%2520from%25202010%2520to%25202012%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D1349%26epage%3D1366%26doi%3D10.1517%2F13543776.2013.821465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, Y.</span></span> <span> </span><span class="NLM_article-title">Gamma-secretase modulators do not induce Abeta-rebound and accumulation of beta-C-terminal fragment</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2011.07560.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1111%2Fj.1471-4159.2011.07560.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=22035227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2012&pages=277-286&author=T.+Liauthor=Y.+Huangauthor=S.+Jinauthor=L.+Yeauthor=N.+Rongauthor=X.+Yangauthor=Y.+Dingauthor=Z.+Chengauthor=J.+Zhangauthor=Z.+Wanauthor=D.+C.+Harrisonauthor=I.+Hussainauthor=A.+Hallauthor=D.+H.+Leeauthor=L.+F.+Lauauthor=Y.+Matsuoka&title=Gamma-secretase+modulators+do+not+induce+Abeta-rebound+and+accumulation+of+beta-C-terminal+fragment&doi=10.1111%2Fj.1471-4159.2011.07560.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment</span></div><div class="casAuthors">Li, Ting; Huang, Yunhong; Jin, Shiyi; Ye, Liang; Rong, Na; Yang, Xiujuan; Ding, Yu; Cheng, Ziqiang; Zhang, Jinqiang; Wan, Zehong; Harrison, David C.; Hussain, Ishrut; Hall, Adrian; Lee, Daniel Hong Seng; Lau, Lit-Fui; Matsuoka, Yasuji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1 & 2</span>),
    <span class="NLM_cas:pages">277-286</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">γ-Secretase inhibitors (GSIs) have been developed to reduce amyloid-β (Aβ) prodn. for the treatment of Alzheimer's disease by inhibiting the cleavage of amyloid precursor protein (APP).  However, cross-inhibitory activity on the processing of Notch can cause adverse reactions.  To avoid these undesirable effects, γ-secretase modulators (GSMs) are being developed to selectively reduce toxic Aβ prodn. without perturbing Notch signaling.  As it is also known that GSIs can cause a paradoxical increase of plasma Aβ over the baseline after a transient redn. (known as Aβ-rebound), we asked if GSMs would cause a similar rebound and what the potential mechanism might be.  Our studies were performed with one GSI (LY-450139) and two chem. distinct GSMs.  Although LY-450139 caused Aβ-rebound as expected in rat plasma, the two GSMs did not.  Inhibition of APP processing by LY-450139 induced an accumulation of γ-secretase substrates, α- and β-C-terminal fragments of APP, but neither GSM caused such an accumulation.  In conclusion, we discover that GSMs, unlike GSIs, do not cause Aβ-rebound, possibly because of the lack of accumulation of β-C-terminal fragments.  GSMs may be superior to GSIs in the treatment of Alzheimer's disease not only by sparing Notch signaling but also by avoiding Aβ-rebound.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbNSd_Jes7MrVg90H21EOLACvtfcHk0liwK0tS7kDXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKlt7s%253D&md5=a5c6183ca9a10de3aef6ac83cb770325</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07560.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07560.x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DHarrison%26aufirst%3DD.%2BC.%26aulast%3DHussain%26aufirst%3DI.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLau%26aufirst%3DL.%2BF.%26aulast%3DMatsuoka%26aufirst%3DY.%26atitle%3DGamma-secretase%2520modulators%2520do%2520not%2520induce%2520Abeta-rebound%2520and%2520accumulation%2520of%2520beta-C-terminal%2520fragment%26jtitle%3DJ.%2520Neurochem.%26date%3D2012%26volume%3D121%26spage%3D277%26epage%3D286%26doi%3D10.1111%2Fj.1471-4159.2011.07560.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span>; <span class="NLM_string-name">Goetschi, E.</span>; <span class="NLM_string-name">Green, L.</span>; <span class="NLM_string-name">Jolydon, S.</span>; <span class="NLM_string-name">Knust, H.</span>; <span class="NLM_string-name">Limberg, A.</span>; <span class="NLM_string-name">Luebbers, T.</span>; <span class="NLM_string-name">Thomas, A.</span></span> <span> </span><span class="NLM_article-title">Gamma-secretase modulators</span>. <span class="NLM_patent">WO2011/092272A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Baumann&author=E.+Goetschi&author=L.+Green&author=S.+Jolydon&author=H.+Knust&author=A.+Limberg&author=T.+Luebbers&author=A.+Thomas&title=Gamma-secretase+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DK.%26atitle%3DGamma-secretase%2520modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span> <span> </span><span class="NLM_article-title">Analytical studies on the prediction of photosensitive/phototoxic potential of pharmaceutical substances</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1007/s11095-005-8497-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1007%2Fs11095-005-8497-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=16308671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Clsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=156-164&author=S.+Onoueauthor=Y.+Tsuda&title=Analytical+studies+on+the+prediction+of+photosensitive%2Fphototoxic+potential+of+pharmaceutical+substances&doi=10.1007%2Fs11095-005-8497-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Analytical Studies on the Prediction of Photosensitive/Phototoxic Potential of Pharmaceutical Substances</span></div><div class="casAuthors">Onoue, Satomi; Tsuda, Yoshiko</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Phototoxic responses after administration of photosensitive pharmaceutics were recognized as undesirable side effects, and predicting potential hazardous side effects is gaining importance as new drugs are introduced to the market.  In this work, the authors characterize the photochem./photobiol. properties of model compds. to develop an effective screening method for the prediction of phototoxic/photosensitive potential.  Twenty-one known photosensitive/phototoxic compds. and 5 weak/nonphototoxic compds. were subjected to UV spectral analyses and photochem. evaluation including the detn. of produced reactive oxygen species (ROS) and photostability study.  The photooxidn. of linoleic acid was also monitored in the presence of tested compds., guided on the formation of thiobarbituric acid reactive substances.  Most photosensitive/phototoxic drugs tested, even weak UV absorbers, at a concn. of 200 μM showed significant prodn. of ROS under 18 h light exposure (30,000 lx).  On the other hand, ROS generated from weak/nonphototoxic compds., including strong UV absorber benzocaine, were low or negligible.  Although exposure of quinine to light resulted in significant degrdn. (half-life, t1/2 = 6.4 h), it was dramatically attenuated by the addn. of ROS scavengers, esp. sodium azide (t1/2 = 122.6 h).  Furthermore, concomitant exposure of photosensitive/phototoxic compds. (200 μM) and linoleic acid (1 mM) for 18 h led to the marked formation of lipoperoxide.  Results indicated that known photosensitive/phototoxic compds. tested have the ability to generate ROS under light exposure, and this photochem. reaction could be assocd. with their photoinstability and/or phototoxic responses.  Based on these findings, detn. of ROS, generated from photoirradiated compds., may be an effective predictive model in recognizing their photosensitive/phototoxic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3y9IB1PPBYrVg90H21EOLACvtfcHk0liwK0tS7kDXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Clsbc%253D&md5=2a477fc426e92b1cd5a0b7f465db7445</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs11095-005-8497-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-005-8497-9%26sid%3Dliteratum%253Aachs%26aulast%3DOnoue%26aufirst%3DS.%26aulast%3DTsuda%26aufirst%3DY.%26atitle%3DAnalytical%2520studies%2520on%2520the%2520prediction%2520of%2520photosensitive%252Fphototoxic%2520potential%2520of%2520pharmaceutical%2520substances%26jtitle%3DPharm.%2520Res.%26date%3D2006%26volume%3D23%26spage%3D156%26epage%3D164%26doi%3D10.1007%2Fs11095-005-8497-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, S.</span></span> <span> </span><span class="NLM_article-title">Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development</span>. <i>Curr. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.2174/157488609788173044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.2174%2F157488609788173044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=19442106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OqtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=123-136&author=S.+Onoueauthor=Y.+Setoauthor=G.+Gandyauthor=S.+Yamada&title=Drug-induced+phototoxicity%3B+an+early+in+vitro+identification+of+phototoxic+potential+of+new+drug+entities+in+drug+discovery+and+development&doi=10.2174%2F157488609788173044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced phototoxicity; An early in vitro identification of phototoxic potential of new drug entities in drug discovery and development</span></div><div class="casAuthors">Onoue, Satomi; Seto, Yoshiki; Gandy, Graham; Yamada, Shizuo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-136</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-induced photoirritation can be defined as an inflammatory reaction of the skin after topical or systemic administration of pharmaceutical substances.  In many cases of drug-induced phototoxicity, skin reactions can be triggered by doses of sunlight regarded as harmless and most often in the UV A (320-400 nm).  Several classes of drugs including antibacterials, thiazide diuretics, non-steroidal anti-inflammatory drugs, quinolones, and tricyclic antidepressants, even though nontoxic by themselves, may become reactive under exposure to environmental light, leading to undesired side effects.  At least three types of drug-induced phototoxic skin reactions, including the photoirritant, photogenotoxic and photoallergic skin responses, have been recognized, and their mechanisms and pathol. features are quite different.  The development of effective methodol. to evaluate the photochem./biol. properties has been attempted over the past few years, since it would be a key consideration to predict and avoid the phototoxic risk in the early phase of the drug discovery process.  The aim of this review is to describe the clin. features, pathogenesis and photochem. characteristics of drug-induced phototoxicity, and the current developments in research tools for predicting phototoxic potential of new drug entities are also addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzhnEKB9Mw7Vg90H21EOLACvtfcHk0liwK0tS7kDXqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OqtLnK&md5=2ef8638811b1e1e519adc15a92fd5f43</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F157488609788173044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488609788173044%26sid%3Dliteratum%253Aachs%26aulast%3DOnoue%26aufirst%3DS.%26aulast%3DSeto%26aufirst%3DY.%26aulast%3DGandy%26aufirst%3DG.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DDrug-induced%2520phototoxicity%253B%2520an%2520early%2520in%2520vitro%2520identification%2520of%2520phototoxic%2520potential%2520of%2520new%2520drug%2520entities%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DCurr.%2520Drug%2520Saf.%26date%3D2009%26volume%3D4%26spage%3D123%26epage%3D136%26doi%3D10.2174%2F157488609788173044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamarche, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borawski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacci-Daniel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennehy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drumm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedmann, B.</span></span> <span> </span><span class="NLM_article-title">Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5149</span>– <span class="NLM_lpage">5156</span>, <span class="refDoi"> DOI: 10.1128/AAC.00946-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1128%2FAAC.00946-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=22825118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5149-5156&author=M.+J.+Lamarcheauthor=J.+Borawskiauthor=A.+Boseauthor=C.+Capacci-Danielauthor=R.+Colvinauthor=M.+Dennehyauthor=J.+Dingauthor=M.+Doblerauthor=J.+Drummauthor=L.+A.+Gaitherauthor=J.+Gaoauthor=X.+Jiangauthor=K.+Linauthor=U.+McKeeverauthor=X.+Puyangauthor=P.+Ramanauthor=S.+Thohanauthor=R.+Tommasiauthor=K.+Wagnerauthor=X.+Xiongauthor=T.+Zabawaauthor=S.+Zhuauthor=B.+Wiedmann&title=Anti-hepatitis+C+virus+activity+and+toxicity+of+type+III+phosphatidylinositol-4-kinase+beta+inhibitors&doi=10.1128%2FAAC.00946-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors</span></div><div class="casAuthors">LaMarche, M. J.; Borawski, J.; Bose, A.; Capacci-Daniel, C.; Colvin, R.; Dennehy, M.; Ding, J.; Dobler, M.; Drumm, J.; Gaither, L. A.; Gao, J.; Jiang, X.; Lin, K.; McKeever, U.; Puyang, X.; Raman, P.; Thohan, S.; Tommasi, R.; Wagner, K.; Xiong, X.; Zabawa, T.; Zhu, S.; Wiedmann, B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5149-5156</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Type III phosphatidylinositol-4-kinase beta (PI4KIIIβ) was previously implicated in hepatitis C virus (HCV) replication by small interfering RNA (siRNA) depletion and was therefore proposed as a novel cellular target for the treatment of hepatitis C.  Medicinal chem. efforts identified highly selective PI4KIIIβ inhibitors that potently inhibited the replication of genotype 1a and 1b HCV replicons and genotype 2a virus in vitro.  Replicon cells required more than 5 wk to reach low levels of 3- to 5-fold resistance, suggesting a high resistance barrier to these cellular targets.  Extensive in vitro profiling of the compds. revealed a role of PI4KIIIβ in lymphocyte proliferation.  Previously proposed functions of PI4KIIIβ in insulin secretion and the regulation of several ion channels were not perturbed with these inhibitors.  Moreover, PI4KIIIβ inhibitors were not generally cytotoxic as demonstrated across hundreds of cell lines and primary cells.  However, an unexpected antiproliferative effect in lymphocytes precluded their further development for the treatment of hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg3G6T2U7Lv7Vg90H21EOLACvtfcHk0lhi24CIe0CUtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7jK&md5=fd7a50d1813d04862e5d8fa549c73da5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.00946-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00946-12%26sid%3Dliteratum%253Aachs%26aulast%3DLamarche%26aufirst%3DM.%2BJ.%26aulast%3DBorawski%26aufirst%3DJ.%26aulast%3DBose%26aufirst%3DA.%26aulast%3DCapacci-Daniel%26aufirst%3DC.%26aulast%3DColvin%26aufirst%3DR.%26aulast%3DDennehy%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDobler%26aufirst%3DM.%26aulast%3DDrumm%26aufirst%3DJ.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DMcKeever%26aufirst%3DU.%26aulast%3DPuyang%26aufirst%3DX.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DThohan%26aufirst%3DS.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DXiong%26aufirst%3DX.%26aulast%3DZabawa%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWiedmann%26aufirst%3DB.%26atitle%3DAnti-hepatitis%2520C%2520virus%2520activity%2520and%2520toxicity%2520of%2520type%2520III%2520phosphatidylinositol-4-kinase%2520beta%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5149%26epage%3D5156%26doi%3D10.1128%2FAAC.00946-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span> <span> </span><span class="NLM_article-title">Plasma protein binding: from discovery to development</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2953</span>– <span class="NLM_lpage">2994</span>, <span class="refDoi"> DOI: 10.1002/jps.23614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1002%2Fjps.23614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=23798314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2013&pages=2953-2994&author=T.+Bohnertauthor=L.+S.+Gan&title=Plasma+protein+binding%3A+from+discovery+to+development&doi=10.1002%2Fjps.23614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma protein binding: From discovery to development</span></div><div class="casAuthors">Bohnert, Tonika; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2953-2994</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The importance of plasma protein binding (PPB) in modulating the effective drug concn. at pharmacol. target sites has been the topic of significant discussion and debate amongst drug development groups over the past few decades.  Free drug theory, which states that in absence of energy-dependent processes, after steady state equil. has been attained, free drug concn. in plasma is equal to free drug concn. at the pharmacol. target receptor(s) in tissues, has been used to explain pharmacokinetics/pharmacodynamics relationships in a large no. of cases.  Any sudden increase in free concn. of a drug could potentially cause toxicity and may need dose adjustment.  Free drug concn. is also helpful to est. the effective concn. of drugs that potentially can ppt. metab. (or transporter)-related drug-drug interactions.  Disease models are extensively validated in animals to progress a compd. into development.  Unbound drug concn., and therefore PPB information across species is very informative in establishing safety margins and guiding selection of First in Human (FIH) dose and human efficacious dose.  The scope of this review is to give an overview of reported role of PPB in several therapeutic areas, highlight cases where PPB changes are clin. relevant, and provide drug metab. and pharmacokinetics recommendations in discovery and development settings. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqobJp8eG98XrVg90H21EOLACvtfcHk0lhi24CIe0CUtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D&md5=d676f7490c6e0f09c8acf7cce5183b17</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjps.23614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23614%26sid%3Dliteratum%253Aachs%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DGan%26aufirst%3DL.%2BS.%26atitle%3DPlasma%2520protein%2520binding%253A%2520from%2520discovery%2520to%2520development%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D102%26spage%3D2953%26epage%3D2994%26doi%3D10.1002%2Fjps.23614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">When PPB ≪1% and unspecific binding is high/extreme, it makes difficult the interpretation of the <i>in vitro</i> potency and the <i>in vitro</i> stability data (there is a 10% of serum in the potency assay media and the hepatocytes stability assay), also predictions become innacurate.</p></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span>; <span class="NLM_string-name">Green, L.</span>; <span class="NLM_string-name">Limberg, A.</span>; <span class="NLM_string-name">Luebbers, T.</span>; <span class="NLM_string-name">Thomas, A.</span></span> <span> </span><span class="NLM_article-title">Bridged piperidine derivatives for use as amyloid beta modulators</span>. <span class="NLM_patent">WO2012/116965A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Baumann&author=L.+Green&author=A.+Limberg&author=T.+Luebbers&author=A.+Thomas&title=Bridged+piperidine+derivatives+for+use+as+amyloid+beta+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DK.%26atitle%3DBridged%2520piperidine%2520derivatives%2520for%2520use%2520as%2520amyloid%2520beta%2520modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrecht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lave, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span> <span> </span><span class="NLM_article-title">PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1684</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1016%2Fj.bcp.2013.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=23454189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlKrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=1684-1699&author=A.+Carusoauthor=R.+Alvarez-Sanchezauthor=A.+Hillebrechtauthor=A.+Poirierauthor=F.+Schulerauthor=T.+Laveauthor=C.+Funkauthor=S.+Belli&title=PK%2FPD+assessment+in+CNS+drug+discovery%3A+Prediction+of+CSF+concentration+in+rodents+for+P-glycoprotein+substrates+and+application+to+in+vivo+potency+estimation&doi=10.1016%2Fj.bcp.2013.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation</span></div><div class="casAuthors">Caruso, Antonello; Alvarez-Sanchez, Ruben; Hillebrecht, Alexander; Poirier, Agnes; Schuler, Franz; Lave, Thierry; Funk, Christoph; Belli, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1684-1699</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The unbound drug concn. in brain parenchyma is considered to be the relevant driver for interaction with central nervous system (CNS) biol. targets.  Drug levels in cerebrospinal fluid (C_CSF) are frequently used surrogates for the unbound concns. in brain.  For drugs actively transported across the blood-brain barrier (BBB), C_CSF differs from unbound plasma concn. (Cu_p) to an extent that is commonly unknown.  In this study, the relationship between CSF-to-unbound plasma drug partitioning in rats and the mouse Pgp (Mdr1a) efflux ratio (ER) obtained from in vitro transcellular studies has been investigated for a set of 61 CNS compds. exhibiting substantial diversity in chem. structure and physico-chem. properties.  In order to understand the in vitro-in vivo extrapolation of Pgp efflux, a mechanistic model was derived relating in vivo CNS distribution kinetics to in vitro active transport.  The model was applied to predict C_CSF from Cu_p and ER data for 19 proprietary Roche CNS drug candidates.  The calcd. CSF concns. were correlated with CNS pharmacodynamic responses obsd. in rodent models.  The correlation between in vitro and in vivo potency for different pharmacol. endpoints indicated that the predicted C_CSF is a valuable surrogate of the concn. at the target site.  Overall, C_CSF proved superior description of PK/PD data than unbound plasma or total brain concn. for Mdr1a substrates.  Predicted C_CSF can be used as a default approach to understand the PK/PD relationships in CNS efficacy models and can support the extrapolation of efficacious brain exposure for new drug candidates from rodent to man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruK6k0mONiBbVg90H21EOLACvtfcHk0liKweoPYk3c2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlKrs70%253D&md5=76fec0e52a881f894ed01836bba27db6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DPoirier%26aufirst%3DA.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DLave%26aufirst%3DT.%26aulast%3DFunk%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26atitle%3DPK%252FPD%2520assessment%2520in%2520CNS%2520drug%2520discovery%253A%2520Prediction%2520of%2520CSF%2520concentration%2520in%2520rodents%2520for%2520P-glycoprotein%2520substrates%2520and%2520application%2520to%2520in%2520vivo%2520potency%2520estimation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D1684%26epage%3D1699%26doi%3D10.1016%2Fj.bcp.2013.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.027797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding&doi=10.1124%2Fdmd.109.027797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0liKweoPYk3c2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977%26doi%3D10.1124%2Fdmd.109.027797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/tx034170b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development&doi=10.1021%2Ftx034170b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0ljsc0HWqbesKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16%26doi%3D10.1021%2Ftx034170b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0ljsc0HWqbesKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nettekoven, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic access to 2-amido-5-aryl-8-methoxy-triazolopyridine and 2-amido-5-morpholino-8-methoxy-triazolopyridine derivatives as potential inhibitors of the adenosine receptor subtypes</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2003</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1652</span>, <span class="refDoi"> DOI: 10.1055/s-2003-40874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;key=10.1055%2Fs-2003-40874" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2003&publication_year=2003&pages=1649-1652&author=M.+Nettekovenauthor=B.+Pullmannauthor=S.+Schmitt&title=Synthetic+access+to+2-amido-5-aryl-8-methoxy-triazolopyridine+and+2-amido-5-morpholino-8-methoxy-triazolopyridine+derivatives+as+potential+inhibitors+of+the+adenosine+receptor+subtypes&doi=10.1055%2Fs-2003-40874"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1055%2Fs-2003-40874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2003-40874%26sid%3Dliteratum%253Aachs%26aulast%3DNettekoven%26aufirst%3DM.%26aulast%3DPullmann%26aufirst%3DB.%26aulast%3DSchmitt%26aufirst%3DS.%26atitle%3DSynthetic%2520access%2520to%25202-amido-5-aryl-8-methoxy-triazolopyridine%2520and%25202-amido-5-morpholino-8-methoxy-triazolopyridine%2520derivatives%2520as%2520potential%2520inhibitors%2520of%2520the%2520adenosine%2520receptor%2520subtypes%26jtitle%3DSynthesis%26date%3D2003%26volume%3D2003%26spage%3D1649%26epage%3D1652%26doi%3D10.1055%2Fs-2003-40874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i91"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00909">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24526"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00909?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00909</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC of the described chiral intermediates, HPLC chromatograms of the key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Corresponding pdb-formatted file of the PIK4CB docking model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_001.pdf">jm0c00909_si_001.pdf (957.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_002.pdb">jm0c00909_si_002.pdb (636.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00909/suppl_file/jm0c00909_si_003.csv">jm0c00909_si_003.csv (1.62 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00909&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00909%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00909" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679918a109da3c5e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
